U.S. patent application number 11/986709 was filed with the patent office on 2008-09-18 for polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same.
Invention is credited to Radoje T. Drmanac, Ivan Labat, Juhi Lee, Mitsuo Nishikawa, Birgit Stache-Crain, Y. Tom Tang.
Application Number | 20080227200 11/986709 |
Document ID | / |
Family ID | 23145656 |
Filed Date | 2008-09-18 |
United States Patent
Application |
20080227200 |
Kind Code |
A1 |
Drmanac; Radoje T. ; et
al. |
September 18, 2008 |
Polypeptide having an activity to support proliferation or survival
of hematopoietic stem cell and hematopoietic progenitor cell, and
DNA coding for the same
Abstract
A gene encoding a polypeptide having an activity to support
proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells is isolated by comparing expressed
genes between cells which support proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells and
cells which do not support the proliferation or survival.
Proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells is supported by using stromal cells
in which the isolated gene is expressed or a gene product of the
isolated gene.
Inventors: |
Drmanac; Radoje T.; (Los
Altos Hills, CA) ; Labat; Ivan; (Mountain View,
CA) ; Tang; Y. Tom; (San Jose, CA) ; Lee;
Juhi; (Fremont, CA) ; Stache-Crain; Birgit;
(Sunnyvale, CA) ; Nishikawa; Mitsuo;
(Takasaki-shi, JP) |
Correspondence
Address: |
ROBINS & PASTERNAK
1731 EMBARCADERO ROAD, SUITE 230
PALO ALTO
CA
94303
US
|
Family ID: |
23145656 |
Appl. No.: |
11/986709 |
Filed: |
November 26, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10478926 |
Jun 17, 2004 |
7320880 |
|
|
PCT/JP02/05807 |
Jun 11, 2002 |
|
|
|
11986709 |
|
|
|
|
60297286 |
Jun 11, 2001 |
|
|
|
Current U.S.
Class: |
435/375 ;
435/320.1; 435/325; 435/405; 530/350; 530/387.9; 536/23.1 |
Current CPC
Class: |
C12N 5/0647 20130101;
C07K 14/475 20130101; A61K 38/00 20130101; A61P 7/06 20180101; A61P
43/00 20180101 |
Class at
Publication: |
435/375 ;
536/23.1; 435/320.1; 435/325; 530/350; 530/387.9; 435/405 |
International
Class: |
C12N 5/06 20060101
C12N005/06; C12N 15/11 20060101 C12N015/11; C07K 14/00 20060101
C07K014/00; C07K 16/18 20060101 C07K016/18; C12N 15/00 20060101
C12N015/00 |
Claims
1. An isolated DNA molecule comprising a nucleotide sequence
encoding a polypeptide, wherein the polypeptide comprises: (a) the
amino acid sequence of SEQ ID NO:19; (b) the amino acid sequence of
SEQ ID NO:25; or (c) the amino acid sequence of (a) or (b) which
includes a deletion, substitution or insertion of one or several
amino acids and which has an activity to support proliferation or
survival of hematopoietic stem cells or hematopoietic progenitor
cells.
2. The DNA molecule of claim 1, wherein the DNA molecule comprises
a nucleotide sequence of (a) nucleotides 1 to 444 of SEQ ID NO: 18,
(b) nucleotides 132 to 506 of SEQ ID NO: 24, or (c) a nucleotide
sequence that hybridizes to a nucleotide sequence as defined in (a)
or (b) under one of the following stringent conditions: (1) wash in
6.times.SSC, 5.times.Denhardt, 0.5% SDS at 68.degree. C. or (2)
wash in 6.times.SSC, 5.times.Denhardt, 0.5% SDS 50% formamide at
42.degree. C.; and wherein the nucleotide sequence of (c) encodes a
polypeptide having an activity to support proliferation or survival
of hematopoietic stem cells or hematopoietic progenitor cells.
3. The DNA molecule of claim 1, wherein the DNA molecule comprises
a nucleotide sequence encoding a polypeptide comprising the amino
acid sequence of SEQ ID NO: 19 or the amino acid sequence of SEQ ID
NO:25.
4. An expression vector comprising the DNA of claim 1 and a gene
expression regulatory sequence.
5. An isolated cell comprising the DNA molecule of claim 4.
6. An isolated polypeptide encoded by the DNA molecule of claim 1,
the polypeptide having an activity to support proliferation or
survival of hematopoietic stem cells or hematopoietic progenitor
cells.
7. The polypeptide of claim 6, wherein the polypeptide comprises
the amino acid sequence of SEQ ID NO:19 or 25.
8. The polypeptide of claim 6, which is modified with one or more
modifying agents selected from the group consisting of polyethylene
glycol (PEG), dextran, poly(N-vinyl-pyrrolidone), polypropylene
glycol homopolymer, copolymer of polypropylene oxide/ethylene
oxide, polyoxyethylated polyol and polyvinyl alcohol.
9. An antibody which binds to the polypeptide of claim 6.
10. The antibody of claim 9, wherein the antibody is a monoclonal
antibody.
11. A method for supporting proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells,
comprising the step of co-culturing stromal cells which express the
DNA molecule of claim 2 with CD-34-positive hematopoietic stem
cells, under conditions that support proliferation or survival of
said hematopoietic stem cells or hematopoietic progenitor
cells.
12. The method of claim 10, wherein the DNA molecule encodes a
polypeptide comprising the sequence of SEQ ID NO: 19 or 25.
13. A method for supporting proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells,
comprising the step of culturing CD-34-positive hematopoietic stem
cells or erythroid progenitor cells in the presence of a
polypeptide according to claim 6, under conditions that support
proliferation or survival of said hematopoietic stem cells or
hematopoietic progenitor cells.
14. A method for supporting proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells,
comprising the step of culturing CD-34-positive hematopoietic stem
cells or erythroid progenitor cells in the presence of a
polypeptide according to claim 7, under conditions that support
proliferation or survival of said hematopoietic stem cells or
hematopoietic progenitor cells.
15. A composition having an effect to support proliferation or
survival of hematopoietic stem cells or hematopoietic progenitor
cells, which comprises an effective amount of a polypeptide
according to claim 6.
16. A composition having an effect to support proliferation or
survival of hematopoietic stem cells or hematopoietic progenitor
cells, which comprises an effective amount of a polypeptide
according to claim 7.
17. A composition comprising the polypeptide of claim 6.
18. A composition comprising the polypeptide of claim 7.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 10/478,926, filed Jun. 17, 2004, which is a 35
U.S.C. .sctn.371 filing of PCT/JP02/05807, filed Jun. 11, 2002,
from which priority is claimed pursuant to 35 U.S.C. .sctn.120,
which in turn claims benefit under 35 U.S.C. .sctn. 119(e)(1) of
provisional Patent Application No. 60/297,286, filed Jun. 11, 2001,
which applications are hereby incorporated by reference in their
entireties
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention relates to a polypeptide having an
activity to support proliferation or survival of hematopoietic stem
cells or hematopoietic progenitor cells, a DNA coding the
polypeptide, and a pharmaceutical composition comprising the
polypeptide as active ingredient.
[0004] 2. Description of the Related Art
[0005] Fully differentiated mature hematopoietic cells have limited
short lives. Homeostasis of the blood is maintained due to supply
of the mature blood cells caused by continuous differentiation of
hematopoietic progenitor cells. The hematopoietic progenitor cells
are giving rise from more undifferentiated hematopoietic stem
cells. The hematopoietic stem cells have potential of
differentiating into all of the differentiation lineages
(totipotency) and have potential of self-renew with retaining the
totipotency so as to supply the hematopoietic cells through life.
That is, the hematopoietic stem cells are known to generate
totipotent stem cells by the self-renew and to differentiate in
parts to a variety of the mature blood cells through the
hematopoietic progenitor cells.
[0006] This differentiation of the blood cells is regulated by a
variety of cytokines. Erythropoietin is known to promote the
differentiation of the erythrocytic lineages. G-CSF and
thrombopoietin are also known to promote the differentiation of the
neutrophils, and the megakaryocytes and the platelet productive
cells, respectively. However, a factor required for the self-renew
of the hematopoietic stem cell with retaining the totipotency has
not been clear. Although SCF/MGF (Williams, D. E., Cell, 63:
167-174, 1990; Zsebo, K. M., Cell, 63: 213-224, 1990), SCGF
(WO98/08869), and the like are reported as growth factors for the
hematopoietic stem cells, none of them have potency to sufficiently
retain the totipotency of the hematopoietic stem cells. Although
attempts to culture the hematopoietic stem cells in the presence of
combinations of known cytokines, a system for efficient
amplification of the hematopoietic stem cells was not realized
(Miller, C. L., Proc. Natl. Acad. Sci. USA, 94: 13648-13653, 1997;
Yagi, M., Proc. Natl. Acad. Sci. USA, 96: 8126-8131, 1999; Shih, C.
C., Blood, 94: 5 1623-1636, 1999).
[0007] On the other hand, attempts to allow the hematopoietic stem
cells to survive or proliferate without differentiation by using
stromal cells which supply an environment suitable for survival or
proliferation of the hematopoietic stem cells were reported (Moore
K. A., Blood, 89: 12, 4337-4347, 1997). In addition, WO99/03980
discloses a stromal cell line capable of supporting proliferation
or survival of hematopoietic stem cells and hematopoietic
progenitor cells, which are established from an AGM
(Aorta-Gonad-Mesonephros) region of a fetal mouse.
[0008] It is postulated that there should be more peptides that
efficiently facilitate hematopoietic stem cell and progenitor cell
amplification by themselves or in combination with stromal cells or
stimulating factors such as cytokines, in addition to known factors
affecting hematopoietic cells.
SUMMARY OF THE INVENTION
[0009] Since the proliferation or survival of hematopoietic stem
cells or hematopoietic progenitor cells in vitro can be supported
by co-culture of stromal cells and hematopoietic stem cells and
hematopoietic progenitor cells, the stromal cells are expected to
produce factors supporting the proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells. An
object of the present invention is to provide a factor supporting
the proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells, which is derived from the stromal
cells.
[0010] The inventor of the present invention has assumed that the
mouse stromal cells produce factors supporting the proliferation or
survival of hematopoietic stem cells or hematopoietic progenitor
cells, as mentioned above. Attention is given that there are two
kinds of stromal cells. One has a ability to support the
proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells (hereafter sometimes referred to as
"activity to support hematopoietic stem cells"). The other does not
have the activity to support hematopoietic stem cells. The inventor
of the present invention has assumed that this difference in the
ability is due to the fact that expression of genes encoding the
factors is increased in the supporting stromal cells and that the
expression is low in non-supporting stromal cells. Thus the
inventor think it can be found the factors supporting the
proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells among the genes expressed higher in
the supporting cells compared to in the non-supporting cells. In
this context, the inventor has identified genes of which
expressions are high in AGM-s3-A9 cell line which has the activity
to support hematopoietic stem cells, and low or undetected in
AGM-s3-A7 cell line which does not have the activity to support
hematopoietic stem cells, and has determined the activities to
support hematopoietic stem cells, of cells in which these gene
groups are highly expressed. As a result, the present invention has
been completed.
[0011] That is, the present invention provides the followings.
[0012] (1) A DNA coding for a polypeptide of the following (A) or
(B):
[0013] (A) a polypeptide which comprises an amino acid sequence
selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 23
and SEQ ID NO: 25; or
[0014] (B) a polypeptide which comprises an amino acid sequence
including deletion, substitution or insertion of one or several
amino acids in the amino acid sequence as defined in (A), and which
has an activity to support proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells.
[0015] (2) The DNA according to (1), which is a DNA of the
following (a) or (b):
[0016] (a) a DNA which comprises a nucleotide sequence selected
from the group consisting of the nucleotide sequence of nucleotides
1 to 444 of SEQ ID NO: 18, the nucleotide sequence of nucleotides
630 to 1358 of SEQ ID NO: 22, and the nucleotide sequence of
nucleotides 132 to 506 of SEQ ID NO: 24; or
[0017] (b) a DNA which is hybridizable with a DNA comprising the
nucleotide sequence as defined in (a) or a prove prepared from said
DNA, under the stringent condition, and which has an activity to
support proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells.
[0018] (3) The DNA according to (2), the stringent condition is
6.times.SSC, 5.times.Denhardt, 0.5% SDS and 68.degree. C. (SSC: 3 M
NaCl, 0.3 M sodium citrate; 50.times.Denhardt: 1% BSA, 1% polyvinyl
pyrrolidone, 1% Ficoll 400), or 6.times.SSC, 5.times.Denhardt, 0.5%
SDS, 50% formamide and 42.degree. C.
[0019] (4) A expression vector which comprises the DNA of any one
of (1) to (3) in such a manner that the DNA can be expressed.
[0020] (5) A cell into which the DNA of any one of (1) to (3) is
introduced in such a manner that the DNA can be expressed.
[0021] (6) A polypeptide which is an expression product of the DNA
of any one of (1) to (3), the polypeptide having an activity to
support proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells.
[0022] (7) The polypeptide according to (6), which comprises an
amino acid sequence selected from the group consisting of SEQ ID
NO: 19, SEQ ID NO: 23 and SEQ ID NO: 25, or an amino acid sequence
including deletion, substitution or insertion of one or several
amino acids in the amino acid sequence.
[0023] (8) The polypeptide according to (6) or (7), which is
modified with one or more modifying agents selected from the group
consisting of polyethylene glycol (PEG), dextran,
poly(N-vinyl-pyrrolidone), polypropylene glycol homopolymer,
copolymer of polypropylene oxide/ethylene oxide, polyoxyethylated
polyol and polyvinyl alcohol.
[0024] (9) An monoclonal antibody which binds to the polypeptide of
any one of (6) to (8).
[0025] (10) A method for supporting proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells,
comprising the step of co-culturing stromal cells in which a DNA
coding for a polypeptide of the following (A) or (B) is expressed,
with hematopoietic stem cells or progenitor cells,
[0026] (A) a polypeptide which comprises an amino acid sequence
selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 11,
SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID
NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, and SEQ ID NO:
29; or
[0027] (B) a polypeptide which comprises an amino acid sequence
including deletion, substitution or insertion of one or several
amino acids in the amino acid sequence as defined in (A), and which
has an activity to support proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells.
[0028] (11) The method according to (10), wherein the DNA is a DNA
of the following (a) or (b):
[0029] (a) a DNA which comprises a nucleotide sequence selected
from the group consisting of the nucleotide sequence of nucleotides
1 to 1671 of SEQ ID NO: 8, the nucleotide sequence of nucleotides 1
to 1674 of SEQ ID NO: 10, the nucleotide sequence of nucleotides 1
to 366 of SEQ ID NO: 12, the nucleotide sequence of nucleotides 84
to 1121 of SEQ ID NO: 14, the nucleotide sequence of nucleotides 1
to 1035 of SEQ ID NO: 16, the nucleotide sequence of nucleotides 1
to 444 of SEQ ID NO: 18, the nucleotide sequence of nucleotides 1
to 444 of SEQ ID NO: 20, the nucleotide sequence of nucleotides 630
to 1358 of SEQ ID NO: 22, the nucleotide sequence of nucleotides
132 to 506 of SEQ ID NO: 24, the nucleotide sequence of nucleotides
1 to 2487 of SEQ ID NO: 26, and the nucleotide sequence of
nucleotides 1 to 2496 of SEQ ID NO: 28; or
[0030] (b) a DNA which is hybridizable with a DNA comprising the
nucleotide sequence as defined in (a) or a prove prepared from said
DNA, under the stringent condition, and which has an activity to
support proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells.
[0031] (12) A method for supporting proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells,
comprising the step of culturing hematopoietic stem cells or
progenitor cells in the presence of a polypeptide of the following
(A) or (B), said polypeptide having an activity to support
proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells when the hematopoietic stem cells or
hematopoietic progenitor cells are cultured in the presence of the
polypeptide,
[0032] (A) a polypeptide which comprises an amino acid sequence
selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 11,
SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID
NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, and SEQ ID NO:
29; or
[0033] (B) a polypeptide which comprises an amino acid sequence
including deletion, substitution or insertion of one or several
amino acids in the amino acid sequence as defined in (A), and which
has an activity to support proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells.
[0034] (13) A pharmaceutical composition having an effect to
support proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells, which comprises an effective amount
of a polypeptide of the following (A) or (B), said polypeptide
having an activity to support proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells when
hematopoietic stem cells or hematopoietic progenitor cells are
cultured in the presence of the polypeptide,
[0035] (A) a polypeptide which comprises an amino acid sequence
selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 11,
SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID
NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, and SEQ ID NO:
29; or
[0036] (B) a polypeptide which comprises an amino acid sequence
including deletion, substitution or insertion of one or several
amino acids in the amino acid sequence as defined in (A), and which
has an activity to support proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells.
[0037] Terms used in this specification are defined as follows.
[0038] A hematopoietic stem cell is defined as a cell having
totipotency, that is, ability to differentiate into all the cell
lineages of the blood cells, and having a potency of self-renew
with retaining the totipotency. A hematopoietic progenitor cell is
defined as a cell which can differentiate a single cell lineage of
the blood cell or plural cell lineages but cannot differentiate
into all of the cell lineages. A stromal cell is defined as a cell
which can be co-cultured together with the hematopoietic stem cells
to construct a hematopoietic environment simulating in vivo
hematopoietic environment in vitro. Cells derived from any origin
can be used as long as the cells can be co-cultured with the
hematopoietic cells in vitro.
[0039] Erythrocyte progenitor cells hardly survive and proliferate
in in vitro culture environments and rapidly disappear. If the
survival and proliferation of the erythrocyte progenitor cells are
observed, continuous production of the erythrocyte progenitor cells
is predicted to occur due to the survival and proliferation of the
more immature hematopoietic stem cells or the hematopoietic
progenitor cells. Therefore, in an assessment system of human
hematopoietic stem cells, proliferation of hematopoietic stem cells
or immature hematopoietic progenitor cells can be determined by
using the survival and proliferation of the erythrocyte progenitor
cells (BFU-E, CFU-E, and CFU-E mix) as an index.
BRIEF EXPLANATION OF THE DRAWINGS
[0040] FIG. 1 shows proliferation statuses of hematopoietic stem
cells and hematopoietic progenitor cells determined by a clonogenic
assay after co-culture of CD34-positive hematopoietic stem cells
with AGM-s3 subclone A9, A7, or D11 cells for two weeks.
[0041] FIG. 2 shows proliferation statuses of hematopoietic stem
cells and hematopoietic progenitor cells determined by a clonogenic
assay after co-culture of CD34-positive hematopoietic stem cells
with AGM-s3 subclone A9, A7, or OP9 cells for two weeks.
[0042] FIG. 3 shows time course of donor derived lymphoid lineage
cells or myeloid lineage cells reconstitution in irradiated
recipient mice that received the hematopoietic stem cells
co-cultured with stromal cells.
[0043] FIG. 4 shows proliferation statuses of hematopoietic stem
cells and hematopoietic progenitor cells determined by a clonogenic
assay after co-culture of CD34-positive hematopoietic stem cells
with AGM-S3-A9 cells in which a gene SCR-2 is highly expressed
(A9/SCR-2), AGM-S3-A9 cells into which a control vector is
introduced (A9/pMXIG) or AGM-S3-A9 cells (A9) for two weeks.
[0044] FIG. 5 shows proliferation statuses of hematopoietic stem
cells and hematopoietic progenitor cells determined by a clonogenic
assay after co-culture of CD34-positive hematopoietic stem cells
with AGM-S3-A7 cells in which a gene SCR-2 is highly expressed
(A7/SCR-2), AGM-S3-A7 cells into which a control vector is
introduced (A7/pMXIG) or AGM-S3-A7 cells (A7) for two weeks.
[0045] FIG. 6 shows time course of donor derived lymphoid lineage
cells or myeloid lineage cells reconstitution in peripheral blood
of irradiated recipient mice that received the hematopoietic stem
cells co-cultured with AGM-S3-A7 cells in which a gene SCR-3 is
highly expressed (A7/SCR-3), AGM-S3-A7 cells into which a control
vector is introduced (A7/pMXIG) or AGM-S3-A7 cells.
[0046] FIG. 7 shows proliferation statuses of hematopoietic stem
cells and hematopoietic progenitor cells determined by a clonogenic
assay after co-culture of CD34-positive hematopoietic stem cells
with AGM-S3-A9 cells in which a gene SCR-4 is highly expressed
(A9/SCR-4), AGM-S3-A9 cells into which a control vector is
introduced (A9/pMXIG) or AGM-S3-A9 cells (A9) for two weeks.
[0047] FIG. 8 shows time course of donor derived lymphoid lineage
cells or myeloid lineage cells reconstitution in peripheral blood
of irradiated recipient mice that received the hematopoietic stem
cells co-cultured with AGM-S3-A7 cells in which a gene SCR-5 is
highly expressed (A7/SCR-5), AGM-S3-A7 cells into which a control
vector is introduced (A7/pMXIG) or AGM-S3-A7 cells.
[0048] FIG. 9 shows proliferation statuses of hematopoietic stem
cells and hematopoietic progenitor cells determined by a clonogenic
assay after co-culture of CD34-positive hematopoietic stem cells
with AGM-S3-A9 cells in which a gene SCR-6 is highly expressed
(A9/SCR-6), AGM-S3-A9 cells into which a control vector is
introduced (A9/pMXIG) or AGM-S3-A9 cells (A9) for two weeks.
[0049] FIG. 10 shows proliferation statuses of hematopoietic stem
cells and hematopoietic progenitor cells determined by a clonogenic
assay after co-culture of CD34-positive hematopoietic stem cells
with AGM-S3-A9 cells in which a gene SCR-7 is highly expressed
(A9/SCR-7), AGM-S3-A9 cells into which a control vector is
introduced (A9/pMXIG) or AGM-S3-A9 cells (A9) for two weeks.
[0050] FIG. 11 shows proliferation statuses of hematopoietic stem
cells and hematopoietic progenitor cells determined by a clonogenic
assay after co-culture of CD34-positive hematopoietic stem cells
with AGM-S3-A9 cells in which a gene SCR-8 is highly expressed
(A9/SCR-8), AGM-S3-A9 cells into which a control vector is
introduced (A9/pMXIG) or AGM-S3-A9 cells (A9) for two weeks.
DETAILED DESCRIPTION OF THE INVENTION
[0051] Hereafter, the present invention will be described in detail
below.
[0052] The following genes are those identified as genes of which
expressions are high in AGM-s3-A9 cell line which has the activity
to support hematopoietic stem cells, and low or undetected in
AGM-s3-A7 cell line which does not have the activity to support
hematopoietic stem cells, and determined to have the activities to
support hematopoietic stem cells, of cells in which these gene
groups are highly expressed.
[0053] Gene SCR-2
[0054] The gene is the same gene as a mouse gene, Mus musculus
glypican-1 (GPC-1) of a GenBank accession number AF185613.
[0055] The nucleotide sequence of the gene from mouse and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 8. Only the amino acid sequence is shown in SEQ ID NO:
9.
[0056] The human amino acid sequence of GPC-1 is recorded in
GenBank under an accession number P35052, and the human nucleotide
sequence of GPC-1 is recorded in GenBank database under an
accession number AX020122. It is predicted that the similar
activity is detected in the human gene.
[0057] The nucleotide sequence of the gene from human and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 10. Only the amino acid sequence is shown in SEQ ID NO:
11.
[0058] Glypican is a major hepran sulfate proteoglycan existing on
a cell surface, and have a characteristic structure such as
cysteine rich globular domain, short glycosaminoglycan binding
domain, glycosylphosphatidyl-inositol membrane binding domain. Six
family genes from glypican-1 to glypican-6 have been found (J Biol
Chem 1999 Sep. 17; 274(38):26968-77, Glypican-6, a new member of
the glypican family of cell surface heparan sulfate proteoglycans.
Veugelers M, De Cat B, Ceulemans H, Bruystens A M, Coomans C, Durr
J, Vermeesch J, Marynen P, David G).
[0059] With respect to biological activities of GPC-1, there are a
number of reports: To regulate growth stimulating activity of
heparin binding growth factors (fibroblast growth factor 2 (FGF2),
heparin-binding EGF-like growth factor (HB-EGF)) to promote
proliferation of cancer cells showing autocrine proliferation by
stimulation by the growth factors (J Clin Invest 1998 Nov. 1;
102(9):1662-73, The cell-surface heparan sulfate proteoglycan
glypican-1 regulates growth factor action in pancreatic carcinoma
cells and is overexpressed in human pancreatic cancer, Kleeff J,
Ishiwata T, Kumbasar A, Friess H, Buchler M W, Lander A D, Korc
M).
[0060] To bind HGF (hepatocyte growth factor) to promote reactivity
with cytokines, of antigen-specific B cells. To participate in
association of a cell with an adhesive molecule to involve in
invasion of the cell (J Biol Chem 1998 Aug. 28; 273(35):22825-32,
Heparan sulfate proteoglycans as adhesive and anti-invasive
molecules. Syndecans and glypican have distinct functions, Liu W,
Litwack E D, Stanley M J, Langford J K, Lander A D, Sanderson R D).
These findings show that GPC-1 involves in activity expression of
various cell-stimulating factors. Also, there is a report that
expression of the glypican family gene in bone marrow is confirmed
(Biochem J 1999 Nov. 1; 343 Pt 3:663-8, Expression of proteoglycan
core proteins in human bone marrow stroma, Schofield K P, Gallagher
J T, David G reports, it is not described about effects of GPC-1 on
hematopoietic stem cells or hematopoietic progenitor cells.
[0061] Gene SCR-3
[0062] The gene is the same gene as mouse genes, Mus musculus
chemokine MMRP2 mRNA of a GenBank accession number U15209, Mus
musculus C10-like chemokine mRNA of U19482 and mouse macrophage
inflammatory protein-1gamma mRNA of U49513.
[0063] The nucleotide sequence of the gene from mouse and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 12. Only the amino acid sequence is shown in SEQ ID NO:
13.
[0064] Gene SCR-4
[0065] The nucleotide sequence of the gene from mouse and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 14. Only the amino acid sequence is shown in SEQ ID NO:
15.
[0066] It has been found that the sequence has a high homology to
Homo sapiens clone 25077 mRNA of a GenBank accession number
AF131820, and that it is considered to be a mouse ortholog. This
sequence is described in WO 00/66784.
[0067] The nucleotide sequence of the gene from human and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 16. Only the amino acid sequence is shown in SEQ ID NO:
17.
[0068] Gene SCR-5
[0069] The nucleotide sequence of the gene from mouse and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 18. Only the amino acid sequence is shown in SEQ ID NO:
19.
[0070] It has been found that the sequence has a high homology with
Homo sapiens esophageal cancer related gene 4 protein (ECRG4) mRNA
of a GenBank accession number AF325503, and that it is considered
to be a mouse ortholog of AF325503.
[0071] The nucleotide sequence of the gene from human and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 20. Only the amino acid sequence is shown in SEQ ID NO:
21.
[0072] Gene SCR-6
[0073] The nucleotide sequence of the gene from mouse and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 22. Only the amino acid sequence is shown in SEQ ID NO:
23.
[0074] Gene SCR-7
[0075] The nucleotide sequence of the gene from mouse and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 24. Only the amino acid sequence is shown in SEQ ID NO:
25.
[0076] Gene SCR-8
[0077] The gene is the same gene as Mus musculus mRNA for ADAM23 of
a GenBank accession number AB009673.
[0078] The nucleotide sequence of the gene from mouse and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 26. Only the amino acid sequence is shown in SEQ ID NO:
27.
[0079] The sequence has a high homology with a sequence described
by JP 11155574-A and the sequence described by JP 11155574-A is
considered to be a human ortholog.
[0080] The nucleotide sequence of the gene from human and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 28. Only the amino acid sequence is shown in SEQ ID NO:
29.
[0081] Polypeptides which are products of these genes have an
activity to support proliferation or survival of hematopoietic stem
cells or hematopoietic progenitor cells. The expression that a
polypeptide has an activity to support proliferation or survival of
hematopoietic stem cells or hematopoietic progenitor cells means
that proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells is supported in the presence of the
polypeptide or in the presence of stroma cells expressing the
polypeptide.
[0082] Therefore, the present invention provides use of the
polypeptides and DNAs encoding the polypeptides and novel
polypeptides among the polypeptides and DNAs encoding the novel
polypeptides.
[0083] A stem cell proliferation-supporting factor which is a
polypeptide encoded by the DNA can be produced by introducing the
DNA into a suitable host to prepare a transformant cell, and
allowing the DNA to be expressed in the transformant cell.
[0084] The DNA may encode the above described factors which have
amino acid sequences including substitution, deletion or insertion
of one or several amino acids, as long as the activity of the stem
cell proliferation-supporting factor to be encoded is not lost.
DNAs encoding substantially equivalent polypeptides to this stem
cell proliferation-supporting factor can be obtained by modifying
the nucleotide sequences so as to include substitution, deletion,
insertion, addition, or inversion of amino acid residues in a
specific region using site-directed mutagenesis.
[0085] The DNAs including the above described mutation can be
expressed in appropriate cells and the activity to support
hematopoietic stem cells, of the expressed products can be
examined, so that the DNAs encoding the polypeptide having
functions which are substantially equivalent to this stem cell
proliferation-supporting factor are obtained. In addition, the DNAs
encoding substantially equivalently active protein as this stem
cell proliferation-supporting factor can be obtained by isolating
DNAs which hybridize with DNAs including, for example, the
nucleotide sequence as described in SEQ ID NO: 8, 10, 12, 14, 16,
18, 20, 22, 24, 26 or 28 from the cells having the DNA, or probes
prepared from these DNAs under the stringent condition; and which
encode proteins possessing the activity to support hematopoietic
stem cells. The length of the probe is usually 30 to 1000
nucleotides. The stringent condition is, for example, one in which
DNAs having homology (determinable with homology search in the
compare function of DNASIS version 3.7 (Hitachi Software
Engineering)) at not less than 70%, preferably at not less than
80%, are hybridized each other and DNAs having less homology than
those are not hybridized each other. The above described stringent
condition may be 6.times.SSC, 5.times.Denhardt, 0.5% SDS,
68.degree. C. (SSC; 3 M NaCl, 0.3 M sodium citrate)
(50.times.Denhardt; 1% BSA, 1% polyvinyl pyrrolidone, 1% Ficoll
400) or 6.times.SSC, 5.times.Denhardt, 0.5% SDS, 50% Formamide,
42.degree. C., or the like.
[0086] Microorganisms such as Escherichia coli and yeast, culture
cells derived from animals or plants, and the like are used for
host cells for expressing the DNA. Preferably, culture cells
derived from mammals are used as the host cells. In the case that
prokaryotic cells are used as the host cells, the expression is
preferably performed in a condition in which a signal peptide
region is replaced with a leader sequence suitable for the
prokaryotic cells such as .beta.-lactamase (bla), alkaline
phosphatase (phoA), and outer membrane protein A (ompA) and the
like, or in a form in which a methionine residue is added to the
N-terminal site of the mature protein.
[0087] The introduction of the DNA to the host cell can be carried
out by, for example, incorporating the DNA into a vector suitable
for the host in an expressible form, and introducing the resultant
recombinant vector to the host cell.
[0088] Examples of the culture cells derived from mammals include
CHO cell, 293 cell, COS7 cell, and the like. Gene expression
regulatory sequence such as a promoter to express the DNA may be
originated from the gene itself, or may be derived from other genes
such as cytomegalovirus promoter and elongation factor 1 promoter
and the like.
[0089] Examples of a vector for animal culture cells include
plasmid vectors, retrovirus vectors, adenovirus vectors (Neering,
S. J., Blood, 88: 1147, 1996), herpes virus vectors (Dilloo, D.,
Blood, 89: 119, 1997), HIV vectors, and the like.
[0090] In order to introduce the recombinant vector into culture
cells, the conventional methods which are usually employed for
transformation of culture cells such as calcium phosphate
transfection, the liposome method, the DEAE dextran method, the
electroporation method and the microinjection method are
employed.
[0091] The polypeptides of the present invention also comprise
polypeptides having amino acid sequences in which one or several
amino acids are substituted, deleted or inserted in the amino acid
sequence represented in SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23,
25, 27 or 29, and having activity to support hematopoietic stem
cells in addition to the polypeptides having the amino acid
sequence represented in SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23,
25, 27 or 29. That is, even if mouse and human stem cell
proliferation-supporting factors are modified by substitution,
deletion, insertion or the like, polypeptides holding essential
functions as a stem cell proliferation-supporting factor can be
considered to be substantially equivalent to the stem cell
proliferation-supporting factor.
[0092] These modified stem cell proliferation-supporting factors
can be obtained by treating DNA encoding the stem cell
proliferation-supporting factor or host cells including the above
mentioned DNA with a mutagen, or by mutating the above mentioned
DNA so as to substitute, delete, or insert an amino acid at a
specific site using site-directed mutagenesis. The residual of the
activity to support the hematopoietic stem cells in the obtained
mutant polypeptide is confirmed by tranferring hematopoietic stem
cells cultured in the presence of the mutant polypeptides into
irradiated mice, and monitoring peripheral hematological
cellularity over time, as in the examples described below.
[0093] As for the amino acid deletion, the polypeptide may be a
fragment which lacks an amino acid sequence at the N-terminal end
and/or the C-terminal end. The fragment lacking the amino acid
sequence at the N-terminal end and/or the C-terminal end can be
obtained by a usual method, and the hematopoietic stem
cell-supporting activity of the fragment can be determined by a
similar way to that described with respect to the mutated
polypeptide. In particular, if there is a portion predicted as a
signal sequence or a transmembrane region in the amino acid
sequence, a fragment having the hematopoietic stem cell-supporting
activity is predicted by using it as an index. For example, a
protein encoded by human SCR-8 is a transmembrane protein of type I
passing through the membrane once, and it is therefore predicted
that even if it made to be a soluble protein lacking the
transmembrane region, it has the activity to support to
proliferation or survival of hematopoietic stem cells or
hematopoietic progenitor cells. The transmembrane region can be
predicted with a known program based on the amino acid sequence.
For example, if it is predicted with a program called PSORT II
(available through the Internet, URL:
http://psort.nibb.ac.jp/index.html), the transmembrane region is
amino acids at positions 790 to 806 in SEQ ID NO: 29, and it is
predicted that even if a fragment up to position 789, the fragment
has activity to support proliferation or survival of hematopoietic
stem cells or hematopoietic progenitor cells.
[0094] Since the nucleotide sequences of the above described DNAs
have been clarified by the present invention, the DNAs can be also
obtained by isolating the corresponding DNAs from mouse or human
cDNA or chromosome DNA libraries using PCR in which the
oligonucleotides prepared based on these nucleotide sequences are
used as primers or using hybridization in which the
oligonucleotides prepared based on these nucleotide sequences are
used as probes.
[0095] In order to complete the present invention, the DNAs of the
present invention have been isolated from cDNA library of AGM-s3-A9
cells which are a mouse stromal cell line having the activity to
support the hematopoietic stem cells, using SBH (Sequencing By
Hybridization) method (Drmanac, S., Nat. Biotechnol., 16, 54, 1998;
Drmanac, R., Methods. Enzymol., 303, 165, 1999) as described below.
The mouse stromal cell lines having the activity to support the
hematopoietic stem cells can be obtained using the method disclosed
in WO99/03980 or from Cell Bank of Institute of Physical and
Chemical Research (RIKEN) or ATCC.
[0096] An outline of SBH method will be described below. Probes
having eight or nine nucleotides whose sequences are different from
each other are prepared. When the nucleotide sequences
corresponding to those of the probe exist in a targeted gene, the
probes can hybridize with the gene. The hybridization can be easily
detected with utilization of radio isotope- or
fluorescence-labelled probes. Each clone in the library is picked
up, and blotted on a membrane. Then, the repeated hybridizations
are performed with the each of above described probes, so that one
can identify the combination of probes that hybridize to each
clone. Since the combination of hybridized probes depends on genes,
the combination of probes which hybridize to an identical gene is
the same. That is, the same gene can be identified as one group
(cluster) according to the combination of the hybridized probes.
The number of clones of each gene in the cDNA library can be
determined by classifying each clone in the library based on
patterns of the hybridized probes and counting the classified
clones. Thus, frequency of expression of each gene in the library
can be determined.
[0097] cDNA libraries are prepared from cells having an activity to
support the hematopoietic stem cells and from cells not having the
activity. Clustering is performed for the cDNA libraries. Statuses
of expressed genes among cells are compared, so that the genes
highly expressed with specificity to the supporting cells are
selected. The expression statuses of these genes in each of above
described cells are further examined by Northern blot analysis, so
that genes which are highly expressed in the cells having the
activity to support the hematopoietic stem cells are obtained.
[0098] The above mentioned genes are the genes which are highly
expressed with specificity to the supporting cells and which are
obtained through the above described process. Full-length genes
have been cloned from the cDNA library derived from AGM-s3-A9
cell.
[0099] Further, in order to determine an ability of gene products
to support hematopoiesis, a gene fragment including gene ORF was
transferred into stromal cells using a retrovirus vector, and the
change in the activity to support the hematopoietic stem cells of
the stromal cells was determined. Specifically, after the stromal
cells into which the gene was not introduced or into which a
control vector was introduced and those into which the gene was
introduced were each co-cultured with the mouse hematopoietic stem
cells, the hematopoietic cells were transplanted into irradiated
mice. The engraftment of the co-cultured hematopoietic cells in
recipient mice were examined. As a result, the mice into which the
hematopoietic stem cells co-cultured with the gene-introduced cells
were transplanted, showed increased chimerism after the
transplantation compared with co-culture with the cells into which
the gene was not introduced. This result shows that in the
gene-expressed stromal cells, an activity to support the
proliferation or survival of the hematopoietic stem cells or the
hematopoietic progenitor cells is increased or imparted. As a
result, it has become evident that expression of the above
described genes has a function to increase the above described
activity in the stromal cells or impart the activity to the stromal
cells. Therefore, it is revealed that products of the genes affect
hematopoietic stem cells or hematopoietic progenitor cells to show
an activity to support the survival or the proliferation thereof,
or affect stromal cells to show an activity to increase an activity
to support the hematopoietic stem cells therein or impart the
activity thereto.
[0100] The polypeptides of the present invention can be used as a
medicine to proliferate or support human hematopoietic stem cells
or human hematopoietic progenitor cells when they affect
hematopoietic stem cells or hematopoietic progenitor cells to show
an activity to support survival or proliferation thereof, in other
words, the polypeptides have an activity to support survival or
proliferation of hematopoietic stem cells or hematopoietic
progenitor cells if the hematopoietic stem cells or the
hematopoietic progenitor cells are cultured in the presence of the
polypeptides. The pharmaceutical composition can be used for
supporting proliferation or survival of human hematopoietic stem
cells or human hematopoietic progenitor cells in vitro. For
hematopoietic stem cell transplantation therapies such as
peripheral blood stem cell transplantation and cord blood stem cell
transplantation, a sufficient amount of the hematopoietic stem
cells sometimes cannot be collected and the transplantation may not
be performed. Even if the enough amount of the stem cells can not
be collected, the enough amount of the hematopoietic stem cells can
be obtained and transplanted by amplification of the hematopoietic
stem cells in vitro using this polypeptides. That is, the
hematopoietic stem cells can be amplified without differentiation
by culturing the hematopoietic stem cells in culture medium
including these polypeptides. It may be considered the
hematopoietic stem cells are able to be amplified more efficiently
with addition of a variety of cytokines to the medium.
[0101] When the hematopoietic stem cells or the hematopoietic
progenitor cells are cultured in the medium including the
polypeptides of the present invention, the hematopoietic stem cells
or the hematopoietic progenitor cells used may be isolated one of
these cell types alone or may be both of the cell types. In
addition, the cells may include at least the hematopoietic stem
cells or the hematopoietic progenitor cells, and include other
hematopoietic cells. Further, it can be used a fraction containing
hematopoietic stem cells or progenitor cells fractionated from the
cell population that contain the hematopoietic stem cells or
progenitor cells.
[0102] Examples of sources of the hematopoietic stem cells and the
hematopoietic progenitor cells in the method of the present
invention include a fetal liver, bone marrow, fetal bone marrow,
peripheral blood, the peripheral blood from persons whose stem
cells are mobilized by administration of cytokines and/or antitumor
drugs, cord blood, and the like of mammals such as human and mouse
and the like. Any sources may be used as long as the tissue
includes the hematopoietic stem cells.
[0103] A culture method using petri dishes and flasks for culture
may be employed to culture the hematopoietic stem cells or the
hematopoietic progenitor cells. The cultivation of the
hematopoietic stem cells and/or progenitor cells may be improved by
mechanically controlling medium composition, pH, and the like, and
using a bioreactor capable of high density cultivation (Schwartz,
Proc. Natl. Acad. Sci. U.S.A., 88: 6760, 1991; Koller, M. R.,
Bio/Technology, 11: 358, 1993; Koller, M. R., Blood, 82: 378, 1993;
Palsson, B. O., Bio/Technology, 11: 368, 1993).
[0104] The stromal cells in which DNAs encoding the polypeptide of
the present invention can be obtained as described with respect to
the expression of the DNAs.
[0105] The co-culture of the stromal cells and the hematopoietic
cells can be performed simply after the collection of the bone
marrow cells without further separation. Furthermore, co-culture
can be performed by separating components such as stromal cells,
hematopoietic cells and other cell populations from collected bone
marrow and combining them with the hematopoietic cells and stromal
cells which are not from the individual from which the bone marrow
is collected. Furthermore, after stromal cells are cultured to grow
to the stromal cells, hematopoietic cells can be added to perform
co-culture with the hematopoietic stem cells. At this time, cell
stimulating factors can added to the culture system of stromal
cells to more effectively support proliferation and survival.
Concrete examples of the cell stimulating factor include a growth
factor which is typically a cytokine such as SCF (stem cell
factor), IL-3 (interleukin 3), GM-CSF (granulocyte/macrophage
colony-stimulating factor), IL-6 (interleukin 6), TPO
(thrombopoietin), G-CSF (granulocyte colony-stimulating factor),
TGF-b (transforming growth factor-b), MIP-1a (Davatelis, G., J.
Exp. Med. 167: 1939, 1988); a differentiation and proliferation
control factor such as hematopoietic hormones such as EPO
(erythropoietin), chemokine, Wnt gene product, and notch ligand;
and a development control factor.
[0106] In addition, when the polypeptide of the present invention
affects hematopoietic stem cells or hematopoietic progenitor cells
to show an activity to support survival or proliferation thereof,
in other words, the polypeptide has an activity to support survival
or proliferation of hematopoietic stem cells or hematopoietic
progenitor cells if the hematopoietic stem cells or the
hematopoietic progenitor cells are cultured in the presence of the
polypeptide, the proliferation and the survival of the
hematopoietic stem cells or the hematopoietic progenitor cells can
be retained by allowing the recombinant polypeptide of the present
invention alone or in combination with the cell stimulating factors
to affect hematopoietic stem cells or hematopoietic progenitor
cells, without stromal cells. Examples of the cell stimulating
factors used in this case are above described cell stimulating
factors and the like.
[0107] Medium used for the culture is not specially restricted as
long as the proliferation or the survival of the hematopoietic stem
cells or the hematopoietic progenitor cells is not harmed.
Preferable media are, for example, MEM-.alpha. medium (GIBCO BRL),
SF-02 medium (Sanko Junyaku), Opti-MEM medium (GIBCO BRL), IMDM
medium (GIBCO BRL), and PRMI1640 medium (GIBCO BRL). A culture
temperature is usually ranging from 25 to 39.degree. C., and
preferably ranging from 33 to 39.degree. C. Examples of additives
to the medium are fetal bovine serum, human serum, horse serum,
insulin, transferrin, lactoferrin, ethanolamine, sodium selenite,
monothiolglycerol, 2-mercaptoethanol, bovine serum albumin, sodium
pyruvate, polyethylene glycol, a variety of vitamins, and a variety
of amino acids. A concentration of CO.sub.2 is usually ranging from
four to six percent, and preferably five percent.
[0108] Since the hematopoietic stem cells can differentiate into
all the hematopoietic cell lineages, the hematopoietic stem cells
can be amplified and differentiated into a specific cell type in
vitro, and then the specific cells can be transplanted. For
example, when erythrocytes are necessary, after the cultivation of
the patient's stem cells to amplify them, the hematopoietic cells
whose main component is the erythrocyte can be artificially
produced using an erythrocyte differentiation induction-promoting
factor such as EPO.
[0109] The hematopoietic stem cells or the hematopoietic progenitor
cells cultured using the polypeptides of the present invention can
be used as a graft for blood cell transplantation replacing the
conventional bone marrow transplantation or cord blood
transplantation. Transplantation of the hematopoietic stem cells is
superior to the conventional blood cell transplantation therapy,
since the engraftment can last semipermanently.
[0110] The transplantation of the hematopoietic stem cells can be
employed as therapy for a variety of diseases in addition to
combination therapy with total body X-ray irradiation therapy or
advanced chemotherapy for leukemia. For example, when therapy
accompanied with myelosuppression as an adverse reaction, such as
chemotherapy, radiation therapy, and the like is performed for the
patient with solid cancer, the patient can get benefit of early
recovery and stronger chemotherapy than the conventional one can be
performed to improve the therapeutic effect of the chemotherapy by
collecting the bone marrow before the therapy, allowing the
hematopoietic stem cells or the hematopoietic progenitor cells to
be amplified in vitro and returning the amplified cells to the
patient after the therapy. In addition, by allowing the
hematopoietic stem cells or the hematopoietic progenitor cells
obtained according to the present invention to be differentiated
into a variety of hematopoietic cells and transplanting these cells
into a patient with hypoplasia of a given hematopoietic cells, the
patient's deficient status can be improved. In addition, this
therapy can improve dyshemopoietic anemia to develop anemia such as
aplastic anemia caused by bone marrow hypoplasia. Furthermore,
examples of diseases in which the transplantation of the
hematopoietic stem cells according to the present invention is
effective include immunodeficiency syndrome such as chronic
granulomatous disease, duplicated immunodeficiency syndrome,
agammaglobulinemia, Wiskott-Aldrich syndrome, acquired
immunodeficiency syndrome (AIDS), and the like, thalassemia,
hemolytic anemia due to an enzyme defect, congenital anemia such as
sicklemia, Gaucher's disease, lysosomal storage disease such as
mucopolysaccharidosis, adrenoleukodegeneracy, a variety of cancers
and tumors, and the like.
[0111] Transplantation of the hematopoietic stem cells may be
performed in the same manner as the conventional bone marrow
transplantation or cord blood transplantation other than the
differences of the cells used.
[0112] The source of the hematopoietic stem cells which may be used
for the above described hematopoietic stem cell transplantation is
not restricted to the bone marrow, and the above described fetal
liver, the fetal bone marrow, the peripheral blood, the peripheral
blood with stem cells mobilized by administration of cytokines
and/or antitumor drugs, the cord blood, and the like may be
used.
[0113] The graft may be a composition including buffer solution and
the like in addition to the hematopoietic stem cells and the
hematopoietic progenitor cells produced by the method according to
the present invention.
[0114] The hematopoietic stem cells or the hematopoietic progenitor
cells produced according to the present invention may be used for
ex vivo gene therapy. Because of the low frequency of recombination
of target genes to the chromosome because the stem cells are in the
resting state, differentiation of the stem cells during the culture
period, and the like, the gene therapy to the hematopoietic stem
cells has been hard to be established. However, the present
invention can amplify the stem cells without differentiation, so
that efficacy of gene transfer is expected to be remarkably
improved. In this gene therapy, a foreign gene (a gene for therapy)
is transferred into the hematopoietic stem cells or the
hematopoietic progenitor cells, and then the obtained
gene-transferred cells are used. The foreign gene to be transferred
is appropriately selected according to disease. Examples of
diseases in which the target cells of the gene therapy are the
hematopoietic cells include immunodeficiency syndrome such as
chronic granulomatous disease, duplicated immunodeficiency
syndrome, agammaglobulinemia, Wiskott-Aldrich syndrome, acquired
immunodeficiency syndrome (AIDS), and the like, thalassemia,
hemolytic anemia due to an enzyme defect, congenital anemia such as
sicklemia, Gaucher's disease, lysosomal storage disease such as
mucopolysaccharidosis, adrenoleukodegeneracy, a variety of cancers
and tumors, and the like.
[0115] A usual method used for transfer of a gene into animal cells
is employed for the transfer of the gene for the therapy into the
hematopoietic stem cells or the hematopoietic progenitor cells.
Examples include a method using a vector for animal cells derived
from virus utilized for a gene therapy such as retrovirus vectors
such as Moloney mouse leukemia virus, adenovirus vectors,
adeno-associated virus (AAV) vectors, herpes simplex virus vectors,
and HIV vectors (with respect to a vector for gene therapy, see
Verma, I. M., Nature, 389: 239, 1997); calcium phosphate
transfection, DEAE-dextran transfection, electroporation, the
liposome method, the lipofection method, the microinjection method,
and the like. Among them, the method using the retrovirus vector,
the adeno-associated virus vector, or the HIV vector is preferable,
since permanent expression of a gene is expected due to insertion
into the chromosome DNA of a target cell.
[0116] For example, the adeno-associated virus (AAV) vector can be
prepared as follows. First, a vector plasmid in which a gene for
therapy is inserted into ITR (inverted terminal repeat) at both
ends of wild-type adeno-associated virus DNA and a helper plasmid
for supplementing virus proteins are transfected into 293 cell
line. Next, adenovirus as helper virus is infected, so that virus
particles including the AAV vector are produced. Alternatively,
instead of adenovirus, a plasmid which expresses adenovirus gene
having helper function may be transfected. The hematopoietic stem
cells or the hematopoietic progenitor cells are infected with the
obtained virus particles. Preferably, appropriate promoter,
enhancer, insulator and the like are inserted into the upstream
region of the target gene in the vector DNA, so that the expression
of the gene is regulated. When a marker gene such as a drug
resistant gene is used in addition to the gene for therapy, cells
into which the gene for therapy are transferred are easily
selected. The gene for therapy may be a sense gene or an antisense
gene.
[0117] A composition for gene therapy may include a buffer solution
and a novel active ingredient and the like in addition to the
hematopoietic stem cells or the hematopoietic progenitor cells by
the method according to the present invention.
[0118] A vector for gene therapy can be produced by incorporating
the DNA of the present invention in an expression vector using a
usual method. This vector for gene therapy is useful to treat
diseases which need survival and proliferation of the human
hematopoietic stem cells. That is, the vector for gene therapy is
transferred into the hematopoietic stem cells and the cells are
cultured in vitro, so that the hematopoietic stem cells or the
hematopoietic progenitor cells can proliferate dominatingly. The
proliferation of hematopoietic stem cells in vivo can be caused by
returning these hematopoietic stem cells thus treated. The
proliferation of hematopoietic stem cells in vivo can significantly
promoted by introducing this vector for gene therapy into the body.
Alternatively, the bone marrow cells derived from a patient are
cultured as it is and this vector for gene therapy is transferred
thereto, so that the hematopoietic stem cells or the hematopoietic
progenitor cells can be proliferated in a culture system.
Alternatively, this vector for gene therapy is transferred into the
stromal cells and mesenchaymal stem cells obtained by isolating and
culturing stromal cells from the bone marrow, so that the activity
to support the hematopoietic stem cells can be added or
increased.
[0119] As shown in Examples, since it is possible that by
introducing the DNA of the present invention into the stromal cells
without the activity to support the hematopoietic stem cells, this
activity can be imparted, stromal cells having the activity to
support the hematopoietic stem cells can be prepared by gene
transfer to stromal cells derived from human or mouse. The stromal
cells expressing the DNA of the present invention and the
hematopoietic stem cells or the hematopoietic progenitor cells are
co-cultured, so that the hematopoietic stem cells or the
hematopoietic progenitor cells can survive and proliferate so as to
be useful for a variety treatment.
[0120] Since the hematopoietic stem cells or the hematopoietic
progenitor cells can survive and proliferate by expression of the
DNA of the present invention in the stromal cell, an activity to
support the hematopoietic stem cells of the stromal cells can be
determined using the expression of the DNA of the present invention
as an index. The expression of the DNA of the present invention in
the stromal cells can be confirmed using an antibody against a
polypeptide encoded by the DNA of the present invention. Also, PCR
primers can be prepared based on nucleotide sequences, and RNA is
prepared from the stromal cells of interest, and RT-PCR is
performed, so that the expression of the DNA of the present
invention can be confirmed. The antibody will be described
below.
[0121] The pharmaceutical composition of the present invention can
be administered to human. The pharmaceutical composition having an
activity to proliferate or to support the human hematopoietic stem
cells or the hematopoietic progenitor cells can be produced by
mixing medically acceptable diluent, stabilizer, carrier, and/or
other additives with the polypeptides of the present invention. At
this time, in order to increase the stability of the protein in
vivo, the polypeptides of the present invention may be modified by
a modifying agent. Examples of the modifying agent include
polyethylene glycol (PEG), dextran, poly(N-vinyl-pyrrolidone),
polypropylene glycol homopolymer, polypropylene oxide/ethylene
oxide copolymer, polyoxyethylated polyol, polyvinyl alcohol, and
the like. The modification of the protein with PEG can be performed
by, for example, a method in which activated ester derivatives of
PEG is reacted with the protein, a method in which aldehyde
derivatives at the terminal portion of PEG is reacted with the
protein in the presence of a reducing agent, and the like. Japanese
Patent Application Laid-Open No. 10-510980 discloses such protein
modification in detail.
[0122] When the pharmaceutical composition of the present invention
is administered to human, recovery from hematological suppression
due to an adverse drug reaction of carcinostatics; early recovery
of hematopoietic cells at bone marrow transplantation, peripheral
blood stem cell transplantation, or cord blood transplantation; and
recovery of hematopoietic function at pancytopenia such as aplastic
anemia (AA) and myelodysplastic syndrome (MDS) are expected.
[0123] The antibodies of the present invention react specifically
to the above described polypeptides of the present invention. The
antibodies of the present invention may be monoclonal antibodies or
polyclonal antibodies as long as they react specifically to the
above described polypeptides.
[0124] The antibodies of the present invention can be prepared
according to usual methods. For example, the antibodies can be
prepared either in vivo method in which animals are additionally
immunized by an antigen together with adjuvant once or several
times at an interval of several weeks or in vitro method in which
immune cells are isolated and sensitized in an appropriate culture
system. Examples of immune cells which can produce the antibodies
of the present invention include splenic cells, tonsillar cells,
lymph gland cells, and the like.
[0125] The whole polypeptide according to the present invention is
not necessarily used as an antigen. A part of this polypeptide may
be used as an antigen. When the antigen is a short peptide,
particularly, a peptide made of about 20 amino acid residues, it
may be used by binding it to a carrier protein having high
antigenicity such as keyhole lympet hemocyanin or bovine serum
albumin using chemical modification and the like. Alternatively,
the antigen may be used by covalently binding it to peptide having
branching skeleton such as lysine core MAP peptide instead of the
carrier protein (Posnett et al., J. Biol. Chem., 263, 1719-1725,
1988; Lu et al., Mol. Immunol., 28, 623-630, 1991; Briand et al.,
J. Immunol. Methods, 156, 255-265, 1992).
[0126] Examples of adjuvant include Freund's complete adjuvant,
Freund's incomplete adjuvant, aluminum hydroxide gel, and the like.
Antigen-given animals are, for example, mouse, rat, rabbit, sheep,
goat, chicken, bovine, horse, guinea pig, hamster, and the like.
The blood is collected from these animals and the serum is
separated. Then, immunoglobulin is purified from the serum using an
ammonium sulfate precipitation method, anion exchange
chromatography, protein A chromatography, or protein G
chromatography to obtain polyclonal antibodies.
[0127] With respect to chicken, antibodies can be purified from an
egg. Monoclonal antibodies can be prepared by purification from
supernatant of culture of hybridoma cells which are made by fusion
of the immune cells sensitized in vitro, or immune cells from the
above described animals with parent cells capable of cultivation,
or ascites from animals which received intraperitoneal
administration of hybridoma cells. Examples of parent cells include
X63, NS-1, P3U1, X63.653, SP2/O, Y3, SK0-007, GM1500, UC729-6,
HM2.0, NP4-1 cell lines, and the like. Preparation may be performed
by cultivating the immortalized antibody-forming cells obtained by
sensitization in vitro, or infection of a proper virus such as EB
virus to the immune cells of the above described animals.
[0128] In addition to these cell engineering methods, the
antibodies can be obtained using gene engineering methods. For
example, the antibody gene obtained from the in vitro sensitized
cells or immune cells derived from the above described animals is
amplified by PCR (polymerase chain reaction) and isolated, and the
amplified genes are transferred into microorganisms such as E. coli
to produce the antibodies. Alternatively, the antibodies may be
expressed on surfaces of phages as fused proteins.
[0129] By measuring polypeptides in vivo using the antibodies of
the present invention, the relationship between the polypeptides
and pathological status of a variety of diseases can be clarified.
Moreover, the antibodies can be used for diagnosis and treatment of
diseases, and efficient affinity purification of the
polypeptides.
[0130] The present invention provides polypeptides having an
activity to support survival or proliferation of hematopoietic stem
cells or hematopoietic progenitor cells by effecting thereon, or an
activity to impart an activity to support the hematopoietic stem
cells to stromal cells by effecting thereon, and also provides DNAs
encoding thereof. The polypeptides of the present invention can
efficiently maintain the proliferation or the survival of the
hematopoietic stem cells or the hematopoietic progenitor cells.
BEST MODE FOR CARRYING OUT THE INVENTION
[0131] Hereafter, the present invention will be described in detail
by reference to examples.
Example 1 Preparation of Fragment of Gene which is Specifically
Expressed in Hematopoietic Stem Cell-Supporting Cells
[0132] (I) Preparation of Stromal Cell Line Derived from Mouse AGM
(1) Isolation of AGM Region from Fetal Mouse
[0133] C3H/HeNSLc mice of both genders (purchased from Japan SLC
INC.) were kept under a SPF (specific pathogen-free) environment.
One or two female mice and one male mouse were placed in the same
cage over a night. In the next morning, the female mice in which
the existence of a vaginal plug was observed were transferred to
other cages and kept. The day when the existence of the vaginal
plug was observed was defined to be the 0.5th day of pregnancy. On
the 10.5th day of the pregnancy, after mouse was sacrificed by
cervical dislocation, fetuses were extirpated. Isolation of AGM
regions was performed according to the method by Godin et al.
(Godin, I., Proc. Natl. Acad. Sci. U.S.A., 92: 773-777, 1995) and
the method by Medvinsky et al. (Medvinsky, A. L., Blood, 87:
557-565, 1996). The fetuses were placed in a culture dishes to
which PBS(-) (phosphate buffered saline) (produced by Nissui
Seiyaku) was added in a volume just sufficient to cover the
fetuses. After the AGM regions were carefully excised so as not to
include other regions under a stereoscopic microscope, they were
put in another 24-well culture dish (Nunc).
(2) Establishment of Cell Lines Derived from AGM
[0134] One drop of MEM medium (Sigma) containing 10% FCS (Hyclone)
was added to the AGM regions in the 24-well culture dish (Nunc),
and AGM regions were cultured in an incubator overnight. The
culture was performed in the MEM medium (Sigma) containing 10% FCS
(Hyclone) at 37.degree. C., in an atmosphere of 5% CO.sub.2, and at
a humidity of 100%. When the cells of the AGM regions adhered to
the culture dish due to overnight cultivation, two milliliters of
MEM medium containing 10% FCS was further added. Stromal cells
began to appear around the AGM region tissue fragment after the
continuous cultivation. After one-week cultivation, adhesive cells
were separated by trypsin treatment (0.05% trypsin in PBS
containing 0.53 mM EDTA (Gibco BRL) at 37.degree. C. for three to
five minutes). The stromal cells were then washed twice with the
medium, and seeded on 6-well culture dish (Nunc). On the next day,
the cells which did not adhere to the culture dish and the medium
were removed, and then, fresh medium was added. Two weeks after
transfer to the 6-well culture dish, cells were
.gamma.-ray-irradiated at 900 Rad to eliminate endogenous
hematopoietic cells. An attempt of the direct cell cloning by
limiting dilution from this culture system was made, but no cell
proliferation was observed and the cloning ended in failure. Then,
after the number of seeded cells in one well was increased and
cells were adapted so as to be able to proliferate from a small
number of cells, the cells were cloned by limiting dilution.
[0135] Specifically, the AGM was extirpated and cultured in the
same manner as described above. The culture system two weeks after
the .gamma.-ray radiation was trypsinized (0.05% trypsin in PBS
containing 0.53 mM EDTA at 37.degree. C. for three to five minutes)
to suspend the cells, and the cells were seeded in a 24-well
culture dish at 50 to 100 cells/well. After the culture was
continued for three weeks, the cells were seeded in a 96-well
culture dish (Nunc) by means of limiting dilution, at 0.3
cells/well. The cells which were grown from the well in which only
one cell was seeded were allowed to enlarge culture. As a result,
the cells were successfully cloned to obtain fibroblast-like cells
and cobble stone-like cells.
[0136] A CD34-positive cell fraction derived from the human cord
blood was co-cultured with the fibroblast-like cells for two weeks
to examine the presence of colony-forming cells during the culture.
Colony-forming cells could not be found in the co-culture system
with the fibroblast-like cells. Then, the similar examination was
performed for seven cell clones showing the cobble-stone-like form.
Three clones having an activity to support proliferation of human
hematopoietic stem cells were obtained and were named AGM-s1,
AGM-s2, and AGM-s3.
(II) Preparation of Hematopoietic Stem Cells from Mouse Bone
Marrow
[0137] Bone marrow was collected from a femur of C57BL/6-Ly5.1 pep
(eight- to ten-week age, and male) (the gift from Professor K.
Nakauchi, University of Tsukuba), and suspended in PBS. After the
mouse bone marrow mononuclear cells were concentrated by specific
gravity centrifugation according to the usual method (S. Kouzu,
Fundamental techniques for immunology, YODOSHA, 1995), the cells
were suspended in staining buffer (PBS containing 5% FCS and 0.05%
NaN.sub.3), and a hematopoietic stem cell fraction was obtained as
follows (Osawa, M. et al., Science 273: 242-245, 1996).
[0138] An FITC-conjugated anti-CD34 antibody, a
phycoerythrin-conjugated anti-Sca-1 antibody, an allophycocyanin
anti-c-Kit antibody (all purchased from Pharmingen) and six
biotylated anti-differentiation antigen antibodies (CD45R, CD4,
CD8, Gr-1, Ter119, and CD11c, all purchased from Pharmingen) as
molecular markers (Lin), were added to a suspension of the bone
marrow mononuclear cells and incubated for 20 min on ice to cause
reaction. After the cells were washed twice with staining buffer,
CD34-negative, Sca-1-positive, c-Kit-positive, and Lin-negative
cells were isolated on a cell sorter (FACS Vantage, Becton
Dickinson).
(III) Subcloning of Mouse Stromal Cell Line and Determination of
Activity to Support Hematopoietic Stem Cells of a Variety of Cell
Lines
(1) Subcloning of Mouse Stromal Cell Line
1) Isolation of AGM-s3 Subclone
[0139] Stromal cell line AGM-s3 derived from AGM, which was
subcultured in MEM.alpha. medium (GIBCO BRL) including inactivated
10% FCS (bovine fetal serum, Hyclone), was suspended in PBS
containing 5% FCS (PBS-FCS). Clone sorting was performed in a
96-well culture dish (Falcon) at one cell/well using a cell sorter
(FACS Vantage; Becton Dickinson). Among cells in the 96 wells,
cultures of the cells which grew were expanded, so that thirteen
kinds of AGM-s3 subclones were obtained. The activity to support
the hematopoietic cells of these AGM-s3 subclones were
examined.
2) Isolation of Human Cord Blood CD34-Positive Stem Cell
[0140] The human cord blood was collected at normal delivery
according to the criteria approved by Ethics committee of Kirin
Beer Iyaku Tansaku Kenkyusho. The cord blood was collected using a
heparin-added syringe so as not to coagulate. The heparin treated
cord blood was overlaid on Lymphoprep (NYCOMED PHARMA), and
mononuclear cells were separated by specific gravity centrifugation
(at 400 G, at room temperature, and for 30 minutes). Erythrocytes
contaminated in the mononuclear cell fraction were lyzed by
treatment with an ammonium chloride buffer solution (0.83%
NH.sub.4Cl-Tris HCl, 20 mM, pH 6.8) at room temperature for two
minutes. After the mononuclear cells were washed with PBS-FCS, ten
milligrams of human IgG was added thereto and the mixture was
allowed to stand on ice for ten minutes. Then, the cells were
further washed with PBS-FCS. Biotinylated antibodies against the
antigens specific to the human differentiated blood cells, that is,
the antibodies against CD2, CD11c (purified from ATCC hybridoma),
CD19 (Pharmingen), CD15, and CD41 (Leinco Technologies Inc.), and
Glycophorin A (Cosmo Bio) were added thereto, and the mixture was
allowed to stand on ice for 20 min. After washing with PBS-FCS, the
cells were suspended in one milliliter of PBS containing 5% FCS, 10
mM EDTA, and 0.05% NaN.sub.3 (PBS-FCS-EDTA-NaN.sub.3).
Streptavidin-bound magnetic beads (BioMag. Per Septive Diagnostics)
were added thereto, and the mixture was allowed to stand on ice for
40 min. The differentiated blood cells which expressed
differentiation antigens were removed using a magnetic separator
(Dynal MPC-1 Dynal). An FITC-labeled anti-CD34 antibody (Immunotech
S.A., Marseilles, France) was added to the remaining differentiated
blood cell antigen-negative cell fraction. After incubation on ice
for 20 min., a CD34-positive fraction was recovered using a cell
sorter. This cell population was defined as a hematopoietic stem
cell population derived from the human cord blood.
3) Co-Culture of the Human Hematopoietic Stem Cells and AGM-s3
Subclone
[0141] After 13 kinds of AGM-s3 subclones and stromal cell line
MS-5 derived from the mouse bone marrow were each seeded in a
24-well culture dish (Falcon) at 1.times.10.sup.4 cells/well, and
cells were cultured in one milliliter of MEM.alpha. medium
containing 10% FCS and allowed to grow until the cells covered all
over the bottom surfaces of the wells. CD34-positive hematopoietic
stem cells derived from the human cord blood were placed on the
above described stromal cells at 500 cells/well, and co-cultured in
one milliliter of MEM.alpha. medium containing 10% FCS. One week
after the start of the co-culture, one milliliter of the same
medium was further added. Two weeks after the start of the
co-culture, the stromal cells and the human blood cells were
trypsinized (0.05% trypsin in PBS containing 0.5 mM EDTA (GIBCO
BRL) at 37.degree. C.; standing for two to five min.) to
simultaneously separate them from the culture dish. An activity to
support the hematopoietic stem cells was determined with a
clonogenic assay.
4) Assessment of Proliferation Statuses of the Hematopoietic Stem
Cells and Hematopoietic Progenitor Cells by Clonogenic Assay
[0142] The cells which proliferated in the above described
co-culture system were appropriately diluted, and subjected to one
milliliter of methylcellulose culture system to be analyzed. The
analysis using the methylcellulose culture system was performed
using a 6-well culture dish (Falcon) in MethoCult H4230 (Stem Cell
Technologies Inc.) to which 10 ng/ml of human SCF, human IL-3,
human IL-6, human G-CSF, and human TPO, and 2 IU/ml of EPO were
added. All of a variety of the above described hematopoietic
factors were recombinants and pure. After two-week culture,
developed colonies were observed under a microscope to count
numbers of CFU-GM (granulocyte-macrophage colony-forming unit),
BFU-E (erythroid burst forming unit), and CFU-E mix (erythrocyte
mixed colony-forming unit).
[0143] FIG. 1 shows the result of two-week co-culture of the
CD34-positive hematopoietic stem cells and the AGM-s3 subclone A9,
A7, or D11. As a result of the co-culture, A9 and D11 subclones
among 13 kinds of AGM-s3 subclones supported proliferation of all
three series of CFU-GM, BFU-E, and CFU-E mix. Especially, although
BFU-E and CFU-E mix, that is, the progenitor cells of erythrocytes
were hardly to be supported in usual, their proliferations were
observed in the co-culture system with A9 or D11 cells. The results
showed that proliferation or maintenance of the hematopoietic stem
cells or the hematopoietic progenitor cells occurred in the
co-culture with A9 or D11 cells and the progenitor cells of the
erythrocyte were continuously supplied. In contrast, although
cellular morphology of A7 was similar to that of A9, A7 did not
support CFU-GM, BFU-E, and CFU-E mix.
5) Comparison of an Activity to Support the Human Hematopoietic
Stem Cells Between A9 and a Stromal Cell Line OP9 Derived from
Mouse Fetus
[0144] Comparison of an activity to support the CD34-positive
hematopoietic stem cells derived from the human cord blood between
AGM-s3 subclones A9 and A7, and a stromal cell line OP9 derived
from mouse fetus (RCB1124, the Cell Development Bank of RIKEN) were
performed with CFU-GM, BFU-E, CFU-E and CFU-E mix as indexes, using
the above described determination system. FIG. 2 shows the result
of the two-week co-culture. In the A7 cell culture system, CFU-GM,
BFU-E, and CFU-E were significantly decreased and CFU-E mix was
completely disappeared. In contrast, with OP9 cells, a variety of
blood cell progenitor cells including CFU-E mix were supported,
although the supporting ability was less than that of A9 cells.
Therefore, it has been found that OP9 cells possess the activity to
support the hematopoietic stem cells.
(2) Assessment of Activity to Support the Hematopoietic Stem Cells
in a Variety of Cell Lines
[0145] The above described stromal cell lines (AGM-s3-A9,
AGM-s3-A7, and AGM-s3-G1), 3T3Swiss (ATCC), OP9, and NIH3T3 (ATCC)
were seeded in a 24-well culture dish (Falcon) at 5.times.10.sup.4
cells/well. The cell lines were cultured in MEM.alpha. medium
(GIBCO BRL) containing inactivated 10% FCS (bovine fetal serum,
Hyclone) for one day and allowed to proliferate until the cells
covered all over the bottom surfaces of the wells. Then, the medium
was replaced to one milliliter of fresh medium, thirty cells of the
mouse hematopoietic stem cells (derived from C57BL/6-Ly5.1)
obtained in the above (II) were placed on this cell layer, and
co-culture was started.
[0146] On seventh day of the cultivation, the cells were
trypsinized (0.05% trypsin in PBS containing 0.5 mM EDTA (GIBCO
BRL) at 37.degree. C. for two to five minutes) to separate and
recover all the cells on the culture dish. The recovered whole
cells of each cell line and 200,000 cells of whole bone marrow
cells (derived from C57BL/6-Ly5.2 mouse, Charles River) were
transplanted into C57BL/6-Ly5.2 mice (eight weeks age and male,
Charles River) irradiated with X-ray at 8.5 Gy through the tail
vein. After the transplantation, peripheral blood was collected
from orbit at intervals, and the ratio in number of cells derived
from the C57BL/6-Ly5.1 prep mouse was determined with FACS. The
peripheral blood was analyzed according to the usual method (S.
Kouzu, Fundamental techniques for immunology, YODOSHA, 1995). Three
hundreds and fifty .mu.L of distilled water was added to 50 .mu.L
of the peripheral blood, and the mixture was allowed to stand for
30 seconds so as to lyze the erythrocytes. Then, PBS at twice
concentrations was added and the mixture was centrifuged to recover
white blood cells. After the cells were washed once using the
staining buffer (PBS containing 5% FCS and 0.05% NaN.sub.3),
anti-CD16 antibody, anti-Ly5.1 (CD45.1) antibody labeled with FITC,
anti-Gr-1 and anti-CD11c antibodies labeled with phycoerythrin, and
anti-CD45R (B220) and anti-CD90 (Thy1) antibodies labeled with
allophycocyanin (all of these were purchased from Pharmingen) were
added. After these cells were allowed to stand for reaction in the
ice bath for 30 minutes, they were washed with the staining buffer
and FACS analysis was performed.
[0147] Change in the number of cells capable of reconstitution
during the hematopoietic stem cell culture was determined by
calculating the proportions of Ly5.1-positive cells in the Gr-1- or
CD11c-positive cells (myeloid cells) and Ly5.1-positive cells in
the CD90- or CD45R-positive cells (lymphoid cells) in the
peripheral blood at intervals after transplantation.
[0148] FIG. 3 shows the results. When the cells were co-cultured
with AGM-s3-A9 cells, OP9 cells, or 3T3Swiss cells, high chimerism
of donor cells were maintained after the transplantation.
Therefore, these stromal cells were considered to have a high
activity to support the hematopoietic stem cells. In contrast, when
the cells were co-cultured with AGM-s3-A7 cells, AGM-s3-G1 cells,
or NIH3T3 cells, high chimerism derived from the transplanted cells
was not observed. Therefore, these stromal cells were low in an
activity to support the hematopoietic stem cells or the
hematopoietic progenitor cells.
(IV) Identification of Sequences of Genes which Specifically
Express in Hematopoietic Stem Cell-Supporting Cells
[0149] AGM-s3-A9 cells, AGM-s3-A7 cells and OP9 cells were each
dissolved in 20 mL of ISOGEN (Nippon gene, Japan) and total RNAs
were prepared according to the attachment. Messenger RNAs were
prepared from one milligram of the total RNAs according to the
protocol of the mRNA purification kit (Amersham Pharmacia, U.S.A.).
cDNAs were synthesized from the mRNAs and cDNA libraries
(hereinafter, also called as AGM-s3-A9 cDNA, AGM-s3-A7 cDNA and OP9
cDNA, respectively) were constructed using pSPORT1 (GIBCO Lifetech,
U.S.A.). A clone harboring a cDNA fragment which highly expresses
specifically to AGM-s3-A9 cells or OP9 cells compared with
AGM-s3-A7 cells was obtained from the libraries with SBH method
(Hyseq, U.S.A.). A nucleotide sequence of the obtained clone was
determined using ABI377 DNA sequencer (Perkin Elmer, U.S.A.).
[0150] As a result, it has been found that expression of genes
comprising nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:2,
SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID
NO:7, or parts thereof in AGM-s3-A9 or OP9 cells is higher than
that in AGM-s3-A7 cells. These genes were named as SCR-2, SCR-3,
SCR-4, SCR-5, SCR-6, SCR-7 and SCR-8, respectively.
Example 2 Cloning of SCR-2 and Activity Determination
[0151] By searching GenBank database for the nucleotide sequence
shown in SEQ ID NO: 1 with BLAST, it has been found that SCR-2 is
the same gene as a mouse gene, Mus musculus glypican-1 (Gpc-1) of
an accession number AF185613. The nucleotide sequence of ORF (Open
Reading Frame) of SCR-2 and the amino acid sequence deduced from
the nucleotide sequence are shown in SEQ ID NO: 8. Only the amino
acid sequence is shown in SEQ ID NO: 9.
[0152] The human nucleotide sequence of Gpc-1 is recorded in
GenBank database under an accession number AX020122. The nucleotide
sequence of ORF of AX020122 and the amino acid sequence deduced
from the nucleotide sequence are shown in SEQ ID NO: 10. Only the
amino acid sequence is shown in SEQ ID NO: 11.
[0153] Determination of the activity to support the hematopoietic
stem cells or hematopoietic progenitor cells was performed as
follows.
(1) Construction of Retrovirus Vector for Expression of Mouse
SCR-2
[0154] Based on the nucleotide sequence of SCR-2 ORF, SCR-2Fsal1
and SCR-2Reco primers having the following nucleotide sequences
were prepared, and PCR was performed using OP9 cDNA as a
template.
TABLE-US-00001 SCR-2Fsal (SEQ ID NO: 30)
CCGGTCGACCACCatggaactccggacccgaggctgg SCR-2Reco (SEQ ID NO: 31)
CCGAATTCttaccgccacctgggcctggctgc
[0155] An amplified fragment was digested with restriction enzymes
EcoRI and SalI. After electrophoresis, a DNA fragment was purified
using JETSORB (Genomed, Germany). The purified DNA fragment was
ligated with pMX-IRES-GFP vector digested with EcoRI and XhoI (gift
form Professor T. Kitamura, TOKYO UNIV. INST. OF MEDICAL SCIENCE,
Japan). The pMX-IRES-GFP vector is a plasmid obtained by inserting
sequences encoding IRES (Internal Ribosome Entry Site) and GFP
(Green Fluorescence Protein) into the retrovirus vector pMX. IRES
(Internal Ribosome Entry Site) enables ribosome to access to the
middle of the mRNA. Therefore, two genes can be expressed from one
mRNA by ligation of upward and downward genes separated by IRES in
one transcription unit during the construction of an expression
vector. With respect to the above-described plasmid, SCR-2 cDNA was
inserted in the upward site and GFP (Green Fluorescence Protein)
was inserted in the downward site. Thus, the expression of SCR-2
could be monitored by detecting the expression status of GFP using
FACS.
[0156] The obtained recombinant vector was introduced into E. coli
DH5a, and was seeded on LB agar medium containing 100 .mu.g/ml of
ampicillin, so that independent colonies were formed. After the
isolated colony was cultured in 100 mL of LB medium containing 100
.mu.g/ml of ampicillin, plasmid was purified using QIAGENtip100
(QIAGEN, U.S.A.). The sequence of the inserted gene was determined
using a conventional method, so that the sequence was confirmed to
be identical to the nucleotide sequence of SCR-2 ORF.
(2) Preparation of Stromal Cells Highly Expressing SCR-2
[0157] BOSC23 cells were seeded on a collagen type I-coated 60-mm
dish (Asahi technoglass) at 2.times.10.sup.6 cells/dish, and
cultured in DMEM medium containing 10% FCS at 37.degree. C., under
an atmosphere of 5% CO.sub.2, and at a humidity of 100%. Twelve to
18 hours after the start of the culture, the medium was replaced by
two milliliters of OPTI MEM medium (GIBCO BRL).
[0158] About 3 .mu.g of plasmid obtained by inserting SCR-2 into
the above described pMX-IRES-GFP was added to 18 .mu.l of
LIPOFECTAMINE Reagent (GIBCO BRL) diluted with 100 .mu.l of OPTI
MEM medium, and the mixture was allowed to stand at room
temperature for 30 min. The prepared DNA solution was added to the
prepared BOSC23 cell culture solution. After about five hours, two
milliliters of DMEM medium containing 20% FCS (GIBCO BRL) was
added.
[0159] After about 24 hours, the medium was replaced by 4 ml of
DMEM containing 10% FCS. Further, after about 48 hours, the culture
medium was harvested. After the culture medium was filtrated
through 0.45-.mu.m filter, the filtrate was centrifuged at 1,200 g
for 16 hours and the supernatant was removed to obtain the virus
precipitation.
[0160] AGM-s3-A7 or AGM-s3-A9 cells were cultured in one milliliter
of MEM.alpha. medium containing 10% FCS (GIBCO BRL) on a 24-well
culture dish (FALCON) at 1.times.10.sup.4 cells/well. After 12 to
18 hours, the virus precipitation was suspended in one milliliter
of MEM.alpha. medium containing 10% FCS, and the stromal cell
culture medium was replaced by the virus suspension. Next,
POLYBRENE (Sigma, SEQUA-BRENE) was added to be 10 .mu.g/ml. After
the culture dish was centrifuged at 700 g for 45 minutes, the cells
were cultured at 37.degree. C., under an atmosphere of 5% CO.sub.2,
and at a humidity of 100%. After 48 hours, the medium was replaced
by one milliliter of MEM.alpha. medium containing 10% FCS. After 24
hours, the cells were subcultured on a 6-well culture dish (FALCON)
and cultured in three milliliters of MEM.alpha. medium containing
10% FCS. Forty-eight hours after the subculturing, GFP expression
in the stromal cells was detected using a cell sorter (FACS
Vantage, Becton Dickinson) to indirectly confirm that not less than
80% of cells expressed SCR-2.
[0161] Also, the same procedures were repeated by using
pMX-IRES-GFP vector instead of the plasmid obtained by inserting
SCR-2 into PMX-IRES-GFP to prepare stromal cells into which a
control vector was introduced.
(3) Co-Culture of Human Hematopoietic Stem Cells and Stromal Cells
Highly Expressing SCR-2, and Determination of Proliferation
Statuses of Hematopoietic Stem Cells and Hematopoietic Progenitor
Cells by Clonogenic Assay
[0162] In the same manner as described in (III) (1) 3) to 4) of
Example 1, AGM-s3-A9 or AGM-s3-A7 cells in which SCR-2 was highly
expressed through retrovirus, AGM-s3-A9 or AGM-s3-A7 cells into
which a control vector was introduced, or AGM-s3-A9 or AGM-s3-A7
cells were co-cultured with CD34-positive hematopoietic stem cells
derived from human cord blood, and proliferation statuses of
hematopoietic stem cells and hematopoietic progenitor cells are
determined.
[0163] FIG. 4 shows results when the CD34-positive hematopoietic
stem cells were co-cultured with AGM-S3-A9 cells in which SCR-2 was
highly expressed (A9/SCR-2), AGM-S3-A9 cells into which a control
vector was introduced (A9/pMXIG) or AGM-S3-A9 cells (A9) for two
weeks. Also, FIG. 5 shows results when the CD34-positive
hematopoietic stem cells were co-cultured with AGM-S3-A7 cells in
which SCR-2 was highly expressed, AGM-S3-A7 cells into which a
control vector was introduced or AGM-S3-A7 cells for two weeks. As
a result, by the co-culture with AGM-S3-A9 cells in which SCR-2 was
highly expressed or AGM-S3-A7 cells in which SCR-2 was highly
expressed, increases of BFU-E and CFU-C were observed. Therefore,
it has been revealed that the activity to support hematopoietic
stem cells or hematopoietic progenitor cells, of AGM-S3-A9 or
AGM-S3-A7 increases by allowing SCR-2 to be highly expressed. From
the results, it has been revealed that a gene product of SCR-2 has
an activity to support survival or proliferation of hematopoietic
stem cells or hematopoietic progenitor cells or an activity to
affect stromal cells to enhance a hematopoietic cell-supporting
activity of the stromal cells or impart the activity to the stromal
cells.
Example 3 Cloning of SCR-3 and Activity Determination
[0164] By searching GenBank database for the nucleotide sequence
shown in SEQ ID NO: 2 with BLAST, it has been found that SCR-3 is
the same gene as mouse genes, Mus musculus chemokine MMRP2 mRNA of
an accession number U15209, Mus musculus C10-like chemokine mRNA of
U19482 and mouse macrophage inflammatory protein-1gamma mRNA of
U49513. The nucleotide sequence of SCR-3 ORF and the amino acid
sequence deduced from the nucleotide sequence are shown in SEQ ID
NO: 12. Only the amino acid sequence is shown in SEQ ID NO: 13.
[0165] Determination of the activity of SCR-3 to support the
hematopoietic stem cells or hematopoietic progenitor cells was
performed as follows.
(1) Construction of Retrovirus Vector for Expression of Mouse
SCR-3
[0166] Based on the nucleotide sequence of SCR-3 ORF, SCR-3FxhoI
and SCR-3Reco primers having the following nucleotide sequences
were prepared, and PCR was performed using AGM-s3-A9 cDNA as a
template. An amplified fragment was inserted to the retrovirus
vector PMX-IRES-GFP in the same manner as described in (1) of
Example 2.
TABLE-US-00002 SCR-3FxhoI (SEQ ID NO: 32)
ccgCTCGAGccaccATGAAGCCTTTTCATACTGCC SCR-3Reco (SEQ ID NO: 33)
tccGAATTCttattgtttgtaggtccgtgg
(2) Preparation of Stromal Cells Highly Expressing SCR-3
[0167] AGM-s3-A7 cells in which SCR-3 was highly expressed were
prepared by using the above retrovirus vector in the same manner as
(2) of Example 2.
(3) Determination of Activity to Support Hematopoietic Stem Cells
of Stromal Cells in which SCR-3 is Highly Expressed
[0168] In the same manner as described in (III) (2) of Example 1,
determination of the activity to support hematopoietic stem cells
was performed except that AGM-S3-A7 cells, AGM-S3-A7 cells in which
SCR-3 was highly expressed through retrovirus, and AGM-S3-A7 cells
into which a control vector was introduced were seeded in a 24-well
culture dish (Falcon) at 1.times.10.sup.5 cells/well.
[0169] The results are shown in FIG. 6. Hematopoietic cells
co-cultured with AGM-s3-A7 cells in which SCR-3 was highly
expressed (A7/SCR-3) showed high chimerism in recipient individuals
after the transplantation compared with the parent cell lines or
hematopoietic cells co-cultured with the cells into which a control
vector was introduced. The high chimerism was observed in myeloid
and lymphoid cells two months after the transplantation. Therefore,
it is revealed that hematopoietic stem cells and hematopoietic
progenitor cells which can reconstitute the hematopoietic system in
bodies of irradiated mice have maintained and amplified superiorly
to the co-culture with cells into which SCR-3 is not introduced,
during the co-culture period. From the results, it is revealed that
an activity of stromal cells to support survival or proliferation
of hematopoietic stem cells or hematopoietic progenitor cells is
increased by high expression of SCR-3. Therefore, it is revealed
that a gene product of SCR-3 has an activity to affect
hematopoietic stem cells or hematopoietic progenitor cells to
support survival or proliferation thereof or an activity to affect
stromal cells to enhance a hematopoietic cell-supporting activity
of the stromal cells or impart the activity to the stromal
cells.
Example 4 Cloning of SCR-4 and Activity Determination
[0170] By searching GenBank database for the nucleotide sequence
shown in SEQ ID NO: 3 with BLAST, it has been found that SCR-4 has
a high homology to Homo sapiens clone 25077 mRNA of an accession
number AF131820, and that SCR-4 is a mouse ortholog. This sequence
is described in WO 00/66784.
[0171] The nucleotide sequence of ORF of AF131820 and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 16. Only the amino acid sequence is shown in SEQ ID NO:
17.
[0172] The nucleotide sequence of ORF of SCR-4 and the amino acid
sequence deduced from the nucleotide sequence are shown in SEQ ID
NO: 14. Only the amino acid sequence is shown in SEQ ID NO: 15.
[0173] Determination of the activity of SCR-4 to support the
hematopoietic stem cells or hematopoietic progenitor cells was
performed as follows.
(1) Construction of Retrovirus Vector for Expression of Human
SCR-4
[0174] From 3 .mu.g of mRNA derived from fetal liver (CLONETEC,
U.S.A.), cDNA was synthesized by using oligo-dT primer and reverse
transcriptase (SuperscriptII, GIBCO-BRL). Using the cDNA as a
template, the ORF region of human SCR-4 was amplified by PCR with
HSCR-4FxhoI and HSCR-4RecoRV primers having the following
nucleotide sequences. An amplified fragment was digested with XhoI
and inserted to the retrovirus vector pMX-IRES-GFP in the same
manner as described in (1) of Example 2. For the insertion, the
pMX-IRES-GFP was digested with a restriction enzyme EcoRI,
blunt-ended with KOD DNA synthase (TOYOBO, Japan) and digested with
a restriction enzyme XhoI.
TABLE-US-00003 HSCR-4FxhoI (SEQ ID NO: 34)
CCGCTCGAGCCACCatgttggctgcaaggctggtgt HSCR-4RecoRV (SEQ ID NO: 35)
CCGGATATCtcatttctttctgttgcctcca
(2) Preparation of Stromal Cells Highly Expressing Human SCR-4
[0175] AGM-s3-A9 cells in which human SCR-4 was highly expressed
were prepared by using the above retrovirus vector in the same
manner as (2) of Example 2.
(3) Co-culture of Human Hematopoietic Stem Cells and Stromal Cells
Highly Expressing Human SCR-4, and Determination of Proliferation
Statuses of Hematopoietic Stem Cells and Hematopoietic Progenitor
Cells by Clonogenic Assay
[0176] In the same manner as described in (III) (1) 3) to 4) of
Example 1, AGM-s3-A9 cells in which SCR-4 was highly expressed
through retrovirus, AGM-s3-A9 cells into which a control vector was
introduced, or AGM-s3-A9 cells were co-cultured with CD34-positive
hematopoietic stem cells derived from human cord blood, and
proliferation statuses of hematopoietic stem cells and
hematopoietic progenitor cells are determined.
[0177] FIG. 6 shows results when the CD34-positive hematopoietic
stem cells were co-cultured with AGM-S3-A9 cells in which human
SCR-4 was highly expressed, AGM-S3-A9 cells into which a control
vector was introduced or AGM-S3-A9 cells for two weeks. As a
result, the co-culture with AGM-S3-A9 cells in which human SCR-4
was highly expressed, increases of BFU-E and CFU-C were observed.
Therefore, it has been revealed that the activity to support
hematopoietic stem cells or hematopoietic progenitor cells, of
AGM-S3-A9 increases by allowing human SCR-4 to be highly expressed.
From the results, it has been revealed that human SCR-4 has an
activity to support survival or proliferation of hematopoietic stem
cells or hematopoietic progenitor cells or an activity to affect
stromal cells to impart a hematopoietic cell-supporting activity to
the stromal cells.
Example 5 Cloning of SCR-5 and Activity Determination
[0178] In the nucleotide sequence of SEQ ID NO: 4 obtained by the
SBH analysis, the presence of ORF was predicted. The nucleotide
sequence of ORF and the amino acid sequence deduced from the
nucleotide sequence are shown in SEQ ID NO: 18. Only the amino acid
sequence is shown in SEQ ID NO: 19.
[0179] By searching GenBank database for the nucleotide sequence of
SEQ ID NO: 18 with BLAST, it has been found that SCR-5 has a high
homology with Homo sapiens esophageal cancer related gene 4 protein
(ECRG4) mRNA of an accession number AF325503, and that SCR-5 is a
mouse ortholog of AF325503. The nucleotide sequence of ORF of
AF325503 and the amino acid sequence deduced from the nucleotide
sequence are shown in SEQ ID NO: 20. Only the amino acid sequence
is shown in SEQ ID NO: 21.
[0180] Determination of the activity of SCR-5 to support the
hematopoietic stem cells or hematopoietic progenitor cells was
performed as follows.
(1) Construction of Retrovirus Vector for Expression of Mouse
SCR-5
[0181] Based on the nucleotide sequence of SCR-5 ORF, SCR-5FxhoI
and SCR-5Rblunt primers having the following nucleotide sequences
were prepared for retrovirus cloning, and PCR was performed using
DNA having the nucleotide sequence shown in SEQ ID NO: 23 as a
template. An amplified fragment was digested with a restriction
enzyme XhoI and inserted to the retrovirus vector pMX-IRES-GFP in
the same manner as described in (1) of Example 2. For the
insertion, the pMX-IRES-GFP was digested with a restriction enzyme
EcoRI, blunt-ended with KOD DNA synthase (TOYOBO, Japan) and
digested with a restriction enzyme XhoI.
TABLE-US-00004 SCR-5FxhoI ccgCTCGAGccaccatgagcacctcgtctgcgcg (SEQ
ID NO: 36) SCR-5Rblunt tccGTTAACttaatagtcatcatagttca (SEQ ID NO:
37)
(2) Preparation of Stromal Cells Highly Expressing SCR-5
[0182] AGM-s3-A7 cells in which SCR-5 was highly expressed were
prepared by using the above retrovirus vector in the same manner as
(2) of Example 2.
(3) Determination of Activity to Support Hematopoietic Stem Cells
of Stromal Cells in which SCR-5 is Highly Expressed
[0183] In the same manner as described in (3) of Example 3,
determination of the activity to support hematopoietic stem cells
was performed.
[0184] The results are shown in FIG. 8. Hematopoietic cells
co-cultured with AGM-s3-A7 cells in which SCR-5 was highly
expressed (A7/SCR-5) showed high chimerism in recipient individuals
after the transplantation compared with the parent cell lines or
hematopoietic cells co-cultured with the cells into which a control
vector was introduced. The high chimerism was observed in myeloid
and lymphoid cells two months after the transplantation. Therefore,
it is revealed that hematopoietic stem cells and hematopoietic
progenitor cells which can reconstitute the hematopoietic system in
bodies of irradiated mice have maintained and amplified superiorly
to the co-culture with cells into which SCR-5 is not introduced,
during the co-culture period. From the results, it is revealed that
an activity of stromal cells to support survival or proliferation
of hematopoietic stem cells or hematopoietic progenitor cells is
increased by high expression of SCR-5. Therefore, it is revealed
that a gene product of SCR-5 has an activity to affect
hematopoietic stem cells or hematopoietic progenitor cells to
support survival or proliferation thereof or an activity to affect
stromal cells to enhance a hematopoietic cell-supporting activity
of the stromal cells or impart the activity to the stromal
cells.
Example 6 Cloning of SCR-6 and Activity Determination
[0185] Based on the nucleotide sequence of SEQ ID NO: 5, a probe
was prepared and AGM-s3-A9 cDNA was screened by hybridization to
obtain a gene containing ORF of mouse SCR-6.
[0186] AGM-s3-A9 cells (1.4.times.10.sup.8 cells) were dissolved in
20 mL of ISOGEN (Nippon gene, Japan) and total RNAs were prepared
according to the attachment. Messenger RNAs were prepared from one
milligram of the total RNAs according to the protocol of the mRNA
purification kit (Amersham Pharmacia, U.S.A.). By using SMART cDNA
library construction kit (CLONTECH, U.S.A.), cDNA libraries divided
to 15 fractions were prepared from the 2 .mu.g of the prepared
mRNAs according to the attachment. The libraries contained about
400,000 of independent clones in total. For each fraction, PCR was
performed under the following conditions to identify a fraction
containing SCR-6 cDNA.
[0187] Based on the sequence of a partial fragment of the mouse
SCR-6 gene, the following primers were prepared, and PCR was
performed with 35 cycles of 94.degree. C., 30 seconds, 55.degree.
C., 30 seconds and 72.degree. C., 1 minute, by using each fraction
of AGM-s3-A9 cDNA libraries as a template.
TABLE-US-00005 SCR-6F AGCTCATTACTGTATATTTA (SEQ ID NO: 22;
1971-1990) (SEQ ID NO: 38) SCR-6R GCTATATTTCATAAGTCATC (SEQ ID NO:
22; 2330-2349) (SEQ ID NO: 39)
[0188] The PCR product was subjected to 2% agarose gel
electrophoresis and a fraction from which the PCR product having
the expected size was obtained was identified. For each of two
fractions among the positive fractions, 50,000 plaques were seeded
on two 15-cm petri dishes and incubated 37.degree. C. for 10 hours.
Then, plaques of each petri dish were replicated to a sheet of
Biodyne nylon filter (Pall, U.S.A.). The replicated nylon filter
was subjected to DNA fixation treatment according to the
attachment, and screening with .sup.32P-labeled DNA probe was
performed.
[0189] The probe was prepared as follows. PCR was performed with 35
cycles of 94.degree. C., 30 seconds, 55.degree. C., 30 seconds and
72.degree. C., 1 minute, by using SCR-6F and SCR-6R and the plasmid
containing a partial fragment of the mouse SCR-6 gene as a
template. The PCR product was subjected to 2% agarose gel
electrophoresis and the amplified fragment was purified by JETSORB.
By using 25 ng of the obtained PCR fragment, .sup.32P-labeled DNA
probe was prepared with Megaprime labeling kit (Amersham Pharmacia,
U.S.A.).
[0190] Hybridization and washing were performed with
ExpressHybSolution (CLONETECH, U.S.A.) according to the attachment.
An X-ray film was exposed to the filter and developed with a Fuji
film auto developer to analyze the result. A plaque at a position
corresponding to the resultant strongly exposed portion was scraped
from the petri dish, and seeded again so that about 200 of plaques
should appear on 10-cm petri dish. Screening was again performed
according to the above-mentioned method to isolate a single plaque.
The obtained clone was transfected to E. coli strain BM25.8
according to the attachment of SMART cDNA library construction kit,
and the transfected cells were cultured on LB agar medium
containing 50 .mu.g/ml ampicilin to form colonies. A single colony
of the transfected E. coli was inoculated to 3 ml of LB medium
containing 50 .mu.g/ml ampicilin and cultured at 30.degree. C.
overnight. Plasmid was extracted with RPM kit (BIO101, U.S.A.) to
obtain about 10 mg of plasmid.
[0191] Sequencing the both ends of the inserted fragment with an
ABI377 DNA sequencer by using .lamda.Trip1Ex5'LD-Insert Screening
Amplimer (CTCGGGAAGCGCGCCATTGTGTTGGT (SEQ ID NO: 40); CLONTECH,
U.S.A.) revealed that it included cDNA containing the nucleotide
sequence from nucleotide 1 of SEQ ID NO: 5. The full-length
nucleotide sequence was also determined with the ABI377 DNA
sequencer. The nucleotide sequence and the amino acid sequence
deduced from a nucleotide sequence predicted as ORF in the
nucleotide sequence are shown in SEQ ID NO: 22. Only the amino acid
sequence is shown in SEQ ID NO: 23.
[0192] Determination of the activity of SCR-6 to support the
hematopoietic stem cells or hematopoietic progenitor cells was
performed as follows.
(1) Construction of Retrovirus Vector for Expression of Mouse
SCR-6
[0193] Based on the nucleotide sequence of SCR-6 ORF, SCR-6FxhoI
and SCR-6Reco primers having the following sequences were prepared
for retrovirus cloning, and PCR was performed by using DNA having
the nucleotide sequence shown in SEQ ID NO: 22 as a template. An
amplified fragment was inserted to the retrovirus vector
pMX-IRES-GFP in the same manner as described in (1) of Example
2.
TABLE-US-00006 SCR-6FxhoI ccgctcgagccaccATGCGTTTTTGCCTCTTCTC (SEQ
ID NO: 41) SCR-6Reco cggaattcTTATTGGTTCACTCTGTCTG (SEQ ID NO:
42)
(2) Preparation of Stromal Cells Highly Expressing SCR-6
[0194] AGM-s3-A9 cells in which SCR-6 was highly expressed were
prepared by using the above retrovirus vector in the same manner as
(2) of Example 2.
(3) Co-Culture of Human Hematopoietic Stem Cells and Stromal Cells
Highly Expressing SCR-6, and Determination of Proliferation
Statuses of Hematopoietic Stem Cells and Hematopoietic Progenitor
Cells by Clonogenic Assay
[0195] In the same manner as described in (III) (1) 3) to 4) of
Example 1, AGM-s3-A9 cells in which SCR-6 was highly expressed
through retrovirus, AGM-s3-A9 cells into which a control vector was
introduced, or AGM-s3-A9 cells were co-cultured with CD34-positive
hematopoietic stem cells derived from human cord blood, and
proliferation statuses of hematopoietic stem cells and
hematopoietic progenitor cells are determined.
[0196] FIG. 9 shows results when the CD34-positive hematopoietic
stem cells were co-cultured with AGM-S3-A9 cells in which SCR-6 was
highly expressed (A9/SCR-9), AGM-S3-A9 cells into which a control
vector was introduced (A9/pMXIG) or AGM-S3-A9 cells (A9) for two
weeks. As a result, the co-culture with AGM-S3-A9 cells in which
SCR-6 was highly expressed, increases of BFU-E and CFU-C were
observed. Therefore, it has been revealed that the activity to
support hematopoietic stem cells or hematopoietic progenitor cells,
of AGM-S3-A9 increases by allowing SCR-6 to be highly expressed.
From the results, it has been revealed that the gene product of
SCR-6 has an activity to support survival or proliferation of
hematopoietic stem cells or hematopoietic progenitor cells or an
activity to affect stromal cells to enhance a hematopoietic
cell-supporting activity of the stromal cells or impart the
activity to the stromal cells.
Example 7 Cloning of SCR-7 and Activity Determination
[0197] In the nucleotide sequence of SEQ ID NO: 6 obtained by the
SBH analysis, the presence of ORF was predicted. The nucleotide
sequence of ORF and the amino acid sequence deduced from the
nucleotide sequence are shown in SEQ ID NO: 24. Only the amino acid
sequence is shown in SEQ ID NO: 25.
[0198] Determination of the activity of SCR-7 to support the
hematopoietic stem cells or hematopoietic progenitor cells was
performed as follows.
(1) Construction of Retrovirus Vector for Expression of Mouse
SCR-7
[0199] Based on the nucleotide sequence of SCR-7 ORF, SCR-7FsalI
and SCR-7Reco primers having the following nucleotide sequences
were prepared for retrovirus cloning, and PCR was performed using
DNA having the nucleotide sequence shown in SEQ ID NO: 24 as a
template. An amplified fragment was inserted to the retrovirus
vector pMX-IRES-GFP in the same manner as described in (1) of
Example 2.
TABLE-US-00007 SCR-7FSalI acgcgtcgacccaccATGCCCCGCTACGAGTTG (SEQ ID
NO: 43) SCR-7Reco attGAATTCTCACTTCTTCCTCCTCTTTG (SEQ ID NO: 44)
(2) Preparation of Stromal Cells Highly Expressing SCR-7
[0200] AGM-s3-A9 cells in which SCR-7 was highly expressed were
prepared by using the above retrovirus vector in the same manner as
(2) of Example 2.
(3) Co-Culture of Human Hematopoietic Stem Cells and Stromal Cells
Highly Expressing SCR-7, and Determination of Proliferation
Statuses of Hematopoietic Stem Cells and Hematopoietic Progenitor
Cells by Clonogenic Assay
[0201] In the same manner as described in (III) (1) 3) to 4) of
Example 1, AGM-s3-A9 cells in which SCR-7 was highly expressed
through retrovirus, AGM-s3-A9 cells into which a control vector was
introduced, or AGM-s3-A9 cells were co-cultured with CD34-positive
hematopoietic stem cells derived from human cord blood, and
proliferation statuses of hematopoietic stem cells and
hematopoietic progenitor cells are determined.
[0202] FIG. 10 shows results when the CD34-positive hematopoietic
stem cells were co-cultured with AGM-S3-A9 cells in which SCR-7 was
highly expressed (A9/SCR-7), AGM-S3-A9 cells into which a control
vector was introduced (A9/pMXIG) or AGM-S3-A9 cells (A9) for two
weeks. As a result, the co-culture with AGM-S3-A9 cells in which
SCR-7 was highly expressed, increases of BFU-E and CFU-C were
observed. Therefore, it has been revealed that the activity to
support hematopoietic stem cells or hematopoietic progenitor cells,
of AGM-S3-A9 increases by allowing SCR-7 to be highly expressed.
From the results, it has been revealed that the gene product of
SCR-7 has an activity to support survival or proliferation of
hematopoietic stem cells or hematopoietic progenitor cells or an
activity to affect stromal cells to enhance a hematopoietic
cell-supporting activity of the stromal cells or impart the
activity to the stromal cells.
Example 8 Cloning of SCR-8 and Activity Determination
[0203] By searching GenBank database for the nucleotide sequence
shown in SEQ ID NO: 7 with BLAST, it has been found that SCR-8 is
the same gene as Mus musculus mRNA for ADAM23 of an accession
number AB009673. The nucleotide sequence of SCR-8 ORF and the amino
acid sequence deduced from the nucleotide sequence are shown in SEQ
ID NO: 26. Only the amino acid sequence is shown in SEQ ID NO:
27.
[0204] Also, the sequence encoding Human MDC3 protein [Homo
sapiens] described by JP 11155574-A has a homology of not less than
90% with SCR-8 and, therefore, is a human ortholog of SCR-8. The
nucleotide sequence of this ORF and the amino acid sequence deduced
from the nucleotide sequence are shown in SEQ ID NO: 28. Only the
amino acid sequence is shown in SEQ ID NO: 29.
[0205] Determination of the activity of SCR-8 to support the
hematopoietic stem cells or hematopoietic progenitor cells was
performed as follows.
(1) Construction of Retrovirus Vector for Expression of Mouse
SCR-8
[0206] Based on the nucleotide sequence of SCR-8 ORF, SCR-8FxhoI
and SCR-8Reco primers having the following nucleotide sequences
were prepared, and PCR was performed using AGM-s3-A9 cDNA as a
template. An amplified fragment was inserted to the retrovirus
vector pMX-IRES-GFP in the same manner as described in (1) of
Example 2.
TABLE-US-00008 SCR-8FxhoI (SEQ ID NO: 45)
ccgctcgagccaccATGAAGCCGCCCGGCAGCATC SCR-8Reco (SEQ ID NO: 46)
cggaattcTCAGATGGGGCCTTGCTGAGT
(2) Preparation of Stromal Cells Highly Expressing SCR-8
[0207] AGM-s3-A9 cells in which SCR-8 was highly expressed were
prepared by using the above retrovirus vector in the same manner as
(2) of Example 2.
(3) Co-Culture of Human Hematopoietic Stem Cells and Stromal Cells
Highly Expressing SCR-8, and Determination of Proliferation
Statuses of Hematopoietic Stem Cells and Hematopoietic Progenitor
Cells by Clonogenic Assay
[0208] In the same manner as described in (III) (1) 3) to 4) of
Example 1, AGM-s3-A9 cells in which SCR-8 was highly expressed
through retrovirus, AGM-s3-A9 cells into which a control vector was
introduced, or AGM-s3-A9 cells were co-cultured with CD34-positive
hematopoietic stem cells derived from human cord blood, and
proliferation statuses of hematopoietic stem cells and
hematopoietic progenitor cells are determined.
[0209] FIG. 11 shows results when the CD34-positive hematopoietic
stem cells were co-cultured with AGM-S3-A9 cells in which SCR-8 was
highly expressed, AGM-S3-A9 cells into which a control vector was
introduced or AGM-S3-A9 cells for two weeks. As a result, the
co-culture with AGM-S3-A9 cells in which SCR-8 was highly
expressed, increases of BFU-E and CFU-C were observed. Therefore,
it has been revealed that the activity to support hematopoietic
stem cells or hematopoietic progenitor cells, of AGM-S3-A9
increases by allowing SCR-8 to be highly expressed. From the
results, it has been revealed that the gene product of SCR-8 has an
activity to support survival or proliferation of hematopoietic stem
cells or hematopoietic progenitor cells or an activity to affect
stromal cells to enhance a hematopoietic cell-supporting activity
of the stromal cells or impart the activity to the stromal cells.
Sequence CWU 1
1
461343DNAMus musculus 1cctatggcgg caacgacgtg gacttccagg atgctagtga
tgacggcagt ggctccggca 60gcggtggcgg atgcccagat gacacctgtg gccggagggt
cagcaagaag agttccagct 120cccggacccc cttgacccat gccctccccg
gcctgtcaga acaggaggga cagaagacct 180cagctgccac ctgcccagag
ccccacagct tcttcctgct cttcctcgtc accttggtcc 240ttgcggcagc
caggcccagg tggcggtaac tgccccctat cccagacagt aactctgagt
300gctgcggcag ggtgcatgga ggggtccctc cctccttgag tcg 3432546DNAMus
musculus 2tgtaccccag ggacttcctg atcctcttac atgtataaat agcaagaccg
ggccaggaac 60agcaagcagt ctgaaggcca gctgggtctg cccactaaga agatgaagcc
ttttcatact 120gccctctcct tcctcattct tacaactgct cttggaatct
gggcccagat cacacatgca 180acagagacaa aagaagtcca gagcagtctg
aaggcacagc aagggcttga aattgaaatg 240tttcacatgg gctttcaaga
ctcttcagat tgctgcctgt cctataactc acggattcag 300tgttcaagat
ttataggtta ttttcccacc agtggtgggt gtaccaggcc gggcatcatc
360tttatcagca agagggggtt ccaggtctgt gccaacccca gtgatcggag
agttcagaga 420tgcattgaaa gattggagca aaactcacaa ccacggacct
acaaacaata acatttgctt 480gaagagaagg gtgtgaactg ccagctactt
tctttggtct tccccagtga ccacctaagt 540ggctct 54631223DNAMus musculus
3gtgacccgga agggagcccc gtggtagagg tgaccggagc tgagcatttc agatctgctt
60agtaaaccgg tgtatcgccc accatgttgg ctgcaaggct tgtgtgtctc cggacactac
120cttccagggt tttccagccc actttcatca ccaaggcctc tccacttgtg
aagaattcca 180tcacaaagaa ccaatggctc gtaacaccca gcagggaata
tgctaccaag acaagaatta 240ggactcaccg tgggaaaact ggacaagaac
tgaaagaggc agccttggaa ccatcaatgg 300aaaaaatctt taaaatcgat
caaatgggaa ggtggtttgt tgctggagga gcagctgttg 360gtcttggagc
gctctgctac tatggcttgg gaatgtctaa tgagattgga gctatcgaaa
420aggctgtaat ttggcctcag tatgtaaagg atagaattca ttctacttac
atgtacttag 480caggaaggta ttgtttaaca gctttgtctg ccttggcagt
agccagaaca cctgctctca 540tgaacttcat gatgacaggc tcttgggtga
caattggtgc gacctttgca gccatgattg 600gagctggaat gcttgtacac
tcaatatcat atgagcagag cccaggccca aagcatctgg 660cttggatgct
gcattctggt gtgatgggtg cagttgtggc tcctctgacg atcttagggg
720ggcctcttct cctgagagcc gcatggtaca ccgctggtat tgtgggaggc
ctctctactg 780tggccatgtg tgcgcctagt gagaagtttc tgaacatggg
agcacccctg ggagtgggcc 840tgggtcttgt ctttgcgtct tctctggggt
ctatgtttct tccccctacc tctgtggctg 900gtgccactct gtactcagtg
gcaatgtatg gtggattagt tcttttcagc atgttccttc 960tgtatgatac
tcagaaagta atcaaacgtg cagaaataac acccatgtat ggagctcaaa
1020agtatgatcc catcaattcg atgttgacaa tctacatgga tacattaaat
atatttatgc 1080gagttgcaac tatgctagca actggaagca acagaaagaa
atgaagtaac cgcttgtgat 1140gtctccgctc actgatgtct tgcttgttta
ataggagcag atagtcatta cagtttgcat 1200cagcagaatt cccgcgcggc cgc
12234839DNAMus musculus 4gctgtgcctg gcatcagtct tgccctctcc
cctttggcca cgcggccctt ctcagcgatt 60tgcagcagac ccgcagggca gtgtgcctcg
gtggcattga actgaagctt ggctctcggc 120ctggcctgct ggctagttgc
ccaccctgtg ggtcccgccc agagcaagga tactggagct 180ttcgcctgcc
tcactgagcc tgggtctcca ctccagtcat ccctccagct actttgcagc
240actctgtcgc catgagcacc tcgtctgcgc ggcctgcagt cctggccctt
gccgggctgg 300ctctgctcct tctgctgtgc ctgggtccag atggcataag
tggaaacaaa ctcaagaaga 360tgctccagaa acgagaagga cctgtcccgt
caaagactaa tgtagctgta gccgagaaca 420cagcaaagga attcctaggt
ggcctgaagc gtgccaaacg acagctgtgg gaccgtacgc 480ggcctgaggt
acagcagtgg taccagcagt tcctctacat gggctttgat gaggctaaat
540ttgaagatga tgtcaactat tggctaaaca gaaatcgaaa cggccatgac
tactatggtg 600actactacca gcgtcattat gatgaagatg cggccattgg
tccccacagc cgggaaagct 660tcaggcatgg agccagtgtg aactatgatg
actattaagc ttcctgaggt gcccacagag 720cttgtgcctg cttcagtagg
ccttctctac ctataccacg tgaccatcag gctaaaggaa 780agaatataag
tgctttttgc atttcatgca tgtgcttaac gatatgtctc acttaaaaa
83951420DNAMus musculus 5cctgtgccta ttttgatgga tggcaatgct
aagcaagcaa gcactgttca cttgtgactt 60tcatttctca cactgtgcac tgtcaaagac
aaatgtgcat ggaaaaatgt ttagtgtcac 120ctcatggcgt tctcagcatc
agtgaccttc aaacggtcct acaatgagac tgtgttctag 180ctaggggtat
gctgtggaaa ttcctgctac atttcatctt agtgctaaca tgtacagatt
240ctgctgcgct acattcaaag ctcattactg tatatttatg ctttctctgt
gtaacaagtt 300atacctgata agatgtcact ttgtttctag tgattcttaa
ccatggtctg gtacatggct 360attctagttt tggaaattaa caagtgtttt
gttgcctctt gttttctttt gttcctatca 420tttttggcgg gggttgggtg
ggcttgattc taaccgtaag tataggataa gctagttttg 480tatatagagt
caaatgactg atgtcagagg atcagtgctg atagaacttc cccagttcat
540gtcacgatac acacagagag aaagcagcat gaggcatctt gccatcagaa
gccaaatttc 600ttttgagtcc caaaattgat gacttatgaa atatagctga
aaacaagatt tgggtgtagt 660tacttgtatt tattatacaa tttccaatta
catttttttt caaactcaaa ataacccatg 720actttgagtg ataggtcact
tggcaatgtt cttgaattac tggggaagct gttgtcacta 780agataatgag
agagaaaata gaatggcttc gcccaagtga gagccacatc ttacatttct
840ctgttgaatc ggaatcaact atattagaac agaagcctga tagaagcttt
ctagttaaca 900cacacaaggc catggtttca aaaacatctt tgtcccctta
ggtcagtttg tccttagatt 960atgaattggc aggttctaat tgcattattt
ccctggctga tccaggaaaa agttagaaca 1020aaataagttg catagttttg
aggaaacatc caaagcaagg cgaagccttt ccttgccttg 1080cattggcaaa
actacctctt tagcatttat gttgattcag aaacatcttg ctgatatgtg
1140tagatgtttt aagcttcatt gtgaaaatat tgatgcaaga taagccatat
atgaatgttg 1200tattcaactt tagggcttga aattaatcct aaagtgttca
cctctctcca tgtctattta 1260cactctgttc ctatttacta agagggtagg
ggtctcctta atatcatact tcattgttaa 1320taagtcaatg cttgttatgt
ttcttggctg ttgtttttgt gcattaaaaa ctcaaaattg 1380gaaaaaaaaa
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 14206763DNAMus musculus
6cccgccctcg cgaccccggc tctcctggac tcggcgccgc caacctgggc gatgccccgc
60tacgagttgg ctttgattct gaaagccatg cggcggccag agaccgctgc tgctttgaaa
120cgtacaatag aatccctgat ggaccgagga gccatagtga ggaacttgga
aagcctgggt 180gagcgtgcgc tcccctacag gatctcgagt cacagccagc
agcacagccg aggagggtat 240ttcctggtgg atttttatgc tccgacaagt
gctgtggaga acatactgga acacttggcg 300cgagacattg acgtggttag
accaaatatt gtgaaacacc ctctgaccca ggaagtaaaa 360gagtgtgacg
gcatagtccc agtcccactt gaagaaaaac tgtattcaac aaagaggagg
420aagaagtgag aagattcacc agattctggc cttatattta atcctaaggg
cactatgggt 480gctgctaggt tgttgtctag gatactttag cccatgacca
ttttgctgca ggaggtagaa 540actgctggcc gagacctgcc ctgatgtctc
tgctgagatt tcatcccact tgtggggttt 600gtcgggagtg ggggtgttca
cagtaccact gtagcgtttc caagagcaaa atgtttgtca 660ttcacacttg
gttgtcttgc aagcctatat ggaacactgg gagcagagta ataaacatga
720ctttatcaac actggaaaaa aaaaaaaaaa aaaaaaaaaa aaa 76371300DNAMus
musculus 7ggtatgcagt ctttcgcttg aatttgctgt ttgtttatat agtaataaca
gcgctatcta 60taaggcttac tggccttatt cctggttcca taagacacag gctgtacccc
tttactgaat 120ggcatgggct cagcttggag gaaagtcaga ggaaattcag
ataacttggt atctcttcct 180gtcgttgcaa tgtttcgggg tccacttcac
tatgagatac caagcagctg ccaacctcac 240catactcatt tcgttacaat
ttctgaggca ccgtggtgac ttgatccgac atacgaccac 300gtcagttaca
aaccagatct ttatggttaa cttttgaaca tttcacaaac aacattgtaa
360atgtgcgatg ttatgtttta aatcagacca cagtggtccc caaatattat
gtacatatga 420caaatgtcag tgtaactttt tgttacactg acagtttcat
aggtaaacaa acctacgctc 480caatgttaaa ttatgcttgt gtatgtaaaa
tacacaagca ttgggctatg tgtgtacgga 540catgagggta gtgcaatcgt
actgtacgaa atgggtcaga atcattttca gtggtgttag 600gttatgtagt
ttcagactcc atgctgcatt ttctcttgca catgccatcc atttgcttat
660tttggagtgt gagtattcct tcttattaat ttgaattcaa agcacaagcc
tcccattgtt 720caacattacc caacaagagt gtccagtgat gaccgagtta
tctcacctgc tatactttta 780ctgcaataat taatgacacc tggatgagga
ggcgtgcgct gacttcattg ttcacccggg 840atagtgcatg agcccactga
attagagctg cttctaccag caaaagtgag cagtacacat 900aggtgcatgt
ttgaaacatg aatcacatag agctatggag ttttgccaag tgatgtgttt
960tctttttctt ttttcttttt ttttcttttt cttctttttt ttccttttct
tcttcttctt 1020cttttttttt ttttttacta tgcaaagatg ggaaatgcac
aaacttccaa gacatgtctg 1080aagaacttta caatacttga attttttctt
taatcatccc atcacattta tggcattgat 1140gcttccattg tatttttctt
ttgtcccttc aacttcaatg gtttgtaatt tcaatgcaca 1200acctaacttt
tgtttgcagt aacttccaat cctattggct gcctggaacg gagattctgt
1260catcctacac gcatctttta gttgactgtg cataaaagtt 130081674DNAMus
musculusCDS(1)..(1671) 8atg gaa ctc cgg acc cga ggc tgg tgg ctg ctg
tgc gcg gcc gcc gcg 48Met Glu Leu Arg Thr Arg Gly Trp Trp Leu Leu
Cys Ala Ala Ala Ala1 5 10 15ctg gtc gtc tgc gcc cgc ggg gac ccc gcc
agc aag agc cgg agc tgc 96Leu Val Val Cys Ala Arg Gly Asp Pro Ala
Ser Lys Ser Arg Ser Cys 20 25 30agc gaa gtc cgc cag atc tac ggg gct
aag ggc ttt agc ctg agc gat 144Ser Glu Val Arg Gln Ile Tyr Gly Ala
Lys Gly Phe Ser Leu Ser Asp 35 40 45gtg ccc cag gca gag atc tcg ggt
gag cac ctg cgg atc tgc ccc cag 192Val Pro Gln Ala Glu Ile Ser Gly
Glu His Leu Arg Ile Cys Pro Gln 50 55 60ggc tac act tgc tgt acc agt
gag atg gag gag aat ttg gcc aac cac 240Gly Tyr Thr Cys Cys Thr Ser
Glu Met Glu Glu Asn Leu Ala Asn His65 70 75 80agc cga atg gag ctg
gag agc gca ctc cat gac agc agc cgc gcc ctg 288Ser Arg Met Glu Leu
Glu Ser Ala Leu His Asp Ser Ser Arg Ala Leu 85 90 95cag gcc aca ctg
gcc acc cag ctg cat ggc atc gat gac cac ttc cag 336Gln Ala Thr Leu
Ala Thr Gln Leu His Gly Ile Asp Asp His Phe Gln 100 105 110cgc ctg
ctg aat gac tcg gag cgc aca ctg cag gag gct ttc cct ggg 384Arg Leu
Leu Asn Asp Ser Glu Arg Thr Leu Gln Glu Ala Phe Pro Gly 115 120
125gcc ttt ggg gac ctg tat acg cag aac act cgt gcc ttc cgg gac cta
432Ala Phe Gly Asp Leu Tyr Thr Gln Asn Thr Arg Ala Phe Arg Asp Leu
130 135 140tat gtt gag ctg cgc ctc tac tac cgt ggg gcc aac ctg cac
ctt gag 480Tyr Val Glu Leu Arg Leu Tyr Tyr Arg Gly Ala Asn Leu His
Leu Glu145 150 155 160gag acg ctg gcc gag ttc tgg gca cgg ctg ctg
gag cgc ctc ttc aag 528Glu Thr Leu Ala Glu Phe Trp Ala Arg Leu Leu
Glu Arg Leu Phe Lys 165 170 175cag ctg cac ccc cag ctg ctg cct gat
gac tac ctg gac tgc ctg ggc 576Gln Leu His Pro Gln Leu Leu Pro Asp
Asp Tyr Leu Asp Cys Leu Gly 180 185 190aag cag gcg gag gca ctg cgg
ccg ttt gga gat gcc cct cga gaa ctg 624Lys Gln Ala Glu Ala Leu Arg
Pro Phe Gly Asp Ala Pro Arg Glu Leu 195 200 205cgc ctg cgg gcc acc
cgt gcc ttt gtg gct gca cgt tcc ttt gtg cag 672Arg Leu Arg Ala Thr
Arg Ala Phe Val Ala Ala Arg Ser Phe Val Gln 210 215 220ggc ctg ggt
gtg gcc agt gat gta gtc cgg aag gtg gcc cag gta cct 720Gly Leu Gly
Val Ala Ser Asp Val Val Arg Lys Val Ala Gln Val Pro225 230 235
240ctg gcc cca gaa tgt tct cgg gcc atc atg aag ttg gtc tac tgt gct
768Leu Ala Pro Glu Cys Ser Arg Ala Ile Met Lys Leu Val Tyr Cys Ala
245 250 255cat tgc cgg gga gtc ccg ggc gcc cgg ccc tgc ccc gac tat
tgc cga 816His Cys Arg Gly Val Pro Gly Ala Arg Pro Cys Pro Asp Tyr
Cys Arg 260 265 270aat gtg ctc aaa ggc tgc ctt gcc aac cag gcc gac
ctg gat gcc gag 864Asn Val Leu Lys Gly Cys Leu Ala Asn Gln Ala Asp
Leu Asp Ala Glu 275 280 285tgg agg aac ctc ctg gac tcc atg gtg ctc
atc act gac aag ttc tgg 912Trp Arg Asn Leu Leu Asp Ser Met Val Leu
Ile Thr Asp Lys Phe Trp 290 295 300ggc ccg tcg ggt gcg gag agt gtc
att ggc ggt gtg cac gtg tgg ctg 960Gly Pro Ser Gly Ala Glu Ser Val
Ile Gly Gly Val His Val Trp Leu305 310 315 320gcg gag gcc atc aac
gcc ctc cag gac aac aag gac aca ctc aca gct 1008Ala Glu Ala Ile Asn
Ala Leu Gln Asp Asn Lys Asp Thr Leu Thr Ala 325 330 335aag gtc atc
cag gcc tgt gga aac ccc aag gtc aat ccc cac ggc tct 1056Lys Val Ile
Gln Ala Cys Gly Asn Pro Lys Val Asn Pro His Gly Ser 340 345 350ggg
ccc gag gag aag cgt cgc cgt ggc aaa ttg gca ctg cag gag aag 1104Gly
Pro Glu Glu Lys Arg Arg Arg Gly Lys Leu Ala Leu Gln Glu Lys 355 360
365ccc tcc aca ggt act ctg gaa aaa ctg gtc tct gag gcc aag gcc cag
1152Pro Ser Thr Gly Thr Leu Glu Lys Leu Val Ser Glu Ala Lys Ala Gln
370 375 380ctc cga gac att cag gac ttc tgg atc agc ctc cca ggg aca
ctg tgc 1200Leu Arg Asp Ile Gln Asp Phe Trp Ile Ser Leu Pro Gly Thr
Leu Cys385 390 395 400agt gag aag atg gcc atg agt cct gcc agt gat
gac cgc tgc tgg aat 1248Ser Glu Lys Met Ala Met Ser Pro Ala Ser Asp
Asp Arg Cys Trp Asn 405 410 415gga att tcc aag ggc cgg tac cta cca
gag gtg atg ggt gac ggg ctg 1296Gly Ile Ser Lys Gly Arg Tyr Leu Pro
Glu Val Met Gly Asp Gly Leu 420 425 430gcc aac cag atc aac aac cct
gag gtg gaa gtg gac atc acc aag cca 1344Ala Asn Gln Ile Asn Asn Pro
Glu Val Glu Val Asp Ile Thr Lys Pro 435 440 445gac atg acc atc cgc
cag cag att atg cag ctc aag atc atg acc aac 1392Asp Met Thr Ile Arg
Gln Gln Ile Met Gln Leu Lys Ile Met Thr Asn 450 455 460cgt tta cgt
ggc gcc tat ggc ggc aac gac gtg gac ttc cag gat gct 1440Arg Leu Arg
Gly Ala Tyr Gly Gly Asn Asp Val Asp Phe Gln Asp Ala465 470 475
480agt gat gac ggc agt ggc tcc ggc agc ggt ggc gga tgc cca gat gac
1488Ser Asp Asp Gly Ser Gly Ser Gly Ser Gly Gly Gly Cys Pro Asp Asp
485 490 495acc tgt ggc cgg agg gtc agc aag aag agt tcc agc tcc cgg
acc ccc 1536Thr Cys Gly Arg Arg Val Ser Lys Lys Ser Ser Ser Ser Arg
Thr Pro 500 505 510ttg acc cat gcc ctc ccc ggc ctg tca gaa cag gag
gga cag aag acc 1584Leu Thr His Ala Leu Pro Gly Leu Ser Glu Gln Glu
Gly Gln Lys Thr 515 520 525tca gct gcc acc tgc cca gag ccc cac agc
ttc ttc ctg ctc ttc ctc 1632Ser Ala Ala Thr Cys Pro Glu Pro His Ser
Phe Phe Leu Leu Phe Leu 530 535 540gtc acc ttg gtc ctt gcg gca gcc
agg ccc agg tgg cgg taa 1674Val Thr Leu Val Leu Ala Ala Ala Arg Pro
Arg Trp Arg545 550 5559557PRTMus musculus 9Met Glu Leu Arg Thr Arg
Gly Trp Trp Leu Leu Cys Ala Ala Ala Ala1 5 10 15Leu Val Val Cys Ala
Arg Gly Asp Pro Ala Ser Lys Ser Arg Ser Cys 20 25 30Ser Glu Val Arg
Gln Ile Tyr Gly Ala Lys Gly Phe Ser Leu Ser Asp 35 40 45Val Pro Gln
Ala Glu Ile Ser Gly Glu His Leu Arg Ile Cys Pro Gln 50 55 60Gly Tyr
Thr Cys Cys Thr Ser Glu Met Glu Glu Asn Leu Ala Asn His65 70 75
80Ser Arg Met Glu Leu Glu Ser Ala Leu His Asp Ser Ser Arg Ala Leu
85 90 95Gln Ala Thr Leu Ala Thr Gln Leu His Gly Ile Asp Asp His Phe
Gln 100 105 110Arg Leu Leu Asn Asp Ser Glu Arg Thr Leu Gln Glu Ala
Phe Pro Gly 115 120 125Ala Phe Gly Asp Leu Tyr Thr Gln Asn Thr Arg
Ala Phe Arg Asp Leu 130 135 140Tyr Val Glu Leu Arg Leu Tyr Tyr Arg
Gly Ala Asn Leu His Leu Glu145 150 155 160Glu Thr Leu Ala Glu Phe
Trp Ala Arg Leu Leu Glu Arg Leu Phe Lys 165 170 175Gln Leu His Pro
Gln Leu Leu Pro Asp Asp Tyr Leu Asp Cys Leu Gly 180 185 190Lys Gln
Ala Glu Ala Leu Arg Pro Phe Gly Asp Ala Pro Arg Glu Leu 195 200
205Arg Leu Arg Ala Thr Arg Ala Phe Val Ala Ala Arg Ser Phe Val Gln
210 215 220Gly Leu Gly Val Ala Ser Asp Val Val Arg Lys Val Ala Gln
Val Pro225 230 235 240Leu Ala Pro Glu Cys Ser Arg Ala Ile Met Lys
Leu Val Tyr Cys Ala 245 250 255His Cys Arg Gly Val Pro Gly Ala Arg
Pro Cys Pro Asp Tyr Cys Arg 260 265 270Asn Val Leu Lys Gly Cys Leu
Ala Asn Gln Ala Asp Leu Asp Ala Glu 275 280 285Trp Arg Asn Leu Leu
Asp Ser Met Val Leu Ile Thr Asp Lys Phe Trp 290 295 300Gly Pro Ser
Gly Ala Glu Ser Val Ile Gly Gly Val His Val Trp Leu305 310 315
320Ala Glu Ala Ile Asn Ala Leu Gln Asp Asn Lys Asp Thr Leu Thr Ala
325 330 335Lys Val Ile Gln Ala Cys Gly Asn Pro Lys Val Asn Pro His
Gly Ser 340 345 350Gly Pro Glu Glu Lys Arg Arg Arg Gly Lys Leu Ala
Leu Gln Glu Lys 355 360 365Pro Ser Thr Gly Thr Leu Glu Lys Leu Val
Ser Glu Ala Lys Ala Gln 370 375 380Leu Arg Asp Ile Gln Asp Phe Trp
Ile Ser Leu Pro Gly Thr Leu Cys385 390 395 400Ser Glu Lys Met Ala
Met Ser Pro Ala Ser Asp Asp Arg Cys Trp Asn 405 410 415Gly Ile Ser
Lys Gly Arg Tyr Leu Pro Glu Val Met Gly Asp Gly Leu 420 425 430Ala
Asn Gln Ile Asn Asn Pro Glu Val Glu Val Asp Ile Thr Lys Pro 435 440
445Asp Met Thr Ile Arg Gln Gln Ile Met Gln Leu Lys Ile Met Thr Asn
450 455 460Arg Leu Arg Gly Ala Tyr Gly Gly
Asn Asp Val Asp Phe Gln Asp Ala465 470 475 480Ser Asp Asp Gly Ser
Gly Ser Gly Ser Gly Gly Gly Cys Pro Asp Asp 485 490 495Thr Cys Gly
Arg Arg Val Ser Lys Lys Ser Ser Ser Ser Arg Thr Pro 500 505 510Leu
Thr His Ala Leu Pro Gly Leu Ser Glu Gln Glu Gly Gln Lys Thr 515 520
525Ser Ala Ala Thr Cys Pro Glu Pro His Ser Phe Phe Leu Leu Phe Leu
530 535 540Val Thr Leu Val Leu Ala Ala Ala Arg Pro Arg Trp Arg545
550 555101677DNAHomo sapiensCDS(1)..(1674) 10atg gag ctc cgg gcc
cga ggc tgg tgg ctg cta tgt gcg gcc gca gcg 48Met Glu Leu Arg Ala
Arg Gly Trp Trp Leu Leu Cys Ala Ala Ala Ala1 5 10 15ctg gtc gcc tgc
gcc cgc ggg gac ccg gcc agc aag agc cgg agc tgc 96Leu Val Ala Cys
Ala Arg Gly Asp Pro Ala Ser Lys Ser Arg Ser Cys 20 25 30ggc gag gtc
cgc cag atc tac gga gcc aag ggc ttc agc ctg agc gac 144Gly Glu Val
Arg Gln Ile Tyr Gly Ala Lys Gly Phe Ser Leu Ser Asp 35 40 45gtg ccc
cag gcg gag atc tcg ggt gag cac ctg cgg atc tgt ccc cag 192Val Pro
Gln Ala Glu Ile Ser Gly Glu His Leu Arg Ile Cys Pro Gln 50 55 60ggc
tac acc tgc tgc acc agc gag atg gag gag aac ctg gcc aac cgc 240Gly
Tyr Thr Cys Cys Thr Ser Glu Met Glu Glu Asn Leu Ala Asn Arg65 70 75
80agc cat gcc gag ctg gag acc gcg ctc cgg gac agc agc cgc gtc ctg
288Ser His Ala Glu Leu Glu Thr Ala Leu Arg Asp Ser Ser Arg Val Leu
85 90 95cag gcc atg ctt gcc acc cag ctg cgc agc ttc gat gac cac ttc
cag 336Gln Ala Met Leu Ala Thr Gln Leu Arg Ser Phe Asp Asp His Phe
Gln 100 105 110cac ctg ctg aac gac tcg gag cgg acg ctg cag gcc acc
ttc ccc ggc 384His Leu Leu Asn Asp Ser Glu Arg Thr Leu Gln Ala Thr
Phe Pro Gly 115 120 125gcc ttc gga gag ctg tac acg cag aac gcg agg
gcc ttc cgg gac ctg 432Ala Phe Gly Glu Leu Tyr Thr Gln Asn Ala Arg
Ala Phe Arg Asp Leu 130 135 140tac tca gag ctg cgc ctg tac tac cgc
ggt gcc aac ctg cac ctg gag 480Tyr Ser Glu Leu Arg Leu Tyr Tyr Arg
Gly Ala Asn Leu His Leu Glu145 150 155 160gag acg ctg gcc gag ttc
tgg gcc cgc ctg ctc gag cgc ctc ttc aag 528Glu Thr Leu Ala Glu Phe
Trp Ala Arg Leu Leu Glu Arg Leu Phe Lys 165 170 175cag ctg cac ccc
cag ctg ctg ctg cct gat gac tac ctg gac tgc ctg 576Gln Leu His Pro
Gln Leu Leu Leu Pro Asp Asp Tyr Leu Asp Cys Leu 180 185 190ggc aag
cag gcc gag gcg ctg cgg ccc ttc ggg gag gcc ccg aga gag 624Gly Lys
Gln Ala Glu Ala Leu Arg Pro Phe Gly Glu Ala Pro Arg Glu 195 200
205ctg cgc ctg cgg gcc acc cgt gcc ttc gtg gct gct cgc tcc ttt gtg
672Leu Arg Leu Arg Ala Thr Arg Ala Phe Val Ala Ala Arg Ser Phe Val
210 215 220cag ggc ctg ggc gtg gcc agc gac gtg gtc cgg aaa gtg gct
cag gtc 720Gln Gly Leu Gly Val Ala Ser Asp Val Val Arg Lys Val Ala
Gln Val225 230 235 240ccc ctg ggc ccg gag tgc tcg aga gct gtc atg
aag ctg gtc tac tgt 768Pro Leu Gly Pro Glu Cys Ser Arg Ala Val Met
Lys Leu Val Tyr Cys 245 250 255gct cac tgc ctg gga gtc ccc ggc gcc
agg ccc tgc cct gac tat tgc 816Ala His Cys Leu Gly Val Pro Gly Ala
Arg Pro Cys Pro Asp Tyr Cys 260 265 270cga aat gtg ctc aag ggc tgc
ctt gcc aac cag gcc gac ctg gac gcc 864Arg Asn Val Leu Lys Gly Cys
Leu Ala Asn Gln Ala Asp Leu Asp Ala 275 280 285gag tgg agg aac ctc
ctg gac tcc atg gtg ctc atc acc gac aag ttc 912Glu Trp Arg Asn Leu
Leu Asp Ser Met Val Leu Ile Thr Asp Lys Phe 290 295 300tgg ggt aca
tcg ggt gtg gag agt gtc atc ggc agc gtg cac acg tgg 960Trp Gly Thr
Ser Gly Val Glu Ser Val Ile Gly Ser Val His Thr Trp305 310 315
320ctg gcg gag gcc atc aac gcc ctc cag gac aac agg gac acg ctc acg
1008Leu Ala Glu Ala Ile Asn Ala Leu Gln Asp Asn Arg Asp Thr Leu Thr
325 330 335gcc aag gtc atc cag ggc tgc ggg aac ccc aag gtc aac ccc
cag ggc 1056Ala Lys Val Ile Gln Gly Cys Gly Asn Pro Lys Val Asn Pro
Gln Gly 340 345 350cct ggg cct gag gag aag cgg cgc cgg ggc aag ctg
gcc ccg cgg gag 1104Pro Gly Pro Glu Glu Lys Arg Arg Arg Gly Lys Leu
Ala Pro Arg Glu 355 360 365agg cca cct tca ggc acg ctg gag aag ctg
gtc tct gaa gcc aag gcc 1152Arg Pro Pro Ser Gly Thr Leu Glu Lys Leu
Val Ser Glu Ala Lys Ala 370 375 380cag ctc cgc gac gtc cag gac ttc
tgg atc agc ctc cca ggg aca ctg 1200Gln Leu Arg Asp Val Gln Asp Phe
Trp Ile Ser Leu Pro Gly Thr Leu385 390 395 400tgc agt gag aag atg
gcc ctg agc act gcc agt gat gac cgc tgc tgg 1248Cys Ser Glu Lys Met
Ala Leu Ser Thr Ala Ser Asp Asp Arg Cys Trp 405 410 415aac ggg atg
gcc aga ggc cgg tac ctc ccc gag gtc atg ggt gac ggc 1296Asn Gly Met
Ala Arg Gly Arg Tyr Leu Pro Glu Val Met Gly Asp Gly 420 425 430ctg
gcc aac cag atc aac aac ccc gag gtg gag gtg gac atc acc aag 1344Leu
Ala Asn Gln Ile Asn Asn Pro Glu Val Glu Val Asp Ile Thr Lys 435 440
445ccg gac atg acc atc cgg cag cag atc atg cag ctg aag atc atg acc
1392Pro Asp Met Thr Ile Arg Gln Gln Ile Met Gln Leu Lys Ile Met Thr
450 455 460aac cgg ctg cgc agc gcc tac aac ggc aac gac gtg gac ttc
cag gac 1440Asn Arg Leu Arg Ser Ala Tyr Asn Gly Asn Asp Val Asp Phe
Gln Asp465 470 475 480gcc agt gac gac ggc agc ggc tcg ggc agc ggt
gat ggc tgt ctg gat 1488Ala Ser Asp Asp Gly Ser Gly Ser Gly Ser Gly
Asp Gly Cys Leu Asp 485 490 495gac ctc tgc ggc cgg aag gtc agc agg
aag agc tcc agc tcc cgg acg 1536Asp Leu Cys Gly Arg Lys Val Ser Arg
Lys Ser Ser Ser Ser Arg Thr 500 505 510ccc ttg acc cat gcc ctc cca
ggc ctg tca gag cag gaa gga cag aag 1584Pro Leu Thr His Ala Leu Pro
Gly Leu Ser Glu Gln Glu Gly Gln Lys 515 520 525acc tcg gct gcc agc
tgc ccc cag ccc ccg acc ttc ctc ctg ccc ctc 1632Thr Ser Ala Ala Ser
Cys Pro Gln Pro Pro Thr Phe Leu Leu Pro Leu 530 535 540ctc ctc ttc
ctg gcc ctt aca gta gcc agg ccc cgg tgg cgg taa 1677Leu Leu Phe Leu
Ala Leu Thr Val Ala Arg Pro Arg Trp Arg545 550 55511558PRTHomo
sapiens 11Met Glu Leu Arg Ala Arg Gly Trp Trp Leu Leu Cys Ala Ala
Ala Ala1 5 10 15Leu Val Ala Cys Ala Arg Gly Asp Pro Ala Ser Lys Ser
Arg Ser Cys 20 25 30Gly Glu Val Arg Gln Ile Tyr Gly Ala Lys Gly Phe
Ser Leu Ser Asp 35 40 45Val Pro Gln Ala Glu Ile Ser Gly Glu His Leu
Arg Ile Cys Pro Gln 50 55 60Gly Tyr Thr Cys Cys Thr Ser Glu Met Glu
Glu Asn Leu Ala Asn Arg65 70 75 80Ser His Ala Glu Leu Glu Thr Ala
Leu Arg Asp Ser Ser Arg Val Leu 85 90 95Gln Ala Met Leu Ala Thr Gln
Leu Arg Ser Phe Asp Asp His Phe Gln 100 105 110His Leu Leu Asn Asp
Ser Glu Arg Thr Leu Gln Ala Thr Phe Pro Gly 115 120 125Ala Phe Gly
Glu Leu Tyr Thr Gln Asn Ala Arg Ala Phe Arg Asp Leu 130 135 140Tyr
Ser Glu Leu Arg Leu Tyr Tyr Arg Gly Ala Asn Leu His Leu Glu145 150
155 160Glu Thr Leu Ala Glu Phe Trp Ala Arg Leu Leu Glu Arg Leu Phe
Lys 165 170 175Gln Leu His Pro Gln Leu Leu Leu Pro Asp Asp Tyr Leu
Asp Cys Leu 180 185 190Gly Lys Gln Ala Glu Ala Leu Arg Pro Phe Gly
Glu Ala Pro Arg Glu 195 200 205Leu Arg Leu Arg Ala Thr Arg Ala Phe
Val Ala Ala Arg Ser Phe Val 210 215 220Gln Gly Leu Gly Val Ala Ser
Asp Val Val Arg Lys Val Ala Gln Val225 230 235 240Pro Leu Gly Pro
Glu Cys Ser Arg Ala Val Met Lys Leu Val Tyr Cys 245 250 255Ala His
Cys Leu Gly Val Pro Gly Ala Arg Pro Cys Pro Asp Tyr Cys 260 265
270Arg Asn Val Leu Lys Gly Cys Leu Ala Asn Gln Ala Asp Leu Asp Ala
275 280 285Glu Trp Arg Asn Leu Leu Asp Ser Met Val Leu Ile Thr Asp
Lys Phe 290 295 300Trp Gly Thr Ser Gly Val Glu Ser Val Ile Gly Ser
Val His Thr Trp305 310 315 320Leu Ala Glu Ala Ile Asn Ala Leu Gln
Asp Asn Arg Asp Thr Leu Thr 325 330 335Ala Lys Val Ile Gln Gly Cys
Gly Asn Pro Lys Val Asn Pro Gln Gly 340 345 350Pro Gly Pro Glu Glu
Lys Arg Arg Arg Gly Lys Leu Ala Pro Arg Glu 355 360 365Arg Pro Pro
Ser Gly Thr Leu Glu Lys Leu Val Ser Glu Ala Lys Ala 370 375 380Gln
Leu Arg Asp Val Gln Asp Phe Trp Ile Ser Leu Pro Gly Thr Leu385 390
395 400Cys Ser Glu Lys Met Ala Leu Ser Thr Ala Ser Asp Asp Arg Cys
Trp 405 410 415Asn Gly Met Ala Arg Gly Arg Tyr Leu Pro Glu Val Met
Gly Asp Gly 420 425 430Leu Ala Asn Gln Ile Asn Asn Pro Glu Val Glu
Val Asp Ile Thr Lys 435 440 445Pro Asp Met Thr Ile Arg Gln Gln Ile
Met Gln Leu Lys Ile Met Thr 450 455 460Asn Arg Leu Arg Ser Ala Tyr
Asn Gly Asn Asp Val Asp Phe Gln Asp465 470 475 480Ala Ser Asp Asp
Gly Ser Gly Ser Gly Ser Gly Asp Gly Cys Leu Asp 485 490 495Asp Leu
Cys Gly Arg Lys Val Ser Arg Lys Ser Ser Ser Ser Arg Thr 500 505
510Pro Leu Thr His Ala Leu Pro Gly Leu Ser Glu Gln Glu Gly Gln Lys
515 520 525Thr Ser Ala Ala Ser Cys Pro Gln Pro Pro Thr Phe Leu Leu
Pro Leu 530 535 540Leu Leu Phe Leu Ala Leu Thr Val Ala Arg Pro Arg
Trp Arg545 550 55512369DNAMus musculusCDS(1)..(366) 12atg aag cct
ttt cat act gcc ctc tcc ttc ctc att ctt aca act gct 48Met Lys Pro
Phe His Thr Ala Leu Ser Phe Leu Ile Leu Thr Thr Ala1 5 10 15ctt gga
atc tgg gcc cag atc aca cat gca aca gag aca aaa gaa gtc 96Leu Gly
Ile Trp Ala Gln Ile Thr His Ala Thr Glu Thr Lys Glu Val 20 25 30cag
agc agt ctg aag gca cag caa ggg ctt gaa att gaa atg ttt cac 144Gln
Ser Ser Leu Lys Ala Gln Gln Gly Leu Glu Ile Glu Met Phe His 35 40
45atg ggc ttt caa gac tct tca gat tgc tgc ctg tcc tat aac tca cgg
192Met Gly Phe Gln Asp Ser Ser Asp Cys Cys Leu Ser Tyr Asn Ser Arg
50 55 60att cag tgt tca aga ttt ata ggt tat ttt ccc acc agt ggt ggg
tgt 240Ile Gln Cys Ser Arg Phe Ile Gly Tyr Phe Pro Thr Ser Gly Gly
Cys65 70 75 80acc agg ccg ggc atc atc ttt atc agc aag agg ggg ttc
cag gtc tgt 288Thr Arg Pro Gly Ile Ile Phe Ile Ser Lys Arg Gly Phe
Gln Val Cys 85 90 95gcc aac ccc agt gat cgg aga gtt cag aga tgc att
gaa aga ttg gag 336Ala Asn Pro Ser Asp Arg Arg Val Gln Arg Cys Ile
Glu Arg Leu Glu 100 105 110caa aac tca caa cca cgg acc tac aaa caa
taa 369Gln Asn Ser Gln Pro Arg Thr Tyr Lys Gln 115 12013122PRTMus
musculus 13Met Lys Pro Phe His Thr Ala Leu Ser Phe Leu Ile Leu Thr
Thr Ala1 5 10 15Leu Gly Ile Trp Ala Gln Ile Thr His Ala Thr Glu Thr
Lys Glu Val 20 25 30Gln Ser Ser Leu Lys Ala Gln Gln Gly Leu Glu Ile
Glu Met Phe His 35 40 45Met Gly Phe Gln Asp Ser Ser Asp Cys Cys Leu
Ser Tyr Asn Ser Arg 50 55 60Ile Gln Cys Ser Arg Phe Ile Gly Tyr Phe
Pro Thr Ser Gly Gly Cys65 70 75 80Thr Arg Pro Gly Ile Ile Phe Ile
Ser Lys Arg Gly Phe Gln Val Cys 85 90 95Ala Asn Pro Ser Asp Arg Arg
Val Gln Arg Cys Ile Glu Arg Leu Glu 100 105 110Gln Asn Ser Gln Pro
Arg Thr Tyr Lys Gln 115 120141223DNAMus musculusCDS(84)..(1121)
14gtgacccgga agggagcccc gtggtagagg tgaccggagc tgagcatttc agatctgctt
60agtaaaccgg tgtatcgccc acc atg ttg gct gca agg ctt gtg tgt ctc cgg
113 Met Leu Ala Ala Arg Leu Val Cys Leu Arg 1 5 10aca cta cct tcc
agg gtt ttc cag ccc act ttc atc acc aag gcc tct 161Thr Leu Pro Ser
Arg Val Phe Gln Pro Thr Phe Ile Thr Lys Ala Ser 15 20 25cca ctt gtg
aag aat tcc atc aca aag aac caa tgg ctc gta aca ccc 209Pro Leu Val
Lys Asn Ser Ile Thr Lys Asn Gln Trp Leu Val Thr Pro 30 35 40agc agg
gaa tat gct acc aag aca aga att agg act cac cgt ggg aaa 257Ser Arg
Glu Tyr Ala Thr Lys Thr Arg Ile Arg Thr His Arg Gly Lys 45 50 55act
gga caa gaa ctg aaa gag gca gcc ttg gaa cca tca atg gaa aaa 305Thr
Gly Gln Glu Leu Lys Glu Ala Ala Leu Glu Pro Ser Met Glu Lys 60 65
70atc ttt aaa atc gat caa atg gga agg tgg ttt gtt gct gga gga gca
353Ile Phe Lys Ile Asp Gln Met Gly Arg Trp Phe Val Ala Gly Gly
Ala75 80 85 90gct gtt ggt ctt gga gcg ctc tgc tac tat ggc ttg gga
atg tct aat 401Ala Val Gly Leu Gly Ala Leu Cys Tyr Tyr Gly Leu Gly
Met Ser Asn 95 100 105gag att gga gct atc gaa aag gct gta att tgg
cct cag tat gta aag 449Glu Ile Gly Ala Ile Glu Lys Ala Val Ile Trp
Pro Gln Tyr Val Lys 110 115 120gat aga att cat tct act tac atg tac
tta gca gga agg tat tgt tta 497Asp Arg Ile His Ser Thr Tyr Met Tyr
Leu Ala Gly Arg Tyr Cys Leu 125 130 135aca gct ttg tct gcc ttg gca
gta gcc aga aca cct gct ctc atg aac 545Thr Ala Leu Ser Ala Leu Ala
Val Ala Arg Thr Pro Ala Leu Met Asn 140 145 150ttc atg atg aca ggc
tct tgg gtg aca att ggt gcg acc ttt gca gcc 593Phe Met Met Thr Gly
Ser Trp Val Thr Ile Gly Ala Thr Phe Ala Ala155 160 165 170atg att
gga gct gga atg ctt gta cac tca ata tca tat gag cag agc 641Met Ile
Gly Ala Gly Met Leu Val His Ser Ile Ser Tyr Glu Gln Ser 175 180
185cca ggc cca aag cat ctg gct tgg atg ctg cat tct ggt gtg atg ggt
689Pro Gly Pro Lys His Leu Ala Trp Met Leu His Ser Gly Val Met Gly
190 195 200gca gtt gtg gct cct ctg acg atc tta ggg ggg cct ctt ctc
ctg aga 737Ala Val Val Ala Pro Leu Thr Ile Leu Gly Gly Pro Leu Leu
Leu Arg 205 210 215gcc gca tgg tac acc gct ggt att gtg gga ggc ctc
tct act gtg gcc 785Ala Ala Trp Tyr Thr Ala Gly Ile Val Gly Gly Leu
Ser Thr Val Ala 220 225 230atg tgt gcg cct agt gag aag ttt ctg aac
atg gga gca ccc ctg gga 833Met Cys Ala Pro Ser Glu Lys Phe Leu Asn
Met Gly Ala Pro Leu Gly235 240 245 250gtg ggc ctg ggt ctt gtc ttt
gcg tct tct ctg ggg tct atg ttt ctt 881Val Gly Leu Gly Leu Val Phe
Ala Ser Ser Leu Gly Ser Met Phe Leu 255 260 265ccc cct acc tct gtg
gct ggt gcc act ctg tac tca gtg gca atg tat 929Pro Pro Thr Ser Val
Ala Gly Ala Thr Leu Tyr Ser Val Ala Met Tyr 270 275 280ggt gga tta
gtt ctt ttc agc atg ttc ctt ctg tat gat act cag aaa 977Gly Gly Leu
Val Leu Phe Ser Met Phe Leu Leu Tyr Asp Thr Gln Lys 285 290 295gta
atc aaa cgt gca gaa ata aca ccc atg tat gga gct caa aag tat 1025Val
Ile Lys Arg Ala Glu Ile Thr Pro Met Tyr Gly Ala Gln Lys Tyr 300 305
310gat ccc atc aat tcg atg ttg aca atc tac atg gat aca tta aat ata
1073Asp Pro Ile Asn Ser Met Leu Thr Ile Tyr Met Asp Thr Leu Asn
Ile315 320 325 330ttt atg cga gtt gca act atg cta gca act gga agc
aac aga aag aaa 1121Phe Met Arg Val Ala Thr Met Leu Ala Thr Gly Ser
Asn Arg Lys Lys 335 340 345tgaagtaacc gcttgtgatg tctccgctca
ctgatgtctt gcttgtttaa taggagcaga 1181tagtcattac agtttgcatc
agcagaattc
ccgcgcggcc gc 122315346PRTMus musculus 15Met Leu Ala Ala Arg Leu
Val Cys Leu Arg Thr Leu Pro Ser Arg Val1 5 10 15Phe Gln Pro Thr Phe
Ile Thr Lys Ala Ser Pro Leu Val Lys Asn Ser 20 25 30Ile Thr Lys Asn
Gln Trp Leu Val Thr Pro Ser Arg Glu Tyr Ala Thr 35 40 45Lys Thr Arg
Ile Arg Thr His Arg Gly Lys Thr Gly Gln Glu Leu Lys 50 55 60Glu Ala
Ala Leu Glu Pro Ser Met Glu Lys Ile Phe Lys Ile Asp Gln65 70 75
80Met Gly Arg Trp Phe Val Ala Gly Gly Ala Ala Val Gly Leu Gly Ala
85 90 95Leu Cys Tyr Tyr Gly Leu Gly Met Ser Asn Glu Ile Gly Ala Ile
Glu 100 105 110Lys Ala Val Ile Trp Pro Gln Tyr Val Lys Asp Arg Ile
His Ser Thr 115 120 125Tyr Met Tyr Leu Ala Gly Arg Tyr Cys Leu Thr
Ala Leu Ser Ala Leu 130 135 140Ala Val Ala Arg Thr Pro Ala Leu Met
Asn Phe Met Met Thr Gly Ser145 150 155 160Trp Val Thr Ile Gly Ala
Thr Phe Ala Ala Met Ile Gly Ala Gly Met 165 170 175Leu Val His Ser
Ile Ser Tyr Glu Gln Ser Pro Gly Pro Lys His Leu 180 185 190Ala Trp
Met Leu His Ser Gly Val Met Gly Ala Val Val Ala Pro Leu 195 200
205Thr Ile Leu Gly Gly Pro Leu Leu Leu Arg Ala Ala Trp Tyr Thr Ala
210 215 220Gly Ile Val Gly Gly Leu Ser Thr Val Ala Met Cys Ala Pro
Ser Glu225 230 235 240Lys Phe Leu Asn Met Gly Ala Pro Leu Gly Val
Gly Leu Gly Leu Val 245 250 255Phe Ala Ser Ser Leu Gly Ser Met Phe
Leu Pro Pro Thr Ser Val Ala 260 265 270Gly Ala Thr Leu Tyr Ser Val
Ala Met Tyr Gly Gly Leu Val Leu Phe 275 280 285Ser Met Phe Leu Leu
Tyr Asp Thr Gln Lys Val Ile Lys Arg Ala Glu 290 295 300Ile Thr Pro
Met Tyr Gly Ala Gln Lys Tyr Asp Pro Ile Asn Ser Met305 310 315
320Leu Thr Ile Tyr Met Asp Thr Leu Asn Ile Phe Met Arg Val Ala Thr
325 330 335Met Leu Ala Thr Gly Ser Asn Arg Lys Lys 340
345161038DNAHomo sapiensCDS(1)..(1035) 16atg ttg gct gca agg ctg
gtg tgt ctc cgg aca cta cct tct agg gtt 48Met Leu Ala Ala Arg Leu
Val Cys Leu Arg Thr Leu Pro Ser Arg Val1 5 10 15ttc cac cca gct ttc
acc aag gcc tcc cct gtt gtg aag aat tcc atc 96Phe His Pro Ala Phe
Thr Lys Ala Ser Pro Val Val Lys Asn Ser Ile 20 25 30acg aag aat caa
tgg ctg tta aca cct agc agg gaa tat gcc acc aaa 144Thr Lys Asn Gln
Trp Leu Leu Thr Pro Ser Arg Glu Tyr Ala Thr Lys 35 40 45aca aga att
ggg atc cgg cgt ggg aga act ggc caa gaa ctc aaa gag 192Thr Arg Ile
Gly Ile Arg Arg Gly Arg Thr Gly Gln Glu Leu Lys Glu 50 55 60gca gca
ttg gaa cca tcg atg gaa aaa ata ttt aaa att gat cag atg 240Ala Ala
Leu Glu Pro Ser Met Glu Lys Ile Phe Lys Ile Asp Gln Met65 70 75
80gga aga tgg ttt gtt gct gga ggg gct gct gtt ggt ctt gga gca ttg
288Gly Arg Trp Phe Val Ala Gly Gly Ala Ala Val Gly Leu Gly Ala Leu
85 90 95tgc tac tat ggc ttg gga ctg tct aat gag att gga gct att gaa
aag 336Cys Tyr Tyr Gly Leu Gly Leu Ser Asn Glu Ile Gly Ala Ile Glu
Lys 100 105 110gct gta att tgg cct cag tat gtc aag gat aga att cat
tcc acc tat 384Ala Val Ile Trp Pro Gln Tyr Val Lys Asp Arg Ile His
Ser Thr Tyr 115 120 125atg tac tta gca ggg agt att ggt tta aca gct
ttg tct gcc ata gca 432Met Tyr Leu Ala Gly Ser Ile Gly Leu Thr Ala
Leu Ser Ala Ile Ala 130 135 140atc agc aga acg cct gtt ctc atg aac
ttc atg atg aga ggc tct tgg 480Ile Ser Arg Thr Pro Val Leu Met Asn
Phe Met Met Arg Gly Ser Trp145 150 155 160gtg aca att ggt gtg acc
ttt gca gcc atg gtt gga gct gga atg ctg 528Val Thr Ile Gly Val Thr
Phe Ala Ala Met Val Gly Ala Gly Met Leu 165 170 175gta cga tca ata
cca tat gac cag agc cca ggc cca aag cat ctt gct 576Val Arg Ser Ile
Pro Tyr Asp Gln Ser Pro Gly Pro Lys His Leu Ala 180 185 190tgg ttg
cta cat tct ggt gtg atg ggt gca gtg gtg gct cct ctg aca 624Trp Leu
Leu His Ser Gly Val Met Gly Ala Val Val Ala Pro Leu Thr 195 200
205ata tta ggg ggt cct ctt ctc atc aga gct gca tgg tac aca gct ggc
672Ile Leu Gly Gly Pro Leu Leu Ile Arg Ala Ala Trp Tyr Thr Ala Gly
210 215 220att gtg gga ggc ctc tcc act gtg gcc atg tgt gcg ccc agt
gaa aag 720Ile Val Gly Gly Leu Ser Thr Val Ala Met Cys Ala Pro Ser
Glu Lys225 230 235 240ttt ctg aac atg ggt gca ccc ctg gga gtg ggc
ctg ggt ctc gtc ttt 768Phe Leu Asn Met Gly Ala Pro Leu Gly Val Gly
Leu Gly Leu Val Phe 245 250 255gtg tcc tca ttg gga tct atg ttt ctt
cca cct acc acc gtg gct ggt 816Val Ser Ser Leu Gly Ser Met Phe Leu
Pro Pro Thr Thr Val Ala Gly 260 265 270gcc act ctt tac tca gtg gca
atg tac ggt gga tta gtt ctt ttc agc 864Ala Thr Leu Tyr Ser Val Ala
Met Tyr Gly Gly Leu Val Leu Phe Ser 275 280 285atg ttc ctt ctg tat
gat acc cag aaa gta atc aag cgt gca gaa gta 912Met Phe Leu Leu Tyr
Asp Thr Gln Lys Val Ile Lys Arg Ala Glu Val 290 295 300tca cca atg
tat gga gtt caa aaa tat gat ccc att aac tcg atg ctg 960Ser Pro Met
Tyr Gly Val Gln Lys Tyr Asp Pro Ile Asn Ser Met Leu305 310 315
320agt atc tac atg gat aca tta aat ata ttt atg cga gtt gca act atg
1008Ser Ile Tyr Met Asp Thr Leu Asn Ile Phe Met Arg Val Ala Thr Met
325 330 335ctg gca act gga ggc aac aga aag aaa tga 1038Leu Ala Thr
Gly Gly Asn Arg Lys Lys 340 34517345PRTHomo sapiens 17Met Leu Ala
Ala Arg Leu Val Cys Leu Arg Thr Leu Pro Ser Arg Val1 5 10 15Phe His
Pro Ala Phe Thr Lys Ala Ser Pro Val Val Lys Asn Ser Ile 20 25 30Thr
Lys Asn Gln Trp Leu Leu Thr Pro Ser Arg Glu Tyr Ala Thr Lys 35 40
45Thr Arg Ile Gly Ile Arg Arg Gly Arg Thr Gly Gln Glu Leu Lys Glu
50 55 60Ala Ala Leu Glu Pro Ser Met Glu Lys Ile Phe Lys Ile Asp Gln
Met65 70 75 80Gly Arg Trp Phe Val Ala Gly Gly Ala Ala Val Gly Leu
Gly Ala Leu 85 90 95Cys Tyr Tyr Gly Leu Gly Leu Ser Asn Glu Ile Gly
Ala Ile Glu Lys 100 105 110Ala Val Ile Trp Pro Gln Tyr Val Lys Asp
Arg Ile His Ser Thr Tyr 115 120 125Met Tyr Leu Ala Gly Ser Ile Gly
Leu Thr Ala Leu Ser Ala Ile Ala 130 135 140Ile Ser Arg Thr Pro Val
Leu Met Asn Phe Met Met Arg Gly Ser Trp145 150 155 160Val Thr Ile
Gly Val Thr Phe Ala Ala Met Val Gly Ala Gly Met Leu 165 170 175Val
Arg Ser Ile Pro Tyr Asp Gln Ser Pro Gly Pro Lys His Leu Ala 180 185
190Trp Leu Leu His Ser Gly Val Met Gly Ala Val Val Ala Pro Leu Thr
195 200 205Ile Leu Gly Gly Pro Leu Leu Ile Arg Ala Ala Trp Tyr Thr
Ala Gly 210 215 220Ile Val Gly Gly Leu Ser Thr Val Ala Met Cys Ala
Pro Ser Glu Lys225 230 235 240Phe Leu Asn Met Gly Ala Pro Leu Gly
Val Gly Leu Gly Leu Val Phe 245 250 255Val Ser Ser Leu Gly Ser Met
Phe Leu Pro Pro Thr Thr Val Ala Gly 260 265 270Ala Thr Leu Tyr Ser
Val Ala Met Tyr Gly Gly Leu Val Leu Phe Ser 275 280 285Met Phe Leu
Leu Tyr Asp Thr Gln Lys Val Ile Lys Arg Ala Glu Val 290 295 300Ser
Pro Met Tyr Gly Val Gln Lys Tyr Asp Pro Ile Asn Ser Met Leu305 310
315 320Ser Ile Tyr Met Asp Thr Leu Asn Ile Phe Met Arg Val Ala Thr
Met 325 330 335Leu Ala Thr Gly Gly Asn Arg Lys Lys 340
34518447DNAMus musculusCDS(1)..(444) 18atg agc acc tcg tct gcg cgg
cct gca gtc ctg gcc ctt gcc ggg ctg 48Met Ser Thr Ser Ser Ala Arg
Pro Ala Val Leu Ala Leu Ala Gly Leu1 5 10 15gct ctg ctc ctt ctg ctg
tgc ctg ggt cca gat ggc ata agt gga aac 96Ala Leu Leu Leu Leu Leu
Cys Leu Gly Pro Asp Gly Ile Ser Gly Asn 20 25 30aaa ctc aag aag atg
ctc cag aaa cga gaa gga cct gtc ccg tca aag 144Lys Leu Lys Lys Met
Leu Gln Lys Arg Glu Gly Pro Val Pro Ser Lys 35 40 45act aat gta gct
gta gcc gag aac aca gca aag gaa ttc cta ggt ggc 192Thr Asn Val Ala
Val Ala Glu Asn Thr Ala Lys Glu Phe Leu Gly Gly 50 55 60ctg aag cgt
gcc aaa cga cag ctg tgg gac cgt acg cgg cct gag gta 240Leu Lys Arg
Ala Lys Arg Gln Leu Trp Asp Arg Thr Arg Pro Glu Val65 70 75 80cag
cag tgg tac cag cag ttc ctc tac atg ggc ttt gat gag gct aaa 288Gln
Gln Trp Tyr Gln Gln Phe Leu Tyr Met Gly Phe Asp Glu Ala Lys 85 90
95ttt gaa gat gat gtc aac tat tgg cta aac aga aat cga aac ggc cat
336Phe Glu Asp Asp Val Asn Tyr Trp Leu Asn Arg Asn Arg Asn Gly His
100 105 110gac tac tat ggt gac tac tac cag cgt cat tat gat gaa gat
gcg gcc 384Asp Tyr Tyr Gly Asp Tyr Tyr Gln Arg His Tyr Asp Glu Asp
Ala Ala 115 120 125att ggt ccc cac agc cgg gaa agc ttc agg cat gga
gcc agt gtg aac 432Ile Gly Pro His Ser Arg Glu Ser Phe Arg His Gly
Ala Ser Val Asn 130 135 140tat gat gac tat taa 447Tyr Asp Asp
Tyr14519148PRTMus musculus 19Met Ser Thr Ser Ser Ala Arg Pro Ala
Val Leu Ala Leu Ala Gly Leu1 5 10 15Ala Leu Leu Leu Leu Leu Cys Leu
Gly Pro Asp Gly Ile Ser Gly Asn 20 25 30Lys Leu Lys Lys Met Leu Gln
Lys Arg Glu Gly Pro Val Pro Ser Lys 35 40 45Thr Asn Val Ala Val Ala
Glu Asn Thr Ala Lys Glu Phe Leu Gly Gly 50 55 60Leu Lys Arg Ala Lys
Arg Gln Leu Trp Asp Arg Thr Arg Pro Glu Val65 70 75 80Gln Gln Trp
Tyr Gln Gln Phe Leu Tyr Met Gly Phe Asp Glu Ala Lys 85 90 95Phe Glu
Asp Asp Val Asn Tyr Trp Leu Asn Arg Asn Arg Asn Gly His 100 105
110Asp Tyr Tyr Gly Asp Tyr Tyr Gln Arg His Tyr Asp Glu Asp Ala Ala
115 120 125Ile Gly Pro His Ser Arg Glu Ser Phe Arg His Gly Ala Ser
Val Asn 130 135 140Tyr Asp Asp Tyr14520447DNAHomo
sapiensCDS(1)..(444) 20atg gct gcc tcc ccc gcg cgg cct gct gtc ctg
gcc ctg acc ggg ctg 48Met Ala Ala Ser Pro Ala Arg Pro Ala Val Leu
Ala Leu Thr Gly Leu1 5 10 15gcg ctg ctc ctg ctc ctg tgc tgg ggc cca
ggt ggc ata agt gga aat 96Ala Leu Leu Leu Leu Leu Cys Trp Gly Pro
Gly Gly Ile Ser Gly Asn 20 25 30aaa ctc aag ctg atg ctt caa aaa cga
gaa gca cct gtt cca act aag 144Lys Leu Lys Leu Met Leu Gln Lys Arg
Glu Ala Pro Val Pro Thr Lys 35 40 45act aaa gtg gcc gtt gat gag aat
aaa gcc aaa gaa ttc ctt ggc agc 192Thr Lys Val Ala Val Asp Glu Asn
Lys Ala Lys Glu Phe Leu Gly Ser 50 55 60ctg aag cgc cag aag cgg cag
ctg tgg gac cgg act cgg ccc gag gtg 240Leu Lys Arg Gln Lys Arg Gln
Leu Trp Asp Arg Thr Arg Pro Glu Val65 70 75 80cag cag tgg tac cag
cag ttt ctc tac atg ggc ttt gac gaa gcg aaa 288Gln Gln Trp Tyr Gln
Gln Phe Leu Tyr Met Gly Phe Asp Glu Ala Lys 85 90 95ttt gaa gat gac
atc acc tat tgg ctt aac aga gat cga aat gga cat 336Phe Glu Asp Asp
Ile Thr Tyr Trp Leu Asn Arg Asp Arg Asn Gly His 100 105 110gaa tac
tat ggc gat tac tac caa cgt cac tat gat gaa gac tct gca 384Glu Tyr
Tyr Gly Asp Tyr Tyr Gln Arg His Tyr Asp Glu Asp Ser Ala 115 120
125att ggt ccc cgg agc ccc tac ggc ttt agg cat gga gcc agc gtc aac
432Ile Gly Pro Arg Ser Pro Tyr Gly Phe Arg His Gly Ala Ser Val Asn
130 135 140tac gat gac tac taa 447Tyr Asp Asp Tyr14521148PRTHomo
sapiens 21Met Ala Ala Ser Pro Ala Arg Pro Ala Val Leu Ala Leu Thr
Gly Leu1 5 10 15Ala Leu Leu Leu Leu Leu Cys Trp Gly Pro Gly Gly Ile
Ser Gly Asn 20 25 30Lys Leu Lys Leu Met Leu Gln Lys Arg Glu Ala Pro
Val Pro Thr Lys 35 40 45Thr Lys Val Ala Val Asp Glu Asn Lys Ala Lys
Glu Phe Leu Gly Ser 50 55 60Leu Lys Arg Gln Lys Arg Gln Leu Trp Asp
Arg Thr Arg Pro Glu Val65 70 75 80Gln Gln Trp Tyr Gln Gln Phe Leu
Tyr Met Gly Phe Asp Glu Ala Lys 85 90 95Phe Glu Asp Asp Ile Thr Tyr
Trp Leu Asn Arg Asp Arg Asn Gly His 100 105 110Glu Tyr Tyr Gly Asp
Tyr Tyr Gln Arg His Tyr Asp Glu Asp Ser Ala 115 120 125Ile Gly Pro
Arg Ser Pro Tyr Gly Phe Arg His Gly Ala Ser Val Asn 130 135 140Tyr
Asp Asp Tyr145223132DNAMus musculusCDS(630)..(1358) 22gggggtctgc
atctccatcg gaaagtgcgc tggccacatc ccttcggcct ccgggcagtg 60ttctgtctcc
cttagctcag gcagcgagaa acttcagctg tgaagtggtg gtggagagag
120ccctgggagc agcgactgga cccggacacc aagaagagag tggacgcgcc
cctcgactag 180gaatcgctct cgcaggcgga gacccagcat ctcagcgcct
gcggtcgcgc ttgcccggcc 240gcgcgctttt gctaggcgcc gccagccccg
aaggaccctc ggggtccgcg gacccttctg 300cagccggcgg aatcctaaag
ctgccaagag ctcccggcgg gtgtcggcaa actttttccg 360agcccacgtg
ctgaccaaac agcccggctc gcttccagag cctggcatgg agcgccgcgc
420ctaggcacgc cgtgcagccc gagagacgcg agcgcacggt tcaccgtgga
gggagagatg 480ctcatcgagc caaattgatc attgcagccc cagggcagtg
acatctgtct ctgagtcctc 540cctaggagcg cgacccgcac tgtctccttc
caggagcccg tcatttcctc gacttttgag 600aggtgtctct ccccagcccg accgtccag
atg cgt ttt tgc ctc ttc tca ttt 653 Met Arg Phe Cys Leu Phe Ser Phe
1 5gcc ctc atc att ctg aac tgt atg gat tac agc cag tgc caa ggc aac
701Ala Leu Ile Ile Leu Asn Cys Met Asp Tyr Ser Gln Cys Gln Gly Asn
10 15 20cga tgg aga cgc aat aag cga gct agt tat gta tca aat ccc att
tgc 749Arg Trp Arg Arg Asn Lys Arg Ala Ser Tyr Val Ser Asn Pro Ile
Cys25 30 35 40aag ggt tgt ttg tct tgt tcg aag gac aat ggt tgc agc
cga tgt caa 797Lys Gly Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser
Arg Cys Gln 45 50 55cag aag ttg ttc ttt ttc ctt cga aga gaa gga atg
cgt cag tat gga 845Gln Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met
Arg Gln Tyr Gly 60 65 70gag tgc ctg cat tcc tgc cca tca ggg tat tat
gga cac cga gcc cca 893Glu Cys Leu His Ser Cys Pro Ser Gly Tyr Tyr
Gly His Arg Ala Pro 75 80 85gat atg aac aga tgt gca cga tgc aga ata
gaa aac tgt gat tct tgc 941Asp Met Asn Arg Cys Ala Arg Cys Arg Ile
Glu Asn Cys Asp Ser Cys 90 95 100ttt agc aaa gac ttt tgt acg aag
tgc aaa gta ggc ttt tat ttg cat 989Phe Ser Lys Asp Phe Cys Thr Lys
Cys Lys Val Gly Phe Tyr Leu His105 110 115 120aga ggc cgc tgc ttt
gat gaa tgt cca gat ggt ttt gca ccg tta gat 1037Arg Gly Arg Cys Phe
Asp Glu Cys Pro Asp Gly Phe Ala Pro Leu Asp 125 130 135gag act atg
gaa tgt gta gaa ggt tgt gaa gtt ggt cat tgg agc gaa 1085Glu Thr Met
Glu Cys Val Glu Gly Cys Glu Val Gly His Trp Ser Glu 140 145 150tgg
gga acg tgt agc aga aac aac cgc acg tgt gga ttt aaa tgg ggt 1133Trp
Gly Thr Cys Ser Arg Asn Asn Arg Thr Cys Gly Phe Lys Trp Gly 155 160
165ctg gaa acc aga aca cgg cag att gtt aaa aag cca gca aaa gac aca
1181Leu Glu Thr Arg Thr Arg Gln Ile Val Lys Lys Pro Ala Lys Asp Thr
170 175 180ata cca tgt ccg acc att gcg gag tcc agg aga tgc aag atg
gcc atg
1229Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg Arg Cys Lys Met Ala
Met185 190 195 200agg cac tgt cca gga gga aag aga aca cca aag gca
aaa gag aag aga 1277Arg His Cys Pro Gly Gly Lys Arg Thr Pro Lys Ala
Lys Glu Lys Arg 205 210 215aac aag aag aag agg cgg aag ctg att gag
aga gcc caa gag cag cac 1325Asn Lys Lys Lys Arg Arg Lys Leu Ile Glu
Arg Ala Gln Glu Gln His 220 225 230agc gtc ttc ctc gct aca gac aga
gtg aac caa taaaatacaa gaaatagctg 1378Ser Val Phe Leu Ala Thr Asp
Arg Val Asn Gln 235 240gggcattttg aggttttctg ttttgtttat gttgttgttt
tgcaaaagtg cacaaagcta 1438ctctccagtc cacactggtg gacagcattc
ctgatcctct gaccagtatc cattttcagt 1498aatgctgcag agggaggtgc
ccaagcatgg actcagcgtt atttatgctt tgattggaat 1558ctggggcctg
tgatggcagg agcttgttga gctgagtcag cgggagctga tgcatctgta
1618ctcttgtgat gagcacagtg tgtcataaga acctgtccct ggcacggtgg
acccacagga 1678ggcacaaggc tgtagatcac caccagagaa tgcacctgtg
cctattttga tggatggcaa 1738tgctaagcaa gcaagcactg ttcacttgtg
actttcattt ctcacactgt gcactgtcaa 1798agacaaatgt gcatggaaaa
atgtttagtg tcacctcatg gcgttctcag catcagtgac 1858cttcaaacgg
tcctacaatg agactgtgtt ctagctaggg gtatgctgtg gaaattcctg
1918ctacatttca tcttagtgct aacatgtaca gattctgctg cgctacattc
aaagctcatt 1978actgtatatt tatgctttct ctgtgtaaca agttatacct
gataagatgt cactttgttt 2038ctagtgattc ttaaccatgg tctggtacat
ggctattcta gttttggaaa ttaacaagtg 2098ttttgttgcc tcttgttttc
ttttgttcct atcatttttg gcgggggttg ggtgggcttg 2158attctaaccg
taagtatagg ataagctagt tttgtatata gagtcaaatg actgatgtca
2218gaggatcagt gctgatagaa cttccccagt tcatgtcacg atacacacag
agagaaagca 2278gcatgaggca tcttgccatc agaagccaaa tttcttttga
gtcccaaaat tgatgactta 2338tgaaatatag ctgaaaacaa gatttgggtg
tagttacttg tatttattat acaatttcca 2398attacatttt ttttcaaact
caaaataacc catgactttg agtgataggt cacttggcaa 2458tgttcttgaa
ttactgggga agctgttgtc actaagataa tgagagagaa aatagaatgg
2518cttcgcccaa gtgagagcca catcttacat ttctctgttg aatcggaatc
aactatatta 2578gaacagaagc ctgatagaag ctttctagtt aacacacaca
aggccatggt ttcaaaaaca 2638tctttgtccc cttaggtcag tttgtcctta
gattatgaat tggcaggttc taattgcatt 2698atttccctgg ctgatccagg
aaaaagttag aacaaaataa gttgcatagt tttgaggaaa 2758catccaaagc
aaggcgaagc ctttccttgc cttgcattgg caaaactacc tctttagcat
2818ttatgttgat tcagaaacat cttgctgata tgtgtagatg ttttaagctt
cattgtgaaa 2878atattgatgc aagataagcc atatatgaat gttgtattca
actttagggc ttgaaattaa 2938tcctaaagtg ttcacctctc tccatgtcta
tttacactct gttcctattt actaagaggg 2998taggggtctc cttaatatca
tacttcattg ttaataagtc aatgcttgtt atgtttcttg 3058gctgttgttt
ttgtgcatta aaaactcaaa attggaaaaa aaaaaaaaaa aaaaaaaaaa
3118aaaaaaaaaa aaaa 313223243PRTMus musculus 23Met Arg Phe Cys Leu
Phe Ser Phe Ala Leu Ile Ile Leu Asn Cys Met1 5 10 15Asp Tyr Ser Gln
Cys Gln Gly Asn Arg Trp Arg Arg Asn Lys Arg Ala 20 25 30Ser Tyr Val
Ser Asn Pro Ile Cys Lys Gly Cys Leu Ser Cys Ser Lys 35 40 45Asp Asn
Gly Cys Ser Arg Cys Gln Gln Lys Leu Phe Phe Phe Leu Arg 50 55 60Arg
Glu Gly Met Arg Gln Tyr Gly Glu Cys Leu His Ser Cys Pro Ser65 70 75
80Gly Tyr Tyr Gly His Arg Ala Pro Asp Met Asn Arg Cys Ala Arg Cys
85 90 95Arg Ile Glu Asn Cys Asp Ser Cys Phe Ser Lys Asp Phe Cys Thr
Lys 100 105 110Cys Lys Val Gly Phe Tyr Leu His Arg Gly Arg Cys Phe
Asp Glu Cys 115 120 125Pro Asp Gly Phe Ala Pro Leu Asp Glu Thr Met
Glu Cys Val Glu Gly 130 135 140Cys Glu Val Gly His Trp Ser Glu Trp
Gly Thr Cys Ser Arg Asn Asn145 150 155 160Arg Thr Cys Gly Phe Lys
Trp Gly Leu Glu Thr Arg Thr Arg Gln Ile 165 170 175Val Lys Lys Pro
Ala Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala Glu 180 185 190Ser Arg
Arg Cys Lys Met Ala Met Arg His Cys Pro Gly Gly Lys Arg 195 200
205Thr Pro Lys Ala Lys Glu Lys Arg Asn Lys Lys Lys Arg Arg Lys Leu
210 215 220Ile Glu Arg Ala Gln Glu Gln His Ser Val Phe Leu Ala Thr
Asp Arg225 230 235 240Val Asn Gln24843DNAMus
musculusCDS(132)..(506) 24ggccattatg gccgggggct ttcgccgtcc
gggagctgac cggccgtgtt cctctctcgt 60cttcctctgc gccccgcgtc cccgccctcg
cgaccccggc tctcctggac tcggcgccgc 120caacctgggc g atg ccc cgc tac
gag ttg gct ttg att ctg aaa gcc atg 170 Met Pro Arg Tyr Glu Leu Ala
Leu Ile Leu Lys Ala Met 1 5 10cgg cgg cca gag acc gct gct gct ttg
aaa cgt aca ata gaa tcc ctg 218Arg Arg Pro Glu Thr Ala Ala Ala Leu
Lys Arg Thr Ile Glu Ser Leu 15 20 25atg gac cga gga gcc ata gtg agg
aac ttg gaa agc ctg ggt gag cgt 266Met Asp Arg Gly Ala Ile Val Arg
Asn Leu Glu Ser Leu Gly Glu Arg30 35 40 45gcg ctc ccc tac agg atc
tcg agt cac agc cag cag cac agc cga gga 314Ala Leu Pro Tyr Arg Ile
Ser Ser His Ser Gln Gln His Ser Arg Gly 50 55 60ggg tat ttc ctg gtg
gat ttt tat gct ccg aca agt gct gtg gag aac 362Gly Tyr Phe Leu Val
Asp Phe Tyr Ala Pro Thr Ser Ala Val Glu Asn 65 70 75ata ctg gaa cac
ttg gcg cga gac att gac gtg gtt aga cca aat att 410Ile Leu Glu His
Leu Ala Arg Asp Ile Asp Val Val Arg Pro Asn Ile 80 85 90gtg aaa cac
cct ctg acc cag gaa gta aaa gag tgt gac ggc ata gtc 458Val Lys His
Pro Leu Thr Gln Glu Val Lys Glu Cys Asp Gly Ile Val 95 100 105cca
gtc cca ctt gaa gaa aaa ctg tat tca aca aag agg agg aag aag 506Pro
Val Pro Leu Glu Glu Lys Leu Tyr Ser Thr Lys Arg Arg Lys Lys110 115
120 125tgagaagatt caccagattc tggccttata tttaatccta agggcactat
gggtgctgct 566aggttgttgt ctaggatact ttagcccatg accattttgc
tgcaggaggt agaaactgct 626ggccgagacc tgccctgatg tctctgctga
gatttcatcc cacttgtggg gtttgtcggg 686agtgggggtg ttcacagtac
cactgtagcg tttccaagag caaaatgttt gtcattcaca 746cttggttgtc
ttgcaagcct atatggaaca ctgggagcag agtaataaac atgactttat
806caacactgga aaaaaaaaaa aaaaaaaaaa aaaaaaa 84325125PRTMus musculus
25Met Pro Arg Tyr Glu Leu Ala Leu Ile Leu Lys Ala Met Arg Arg Pro1
5 10 15Glu Thr Ala Ala Ala Leu Lys Arg Thr Ile Glu Ser Leu Met Asp
Arg 20 25 30Gly Ala Ile Val Arg Asn Leu Glu Ser Leu Gly Glu Arg Ala
Leu Pro 35 40 45Tyr Arg Ile Ser Ser His Ser Gln Gln His Ser Arg Gly
Gly Tyr Phe 50 55 60Leu Val Asp Phe Tyr Ala Pro Thr Ser Ala Val Glu
Asn Ile Leu Glu65 70 75 80His Leu Ala Arg Asp Ile Asp Val Val Arg
Pro Asn Ile Val Lys His 85 90 95Pro Leu Thr Gln Glu Val Lys Glu Cys
Asp Gly Ile Val Pro Val Pro 100 105 110Leu Glu Glu Lys Leu Tyr Ser
Thr Lys Arg Arg Lys Lys 115 120 125262490DNAMus
musculusCDS(1)..(2487) 26atg aag ccg ccc ggc agc atc tcc cgg cgg
ccg acc ctg acg ggt tgc 48Met Lys Pro Pro Gly Ser Ile Ser Arg Arg
Pro Thr Leu Thr Gly Cys1 5 10 15agc ctt ccc ggc gcc tcc tgc ggc ccc
ggc cgc tgc ccc gcc ggc ccg 96Ser Leu Pro Gly Ala Ser Cys Gly Pro
Gly Arg Cys Pro Ala Gly Pro 20 25 30gtg ccg gcc cgc gcg ccg ccc tgc
cgc ctg ctc ctc gtc ctt ctc ctg 144Val Pro Ala Arg Ala Pro Pro Cys
Arg Leu Leu Leu Val Leu Leu Leu 35 40 45cta cct gcg ctc gcc acc tca
tcc cgg ccc cgt gcc cgg ggg gcc gct 192Leu Pro Ala Leu Ala Thr Ser
Ser Arg Pro Arg Ala Arg Gly Ala Ala 50 55 60gcg ccc agc gct ccg cac
tgg aat gaa act gca gaa aaa acc ctg gga 240Ala Pro Ser Ala Pro His
Trp Asn Glu Thr Ala Glu Lys Thr Leu Gly65 70 75 80gtc ctg gca gat
gaa gac aac aca ttg caa caa aat agc agc agc aga 288Val Leu Ala Asp
Glu Asp Asn Thr Leu Gln Gln Asn Ser Ser Ser Arg 85 90 95aat acc agc
tac agc agt gca gtg caa aaa gaa atc aca ctg cct tca 336Asn Thr Ser
Tyr Ser Ser Ala Val Gln Lys Glu Ile Thr Leu Pro Ser 100 105 110aga
ctg gtg tat tac atc aac cag gac tca gaa agc ccc tat cat gtt 384Arg
Leu Val Tyr Tyr Ile Asn Gln Asp Ser Glu Ser Pro Tyr His Val 115 120
125ctt gac aca aag gcc aga cac caa cag aaa cac aat aag gct gtg cat
432Leu Asp Thr Lys Ala Arg His Gln Gln Lys His Asn Lys Ala Val His
130 135 140ctg gcc cag gca agc ttc cag atc gaa gct ttc ggc tcc aag
ttc att 480Leu Ala Gln Ala Ser Phe Gln Ile Glu Ala Phe Gly Ser Lys
Phe Ile145 150 155 160ctt gac ctc aca ctg aac aat ggt ttg cta tct
tct gac tac gtg gag 528Leu Asp Leu Thr Leu Asn Asn Gly Leu Leu Ser
Ser Asp Tyr Val Glu 165 170 175atc cac tat gaa gac ggg aag cag atg
tac tct aag ggt gga gag cac 576Ile His Tyr Glu Asp Gly Lys Gln Met
Tyr Ser Lys Gly Gly Glu His 180 185 190tgt tac tac cac gga agc atc
aga ggc gtc aag gat tcc agg gtg gct 624Cys Tyr Tyr His Gly Ser Ile
Arg Gly Val Lys Asp Ser Arg Val Ala 195 200 205cta tcg acc tgc aat
gga ctc cat ggc atg ttt gag gat gac acc ttt 672Leu Ser Thr Cys Asn
Gly Leu His Gly Met Phe Glu Asp Asp Thr Phe 210 215 220gtg tat atg
ata gag cct ctg gaa ctg act gat gat gag aaa agc aca 720Val Tyr Met
Ile Glu Pro Leu Glu Leu Thr Asp Asp Glu Lys Ser Thr225 230 235
240ggc cga ccg cac ata atc cag aaa acc ttg gca gga cag tat tct aag
768Gly Arg Pro His Ile Ile Gln Lys Thr Leu Ala Gly Gln Tyr Ser Lys
245 250 255cag atg aag aat ctc agc aca gat ggc agt gac cag tgg cct
ttg cta 816Gln Met Lys Asn Leu Ser Thr Asp Gly Ser Asp Gln Trp Pro
Leu Leu 260 265 270cct gaa tta caa tgg ctg aga aga agg aaa aga gcg
gtc aat cca tct 864Pro Glu Leu Gln Trp Leu Arg Arg Arg Lys Arg Ala
Val Asn Pro Ser 275 280 285cgt ggt gtg ttt gaa gaa atg aag tat ttg
gag ctt atg att gtt aat 912Arg Gly Val Phe Glu Glu Met Lys Tyr Leu
Glu Leu Met Ile Val Asn 290 295 300gat cac aag acg tat aag aag cac
cgc tct tct cac gcg cat acc aac 960Asp His Lys Thr Tyr Lys Lys His
Arg Ser Ser His Ala His Thr Asn305 310 315 320aac ttc gca aag tct
gtg gtc aac ctt gta gat tct att tac aag gaa 1008Asn Phe Ala Lys Ser
Val Val Asn Leu Val Asp Ser Ile Tyr Lys Glu 325 330 335cag ctc aac
acc agg gtt gtc ctg gtg gct gtc gag acc tgg acc gag 1056Gln Leu Asn
Thr Arg Val Val Leu Val Ala Val Glu Thr Trp Thr Glu 340 345 350aag
gat cac att gac atc acc atc aac ccc gtg cag atg cta cat gac 1104Lys
Asp His Ile Asp Ile Thr Ile Asn Pro Val Gln Met Leu His Asp 355 360
365ttc tcc aag tac cgg cag cga atc aaa cag cac gct gac gcg gtc cac
1152Phe Ser Lys Tyr Arg Gln Arg Ile Lys Gln His Ala Asp Ala Val His
370 375 380ctc atc tcg cgc gtg aca ttc cat tat aag aga agc agt ctg
agt tac 1200Leu Ile Ser Arg Val Thr Phe His Tyr Lys Arg Ser Ser Leu
Ser Tyr385 390 395 400ttt gga ggc gtg tgt tct cga ata aga ggg gtt
ggt gtg aat gag tat 1248Phe Gly Gly Val Cys Ser Arg Ile Arg Gly Val
Gly Val Asn Glu Tyr 405 410 415ggt ctt cca atg gcg gtg gca caa gta
tta tca cag agc ctg gct caa 1296Gly Leu Pro Met Ala Val Ala Gln Val
Leu Ser Gln Ser Leu Ala Gln 420 425 430aac ctt gga atc cag tgg gaa
cct tcg agc agg aag cca aaa tgt gaa 1344Asn Leu Gly Ile Gln Trp Glu
Pro Ser Ser Arg Lys Pro Lys Cys Glu 435 440 445tgc ata gag tcc tgg
ggc ggc tgc atc atg gaa gaa aca ggg gtg tcc 1392Cys Ile Glu Ser Trp
Gly Gly Cys Ile Met Glu Glu Thr Gly Val Ser 450 455 460cac tct cga
aag ttc tca aag tgc agc att ttg gag tac aga gac ttt 1440His Ser Arg
Lys Phe Ser Lys Cys Ser Ile Leu Glu Tyr Arg Asp Phe465 470 475
480tta cag aga ggt ggc gga gca tgt ctt ttc aat agg cca act aag ctg
1488Leu Gln Arg Gly Gly Gly Ala Cys Leu Phe Asn Arg Pro Thr Lys Leu
485 490 495ttt gag ccc acg gaa tgt gga aat gga tat gtg gag gcc ggg
gag gaa 1536Phe Glu Pro Thr Glu Cys Gly Asn Gly Tyr Val Glu Ala Gly
Glu Glu 500 505 510tgc gac tgt ggt ttc cat gtg gaa tgc tat gga gtt
tgc tgt aag aag 1584Cys Asp Cys Gly Phe His Val Glu Cys Tyr Gly Val
Cys Cys Lys Lys 515 520 525tgt tcg ctc tcc aat ggg gcc cac tgc agt
gac ggc ccc tgc tgt aac 1632Cys Ser Leu Ser Asn Gly Ala His Cys Ser
Asp Gly Pro Cys Cys Asn 530 535 540aac acc tca tgt ctt ttt cag tca
cga ggg tat gaa tgt cgg gat gcc 1680Asn Thr Ser Cys Leu Phe Gln Ser
Arg Gly Tyr Glu Cys Arg Asp Ala545 550 555 560gta aac agc tgt gat
atc acc gag tac tgc act gga gac tct ggc cag 1728Val Asn Ser Cys Asp
Ile Thr Glu Tyr Cys Thr Gly Asp Ser Gly Gln 565 570 575tgc cca ccg
aac ctc cat aaa caa gat ggc tat agc tgc aat caa aat 1776Cys Pro Pro
Asn Leu His Lys Gln Asp Gly Tyr Ser Cys Asn Gln Asn 580 585 590cag
ggt cgc tgc tac aat ggc gag tgc aag aca agg gac aat caa tgc 1824Gln
Gly Arg Cys Tyr Asn Gly Glu Cys Lys Thr Arg Asp Asn Gln Cys 595 600
605cag tac atc tgg ggg aca aag gct gcg ggg tca gac aag ttc tgc tat
1872Gln Tyr Ile Trp Gly Thr Lys Ala Ala Gly Ser Asp Lys Phe Cys Tyr
610 615 620gaa aag ctg aac acg gaa ggc acc gag aag ggc aat tgt gga
aag gat 1920Glu Lys Leu Asn Thr Glu Gly Thr Glu Lys Gly Asn Cys Gly
Lys Asp625 630 635 640gga gac cgg tgg atc ccg tgc agc aag cat gat
gtg ttc tgt gga ttt 1968Gly Asp Arg Trp Ile Pro Cys Ser Lys His Asp
Val Phe Cys Gly Phe 645 650 655ctg ctt tgc acc aat ctt acc cga gct
cca cgt atc ggt caa ctt caa 2016Leu Leu Cys Thr Asn Leu Thr Arg Ala
Pro Arg Ile Gly Gln Leu Gln 660 665 670gga gag atc atc ccg act tcc
ttc tat cat caa ggc cga gtg att gac 2064Gly Glu Ile Ile Pro Thr Ser
Phe Tyr His Gln Gly Arg Val Ile Asp 675 680 685tgc agt ggt gct cat
gta gtt tta gac gat gat aca gac gtg ggt tac 2112Cys Ser Gly Ala His
Val Val Leu Asp Asp Asp Thr Asp Val Gly Tyr 690 695 700gtt gaa gat
ggg act ccg tgt ggc ccc tcc atg atg tgc tta gat cgg 2160Val Glu Asp
Gly Thr Pro Cys Gly Pro Ser Met Met Cys Leu Asp Arg705 710 715
720aag tgc cta cag att caa gcc ctg aat atg agc agc tgc cca ctt gac
2208Lys Cys Leu Gln Ile Gln Ala Leu Asn Met Ser Ser Cys Pro Leu Asp
725 730 735tca agg ggt aaa gtc tgc tcc ggc cac ggg gtg tgt agc aac
gaa gcc 2256Ser Arg Gly Lys Val Cys Ser Gly His Gly Val Cys Ser Asn
Glu Ala 740 745 750acc tgc atc tgt gat ttc act tgg gca ggc aca gac
tgc agc atc cgg 2304Thr Cys Ile Cys Asp Phe Thr Trp Ala Gly Thr Asp
Cys Ser Ile Arg 755 760 765gat cca gtt cgg aac ccc aac ccc cct aag
gat gaa ggc cct aag ggt 2352Asp Pro Val Arg Asn Pro Asn Pro Pro Lys
Asp Glu Gly Pro Lys Gly 770 775 780cct agc gcc acc aat ctc ata ata
ggc tcc atc gct ggt gcc atc ctg 2400Pro Ser Ala Thr Asn Leu Ile Ile
Gly Ser Ile Ala Gly Ala Ile Leu785 790 795 800gta gca gct att gtc
ctt ggg ggc aca ggc tgg gga ttt aaa aac gtc 2448Val Ala Ala Ile Val
Leu Gly Gly Thr Gly Trp Gly Phe Lys Asn Val 805 810 815aag aag agg
aga ttc gat ccc act cag caa ggc ccc atc tga 2490Lys Lys Arg Arg Phe
Asp Pro Thr Gln Gln Gly Pro Ile 820 82527829PRTMus musculus 27Met
Lys Pro Pro Gly Ser Ile Ser Arg Arg Pro Thr Leu Thr Gly Cys1 5 10
15Ser Leu Pro Gly Ala Ser Cys Gly Pro Gly Arg Cys Pro Ala Gly Pro
20 25 30Val Pro Ala Arg Ala Pro Pro Cys Arg Leu Leu Leu Val Leu Leu
Leu 35 40 45Leu Pro Ala Leu Ala Thr Ser Ser Arg Pro Arg Ala Arg Gly
Ala Ala 50 55 60Ala Pro Ser Ala Pro His Trp Asn Glu Thr Ala Glu Lys
Thr Leu Gly65 70 75 80Val Leu Ala Asp Glu Asp Asn Thr Leu Gln
Gln
Asn Ser Ser Ser Arg 85 90 95Asn Thr Ser Tyr Ser Ser Ala Val Gln Lys
Glu Ile Thr Leu Pro Ser 100 105 110Arg Leu Val Tyr Tyr Ile Asn Gln
Asp Ser Glu Ser Pro Tyr His Val 115 120 125Leu Asp Thr Lys Ala Arg
His Gln Gln Lys His Asn Lys Ala Val His 130 135 140Leu Ala Gln Ala
Ser Phe Gln Ile Glu Ala Phe Gly Ser Lys Phe Ile145 150 155 160Leu
Asp Leu Thr Leu Asn Asn Gly Leu Leu Ser Ser Asp Tyr Val Glu 165 170
175Ile His Tyr Glu Asp Gly Lys Gln Met Tyr Ser Lys Gly Gly Glu His
180 185 190Cys Tyr Tyr His Gly Ser Ile Arg Gly Val Lys Asp Ser Arg
Val Ala 195 200 205Leu Ser Thr Cys Asn Gly Leu His Gly Met Phe Glu
Asp Asp Thr Phe 210 215 220Val Tyr Met Ile Glu Pro Leu Glu Leu Thr
Asp Asp Glu Lys Ser Thr225 230 235 240Gly Arg Pro His Ile Ile Gln
Lys Thr Leu Ala Gly Gln Tyr Ser Lys 245 250 255Gln Met Lys Asn Leu
Ser Thr Asp Gly Ser Asp Gln Trp Pro Leu Leu 260 265 270Pro Glu Leu
Gln Trp Leu Arg Arg Arg Lys Arg Ala Val Asn Pro Ser 275 280 285Arg
Gly Val Phe Glu Glu Met Lys Tyr Leu Glu Leu Met Ile Val Asn 290 295
300Asp His Lys Thr Tyr Lys Lys His Arg Ser Ser His Ala His Thr
Asn305 310 315 320Asn Phe Ala Lys Ser Val Val Asn Leu Val Asp Ser
Ile Tyr Lys Glu 325 330 335Gln Leu Asn Thr Arg Val Val Leu Val Ala
Val Glu Thr Trp Thr Glu 340 345 350Lys Asp His Ile Asp Ile Thr Ile
Asn Pro Val Gln Met Leu His Asp 355 360 365Phe Ser Lys Tyr Arg Gln
Arg Ile Lys Gln His Ala Asp Ala Val His 370 375 380Leu Ile Ser Arg
Val Thr Phe His Tyr Lys Arg Ser Ser Leu Ser Tyr385 390 395 400Phe
Gly Gly Val Cys Ser Arg Ile Arg Gly Val Gly Val Asn Glu Tyr 405 410
415Gly Leu Pro Met Ala Val Ala Gln Val Leu Ser Gln Ser Leu Ala Gln
420 425 430Asn Leu Gly Ile Gln Trp Glu Pro Ser Ser Arg Lys Pro Lys
Cys Glu 435 440 445Cys Ile Glu Ser Trp Gly Gly Cys Ile Met Glu Glu
Thr Gly Val Ser 450 455 460His Ser Arg Lys Phe Ser Lys Cys Ser Ile
Leu Glu Tyr Arg Asp Phe465 470 475 480Leu Gln Arg Gly Gly Gly Ala
Cys Leu Phe Asn Arg Pro Thr Lys Leu 485 490 495Phe Glu Pro Thr Glu
Cys Gly Asn Gly Tyr Val Glu Ala Gly Glu Glu 500 505 510Cys Asp Cys
Gly Phe His Val Glu Cys Tyr Gly Val Cys Cys Lys Lys 515 520 525Cys
Ser Leu Ser Asn Gly Ala His Cys Ser Asp Gly Pro Cys Cys Asn 530 535
540Asn Thr Ser Cys Leu Phe Gln Ser Arg Gly Tyr Glu Cys Arg Asp
Ala545 550 555 560Val Asn Ser Cys Asp Ile Thr Glu Tyr Cys Thr Gly
Asp Ser Gly Gln 565 570 575Cys Pro Pro Asn Leu His Lys Gln Asp Gly
Tyr Ser Cys Asn Gln Asn 580 585 590Gln Gly Arg Cys Tyr Asn Gly Glu
Cys Lys Thr Arg Asp Asn Gln Cys 595 600 605Gln Tyr Ile Trp Gly Thr
Lys Ala Ala Gly Ser Asp Lys Phe Cys Tyr 610 615 620Glu Lys Leu Asn
Thr Glu Gly Thr Glu Lys Gly Asn Cys Gly Lys Asp625 630 635 640Gly
Asp Arg Trp Ile Pro Cys Ser Lys His Asp Val Phe Cys Gly Phe 645 650
655Leu Leu Cys Thr Asn Leu Thr Arg Ala Pro Arg Ile Gly Gln Leu Gln
660 665 670Gly Glu Ile Ile Pro Thr Ser Phe Tyr His Gln Gly Arg Val
Ile Asp 675 680 685Cys Ser Gly Ala His Val Val Leu Asp Asp Asp Thr
Asp Val Gly Tyr 690 695 700Val Glu Asp Gly Thr Pro Cys Gly Pro Ser
Met Met Cys Leu Asp Arg705 710 715 720Lys Cys Leu Gln Ile Gln Ala
Leu Asn Met Ser Ser Cys Pro Leu Asp 725 730 735Ser Arg Gly Lys Val
Cys Ser Gly His Gly Val Cys Ser Asn Glu Ala 740 745 750Thr Cys Ile
Cys Asp Phe Thr Trp Ala Gly Thr Asp Cys Ser Ile Arg 755 760 765Asp
Pro Val Arg Asn Pro Asn Pro Pro Lys Asp Glu Gly Pro Lys Gly 770 775
780Pro Ser Ala Thr Asn Leu Ile Ile Gly Ser Ile Ala Gly Ala Ile
Leu785 790 795 800Val Ala Ala Ile Val Leu Gly Gly Thr Gly Trp Gly
Phe Lys Asn Val 805 810 815Lys Lys Arg Arg Phe Asp Pro Thr Gln Gln
Gly Pro Ile 820 825282499DNAHomo sapiensCDS(1)..(2496) 28atg aag
ccg ccc ggc agc agc tcg cgg cag ccg ccc ctg gcg ggc tgc 48Met Lys
Pro Pro Gly Ser Ser Ser Arg Gln Pro Pro Leu Ala Gly Cys1 5 10 15agc
ctt gcc ggc gct tcc tgc ggc ccc caa cgc ggc ccc gcc ggc tcg 96Ser
Leu Ala Gly Ala Ser Cys Gly Pro Gln Arg Gly Pro Ala Gly Ser 20 25
30gtg cct gcc agc gcc ccg gcc cgc acg ccg ccc tgc cgc ctg ctt ctc
144Val Pro Ala Ser Ala Pro Ala Arg Thr Pro Pro Cys Arg Leu Leu Leu
35 40 45gtc ctt ctc ctg ctg cct ccg ctc gcc gcc tcg tcc cgg ccc cgc
gcc 192Val Leu Leu Leu Leu Pro Pro Leu Ala Ala Ser Ser Arg Pro Arg
Ala 50 55 60tgg ggg gct gct gcg ccc agc gct ccg cat tgg aat gaa act
gca gaa 240Trp Gly Ala Ala Ala Pro Ser Ala Pro His Trp Asn Glu Thr
Ala Glu65 70 75 80aaa aat ttg gga gtc ctg gca gat gaa gac aat aca
ttg caa cag aat 288Lys Asn Leu Gly Val Leu Ala Asp Glu Asp Asn Thr
Leu Gln Gln Asn 85 90 95agc agc agt aat atc agt tac agc aat gca atg
cag aaa gaa atc aca 336Ser Ser Ser Asn Ile Ser Tyr Ser Asn Ala Met
Gln Lys Glu Ile Thr 100 105 110ctg cct tca aga ctc ata tat tac atc
aac caa gac tcg gaa agc cct 384Leu Pro Ser Arg Leu Ile Tyr Tyr Ile
Asn Gln Asp Ser Glu Ser Pro 115 120 125tat cac gtt ctt gac aca aag
gca aga cac cag caa aaa cat aat aag 432Tyr His Val Leu Asp Thr Lys
Ala Arg His Gln Gln Lys His Asn Lys 130 135 140gct gtc cat ctg gcc
cag gca agc ttc cag att gaa gcc ttc ggc tcc 480Ala Val His Leu Ala
Gln Ala Ser Phe Gln Ile Glu Ala Phe Gly Ser145 150 155 160aaa ttc
att ctt gac ctc ata ctg aac aat ggt ttg ttg tct tct gat 528Lys Phe
Ile Leu Asp Leu Ile Leu Asn Asn Gly Leu Leu Ser Ser Asp 165 170
175tat gtg gag att cac tac gaa aat ggg aaa cca cag tac tct aag ggt
576Tyr Val Glu Ile His Tyr Glu Asn Gly Lys Pro Gln Tyr Ser Lys Gly
180 185 190gga gag cac tgt tac tac cat gga agc atc aga ggc gtc aaa
gac tcc 624Gly Glu His Cys Tyr Tyr His Gly Ser Ile Arg Gly Val Lys
Asp Ser 195 200 205aag gtg gct ctg tca acc tgc aat gga ctt cat ggc
atg ttt gaa gat 672Lys Val Ala Leu Ser Thr Cys Asn Gly Leu His Gly
Met Phe Glu Asp 210 215 220gat acc ttc gtg tat atg ata gag cca cta
gag ctg gtt cat gat gag 720Asp Thr Phe Val Tyr Met Ile Glu Pro Leu
Glu Leu Val His Asp Glu225 230 235 240aaa agc aca ggt cga cca cat
ata atc cag aaa acc ttg gca gga cag 768Lys Ser Thr Gly Arg Pro His
Ile Ile Gln Lys Thr Leu Ala Gly Gln 245 250 255tat tct aag caa atg
aag aat ctc act atg gaa aga ggt gac cag tgg 816Tyr Ser Lys Gln Met
Lys Asn Leu Thr Met Glu Arg Gly Asp Gln Trp 260 265 270ccc ttt ctc
tct gaa tta cag tgg ttg aaa aga agg aag aga gca gtg 864Pro Phe Leu
Ser Glu Leu Gln Trp Leu Lys Arg Arg Lys Arg Ala Val 275 280 285aat
cca tca cgt ggt ata ttt gaa gaa atg aaa tat ttg gaa ctt atg 912Asn
Pro Ser Arg Gly Ile Phe Glu Glu Met Lys Tyr Leu Glu Leu Met 290 295
300att gtt aat gat cac aaa acg tat aag aag cat cgc tct tct cat gca
960Ile Val Asn Asp His Lys Thr Tyr Lys Lys His Arg Ser Ser His
Ala305 310 315 320cat acc aac aac ttt gca aag tcc gtg gtc aac ctt
gtg gat tct att 1008His Thr Asn Asn Phe Ala Lys Ser Val Val Asn Leu
Val Asp Ser Ile 325 330 335tac aag gag cag ctc aac acc agg gtt gtc
ctg gtg gct gta gag acc 1056Tyr Lys Glu Gln Leu Asn Thr Arg Val Val
Leu Val Ala Val Glu Thr 340 345 350tgg act gag aag gat cag att gac
atc acc acc aac cct gtg cag atg 1104Trp Thr Glu Lys Asp Gln Ile Asp
Ile Thr Thr Asn Pro Val Gln Met 355 360 365ctc cat gag ttc tca aaa
tac cgg cag cgc att aag cag cat gct gat 1152Leu His Glu Phe Ser Lys
Tyr Arg Gln Arg Ile Lys Gln His Ala Asp 370 375 380gct gtg cac ctc
atc tcg cgg gtg aca ttt cac tat aag aga agc agt 1200Ala Val His Leu
Ile Ser Arg Val Thr Phe His Tyr Lys Arg Ser Ser385 390 395 400ctg
agt tac ttt gga ggt gtc tgt tct cgc aca aga gga gtt ggt gtg 1248Leu
Ser Tyr Phe Gly Gly Val Cys Ser Arg Thr Arg Gly Val Gly Val 405 410
415aat gag tat ggt ctt cca atg gca gtg gca caa gta tta tcg cag agc
1296Asn Glu Tyr Gly Leu Pro Met Ala Val Ala Gln Val Leu Ser Gln Ser
420 425 430ctg gct caa aac ctt gga atc caa tgg gaa cct tct agc aga
aag cca 1344Leu Ala Gln Asn Leu Gly Ile Gln Trp Glu Pro Ser Ser Arg
Lys Pro 435 440 445aaa tgt gac tgc aca gaa tcc tgg ggt ggc tgc atc
atg gag gaa aca 1392Lys Cys Asp Cys Thr Glu Ser Trp Gly Gly Cys Ile
Met Glu Glu Thr 450 455 460ggg gtg tcc cat tct cga aaa ttt tca aag
tgc agc att ttg gag tat 1440Gly Val Ser His Ser Arg Lys Phe Ser Lys
Cys Ser Ile Leu Glu Tyr465 470 475 480aga gac ttt tta cag aga gga
ggt gga gcc tgc ctt ttc aac agg cca 1488Arg Asp Phe Leu Gln Arg Gly
Gly Gly Ala Cys Leu Phe Asn Arg Pro 485 490 495aca aag cta ttt gag
ccc acg gaa tgt gga aat gga tac gtg gaa gct 1536Thr Lys Leu Phe Glu
Pro Thr Glu Cys Gly Asn Gly Tyr Val Glu Ala 500 505 510ggg gag gag
tgt gat tgt ggt ttt cat gtg gaa tgc tat gga tta tgc 1584Gly Glu Glu
Cys Asp Cys Gly Phe His Val Glu Cys Tyr Gly Leu Cys 515 520 525tgt
aag aaa tgt tcc ctc tcc aac ggg gct cac tgc agc gac ggg ccc 1632Cys
Lys Lys Cys Ser Leu Ser Asn Gly Ala His Cys Ser Asp Gly Pro 530 535
540tgc tgt aac aat acc tca tgt ctt ttt cag cca cga ggg tat gaa tgc
1680Cys Cys Asn Asn Thr Ser Cys Leu Phe Gln Pro Arg Gly Tyr Glu
Cys545 550 555 560cgg gat gct gtg aac gag tgt gat att act gaa tat
tgt act gga gac 1728Arg Asp Ala Val Asn Glu Cys Asp Ile Thr Glu Tyr
Cys Thr Gly Asp 565 570 575tct ggt cag tgc cca cca aat ctt cat aag
caa gac gga tat gca tgc 1776Ser Gly Gln Cys Pro Pro Asn Leu His Lys
Gln Asp Gly Tyr Ala Cys 580 585 590aat caa aat cag ggc cgc tgc tac
aat ggc gag tgc aag acc aga gac 1824Asn Gln Asn Gln Gly Arg Cys Tyr
Asn Gly Glu Cys Lys Thr Arg Asp 595 600 605aac cag tgt cag tac atc
tgg gga aca aag gct gca ggg tct gac aag 1872Asn Gln Cys Gln Tyr Ile
Trp Gly Thr Lys Ala Ala Gly Ser Asp Lys 610 615 620ttc tgc tat gaa
aag ctg aat aca gaa ggc act gag aag gga aac tgc 1920Phe Cys Tyr Glu
Lys Leu Asn Thr Glu Gly Thr Glu Lys Gly Asn Cys625 630 635 640ggg
aag gat gga gac cgg tgg att cag tgc agc aaa cat gat gtg ttc 1968Gly
Lys Asp Gly Asp Arg Trp Ile Gln Cys Ser Lys His Asp Val Phe 645 650
655tgt gga ttc tta ctc tgt acc aat ctt act cga gct cca cgt att ggt
2016Cys Gly Phe Leu Leu Cys Thr Asn Leu Thr Arg Ala Pro Arg Ile Gly
660 665 670caa ctt cag ggt gag atc att cca act tcc ttc tac cat caa
ggc cgg 2064Gln Leu Gln Gly Glu Ile Ile Pro Thr Ser Phe Tyr His Gln
Gly Arg 675 680 685gtg att gac tgc agt ggt gcc cat gta gtt tta gat
gat gat acg gat 2112Val Ile Asp Cys Ser Gly Ala His Val Val Leu Asp
Asp Asp Thr Asp 690 695 700gtg ggc tat gta gaa gat gga acg cca tgt
ggc ccg tct atg atg tgt 2160Val Gly Tyr Val Glu Asp Gly Thr Pro Cys
Gly Pro Ser Met Met Cys705 710 715 720tta gat cgg aag tgc cta caa
att caa gcc cta aat atg agc agc tgt 2208Leu Asp Arg Lys Cys Leu Gln
Ile Gln Ala Leu Asn Met Ser Ser Cys 725 730 735cca ctc gat tcc aag
ggt aaa gtc tgt tcg ggc cat ggg gtg tgt agt 2256Pro Leu Asp Ser Lys
Gly Lys Val Cys Ser Gly His Gly Val Cys Ser 740 745 750aat gaa gcc
acc tgc att tgt gat ttc acc tgg gca ggg aca gat tgc 2304Asn Glu Ala
Thr Cys Ile Cys Asp Phe Thr Trp Ala Gly Thr Asp Cys 755 760 765agt
atc cgg gat cca gtt agg aac ctt cac ccc ccc aag gat gaa gga 2352Ser
Ile Arg Asp Pro Val Arg Asn Leu His Pro Pro Lys Asp Glu Gly 770 775
780ccc aag ggt cct agt gcc acc aat ctc ata ata ggc tcc atc gct ggt
2400Pro Lys Gly Pro Ser Ala Thr Asn Leu Ile Ile Gly Ser Ile Ala
Gly785 790 795 800gcc atc ctg gta gca gct att gtc ctt ggg ggc aca
ggc tgg gga ttt 2448Ala Ile Leu Val Ala Ala Ile Val Leu Gly Gly Thr
Gly Trp Gly Phe 805 810 815aaa aat gtc aag aag aga agg ttc gat cct
act cag caa ggc ccc atc 2496Lys Asn Val Lys Lys Arg Arg Phe Asp Pro
Thr Gln Gln Gly Pro Ile 820 825 830tga 249929832PRTHomo sapiens
29Met Lys Pro Pro Gly Ser Ser Ser Arg Gln Pro Pro Leu Ala Gly Cys1
5 10 15Ser Leu Ala Gly Ala Ser Cys Gly Pro Gln Arg Gly Pro Ala Gly
Ser 20 25 30Val Pro Ala Ser Ala Pro Ala Arg Thr Pro Pro Cys Arg Leu
Leu Leu 35 40 45Val Leu Leu Leu Leu Pro Pro Leu Ala Ala Ser Ser Arg
Pro Arg Ala 50 55 60Trp Gly Ala Ala Ala Pro Ser Ala Pro His Trp Asn
Glu Thr Ala Glu65 70 75 80Lys Asn Leu Gly Val Leu Ala Asp Glu Asp
Asn Thr Leu Gln Gln Asn 85 90 95Ser Ser Ser Asn Ile Ser Tyr Ser Asn
Ala Met Gln Lys Glu Ile Thr 100 105 110Leu Pro Ser Arg Leu Ile Tyr
Tyr Ile Asn Gln Asp Ser Glu Ser Pro 115 120 125Tyr His Val Leu Asp
Thr Lys Ala Arg His Gln Gln Lys His Asn Lys 130 135 140Ala Val His
Leu Ala Gln Ala Ser Phe Gln Ile Glu Ala Phe Gly Ser145 150 155
160Lys Phe Ile Leu Asp Leu Ile Leu Asn Asn Gly Leu Leu Ser Ser Asp
165 170 175Tyr Val Glu Ile His Tyr Glu Asn Gly Lys Pro Gln Tyr Ser
Lys Gly 180 185 190Gly Glu His Cys Tyr Tyr His Gly Ser Ile Arg Gly
Val Lys Asp Ser 195 200 205Lys Val Ala Leu Ser Thr Cys Asn Gly Leu
His Gly Met Phe Glu Asp 210 215 220Asp Thr Phe Val Tyr Met Ile Glu
Pro Leu Glu Leu Val His Asp Glu225 230 235 240Lys Ser Thr Gly Arg
Pro His Ile Ile Gln Lys Thr Leu Ala Gly Gln 245 250 255Tyr Ser Lys
Gln Met Lys Asn Leu Thr Met Glu Arg Gly Asp Gln Trp 260 265 270Pro
Phe Leu Ser Glu Leu Gln Trp Leu Lys Arg Arg Lys Arg Ala Val 275 280
285Asn Pro Ser Arg Gly Ile Phe Glu Glu Met Lys Tyr Leu Glu Leu Met
290 295 300Ile Val Asn Asp His Lys Thr Tyr Lys Lys His Arg Ser Ser
His Ala305 310 315 320His Thr Asn Asn Phe Ala Lys Ser Val Val Asn
Leu Val Asp Ser Ile 325 330 335Tyr Lys Glu Gln Leu Asn Thr Arg Val
Val Leu Val Ala Val Glu Thr 340 345 350Trp Thr Glu Lys Asp Gln Ile
Asp Ile Thr Thr Asn Pro Val Gln Met 355 360 365Leu His Glu Phe Ser
Lys Tyr Arg Gln Arg Ile Lys Gln His Ala Asp 370 375
380Ala Val His Leu Ile Ser Arg Val Thr Phe His Tyr Lys Arg Ser
Ser385 390 395 400Leu Ser Tyr Phe Gly Gly Val Cys Ser Arg Thr Arg
Gly Val Gly Val 405 410 415Asn Glu Tyr Gly Leu Pro Met Ala Val Ala
Gln Val Leu Ser Gln Ser 420 425 430Leu Ala Gln Asn Leu Gly Ile Gln
Trp Glu Pro Ser Ser Arg Lys Pro 435 440 445Lys Cys Asp Cys Thr Glu
Ser Trp Gly Gly Cys Ile Met Glu Glu Thr 450 455 460Gly Val Ser His
Ser Arg Lys Phe Ser Lys Cys Ser Ile Leu Glu Tyr465 470 475 480Arg
Asp Phe Leu Gln Arg Gly Gly Gly Ala Cys Leu Phe Asn Arg Pro 485 490
495Thr Lys Leu Phe Glu Pro Thr Glu Cys Gly Asn Gly Tyr Val Glu Ala
500 505 510Gly Glu Glu Cys Asp Cys Gly Phe His Val Glu Cys Tyr Gly
Leu Cys 515 520 525Cys Lys Lys Cys Ser Leu Ser Asn Gly Ala His Cys
Ser Asp Gly Pro 530 535 540Cys Cys Asn Asn Thr Ser Cys Leu Phe Gln
Pro Arg Gly Tyr Glu Cys545 550 555 560Arg Asp Ala Val Asn Glu Cys
Asp Ile Thr Glu Tyr Cys Thr Gly Asp 565 570 575Ser Gly Gln Cys Pro
Pro Asn Leu His Lys Gln Asp Gly Tyr Ala Cys 580 585 590Asn Gln Asn
Gln Gly Arg Cys Tyr Asn Gly Glu Cys Lys Thr Arg Asp 595 600 605Asn
Gln Cys Gln Tyr Ile Trp Gly Thr Lys Ala Ala Gly Ser Asp Lys 610 615
620Phe Cys Tyr Glu Lys Leu Asn Thr Glu Gly Thr Glu Lys Gly Asn
Cys625 630 635 640Gly Lys Asp Gly Asp Arg Trp Ile Gln Cys Ser Lys
His Asp Val Phe 645 650 655Cys Gly Phe Leu Leu Cys Thr Asn Leu Thr
Arg Ala Pro Arg Ile Gly 660 665 670Gln Leu Gln Gly Glu Ile Ile Pro
Thr Ser Phe Tyr His Gln Gly Arg 675 680 685Val Ile Asp Cys Ser Gly
Ala His Val Val Leu Asp Asp Asp Thr Asp 690 695 700Val Gly Tyr Val
Glu Asp Gly Thr Pro Cys Gly Pro Ser Met Met Cys705 710 715 720Leu
Asp Arg Lys Cys Leu Gln Ile Gln Ala Leu Asn Met Ser Ser Cys 725 730
735Pro Leu Asp Ser Lys Gly Lys Val Cys Ser Gly His Gly Val Cys Ser
740 745 750Asn Glu Ala Thr Cys Ile Cys Asp Phe Thr Trp Ala Gly Thr
Asp Cys 755 760 765Ser Ile Arg Asp Pro Val Arg Asn Leu His Pro Pro
Lys Asp Glu Gly 770 775 780Pro Lys Gly Pro Ser Ala Thr Asn Leu Ile
Ile Gly Ser Ile Ala Gly785 790 795 800Ala Ile Leu Val Ala Ala Ile
Val Leu Gly Gly Thr Gly Trp Gly Phe 805 810 815Lys Asn Val Lys Lys
Arg Arg Phe Asp Pro Thr Gln Gln Gly Pro Ile 820 825
8303037DNAArtificial Sequenceprimer 30ccggtcgacc accatggaac
tccggacccg aggctgg 373132DNAArtificial Sequenceprimer 31ccgaattctt
accgccacct gggcctggct gc 323235DNAArtificial Sequenceprimer
32ccgctcgagc caccatgaag ccttttcata ctgcc 353330DNAArtificial
Sequenceprimer 33tccgaattct tattgtttgt aggtccgtgg
303436DNAArtificial Sequenceprimer 34ccgctcgagc caccatgttg
gctgcaaggc tggtgt 363531DNAArtificial Sequenceprimer 35ccggatatct
catttctttc tgttgcctcc a 313634DNAArtificial Sequenceprimer
36ccgctcgagc caccatgagc acctcgtctg cgcg 343729DNAArtificial
Sequenceprimer 37tccgttaact taatagtcat catagttca
293820DNAArtificial Sequenceprimer 38agctcattac tgtatattta
203920DNAArtificial Sequenceprimer 39gctatatttc ataagtcatc
204026DNAArtificial Sequenceprimer 40ctcgggaagc gcgccattgt gttggt
264134DNAArtificial Sequenceprimer 41ccgctcgagc caccatgcgt
ttttgcctct tctc 344228DNAArtificial Sequenceprimer 42cggaattctt
attggttcac tctgtctg 284333DNAArtificial Sequenceprimer 43acgcgtcgac
ccaccatgcc ccgctacgag ttg 334429DNAArtificial Sequenceprimer
44attgaattct cacttcttcc tcctctttg 294535DNAArtificial
Sequenceprimer 45ccgctcgagc caccatgaag ccgcccggca gcatc
354629DNAArtificial Sequenceprimer 46cggaattctc agatggggcc
ttgctgagt 29
* * * * *
References